Methods for Treating or Inhibiting Cardiovascular Disease - Patent application

Anti-Gal3 antibodies provide a novel approach to treat cardiovascular diseases by inhibiting Gal3 activity, effectively addressing stroke and inflammatory disorders.

JP2024544508AInactive Publication Date: 2024-12-03TRUEBINDING INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024527276
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-09
Filing Date
2022-11-07
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for cardiovascular diseases, such as stroke, traumatic brain injury, and disorders related to fibrin activity or inflammation, lack effective methods to inhibit or treat these conditions by targeting galectin-3 (Gal3) activity.

Method used

Administration of anti-Gal3 antibodies or binding fragments to inhibit, reduce, or treat conditions by blocking Gal3 activity, thereby modulating immune response and reducing inflammation.

Benefits of technology

The use of anti-Gal3 antibodies effectively inhibits or treats stroke, traumatic brain injury, and disorders associated with fibrin activity or inflammation, improving clinical outcomes and reducing disease severity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544508000001_ABST
    Figure 2024544508000001_ABST
Patent Text Reader

Abstract

Disclosed herein are methods and compositions for inhibiting, preventing, ameliorating, reducing, or treating cardiovascular disease, such as stroke, traumatic brain injury, cerebral amyloid angiopathy, atherosclerosis, myocardial infarction, and / or diseases associated with fibrin activity or dysfunction. These methods and compositions involve antibodies that bind to galectin-3 and can inhibit, prevent, ameliorate, reduce, or treat cardiovascular disease in patients by reducing inflammation and / or inhibiting oligomerization of proteins associated with pathology, such as amyloid beta or fibrin.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 263,773, filed November 9, 2021, which is expressly incorporated herein by reference in its entirety, including any appendices filed therewith.

[0002] Sequence Listing Reference This application has been submitted with a Sequence Listing in electronic format. The Sequence Listing is provided as a file named IMMUT032WOSeqListing.XML, created and last updated on October 26, 2022, and is 1,424,975 bytes in size. The information in the electronic Sequence Listing is incorporated herein by reference in its entirety.

[0003] Field Aspects of the present disclosure generally relate to methods and compositions for inhibiting, preventing, ameliorating, reducing, or treating cardiovascular disease. These methods and compositions involve the use of antibodies that bind to galectin-3 (Gal3). [Background technology]

[0004] Galectin-3 (Gal3, GAL3) is a lectin, or carbohydrate-binding protein, with specificity for beta-galactosides. In human cells, Gal3 is expressed and can be found in the nucleus, cytoplasm, cell surface, and extracellular space. Gal3 recognizes and interacts with beta-galactose conjugates on various proteins. Summary of the Invention

[0005] Galectin-3 (Gal3) has been suggested to have immunomodulatory activity. An example of this is the interaction between Gal3 and T-cell immunoglobulin and mucin-domain-containing molecule 3 (TIM-3), which can lead to suppression of the immune response, such as T cell activation, and allow cancer cells to escape immune clearance. This phenomenon and methods for inhibiting it are exemplified in International Publication Nos. WO 2019 / 023247 and WO 2020 / 160156, each of which is expressly incorporated herein by reference in its entirety. Disclosed herein are methods for inhibiting, reducing, preventing, and / or treating stroke in a subject in need thereof. In some embodiments, the method includes administering an anti-Gal3 antibody or binding fragment thereof to the subject, thereby inhibiting, reducing, preventing, and / or treating stroke. In some embodiments, the stroke is an ischemic stroke, a thrombotic stroke, an embolic stroke, a transient ischemic attack, a hemorrhagic stroke, an intracerebral hemorrhage, or a subarachnoid hemorrhage.

[0006] Also disclosed herein are methods for inhibiting, reducing, preventing, and / or treating traumatic brain injury (TBI) in a subject in need thereof. In some embodiments, the method comprises administering an anti-Gal3 antibody or binding fragment thereof to the subject, thereby inhibiting, reducing, preventing, and / or treating TBI. In some embodiments, TBI is associated with concussion, edema, diffuse axonal injury, spinal cord injury, coma, neuroinflammation, microhemorrhage, astrocytosis, activated microglia, and / or hematoma.

[0007] Also disclosed herein are methods for inhibiting, reducing, preventing, and / or treating a disorder associated with fibrin activity or dysfunction in a subject in need thereof. In some embodiments, the method comprises administering an anti-Gal3 antibody or binding fragment thereof to the subject, thereby inhibiting, reducing, preventing, and / or treating the disorder associated with fibrin activity or dysfunction. In some embodiments, the disorder associated with fibrin activity or dysfunction comprises atherosclerosis, thrombosis, thromboembolism, carotid artery disease, coronary artery disease, peripheral artery disease, myocardial infarction, heart failure, heart attack, hypertension, chronic kidney disease, coagulation disorders, or thrombocytopathy.

[0008] Also disclosed herein are methods for inhibiting, reducing, preventing, and / or treating disorders associated with inflammation and elevated levels of pro-inflammatory cytokines in a subject in need thereof. The methods include administering an anti-Gal3 antibody or binding fragment thereof to the subject, thereby treating the disorder associated with inflammation. In some embodiments, the administration reduces pro-inflammatory cytokines, such as circulating cytokines, in the subject.

[0009] Also disclosed herein is a method comprising administering five unit doses of an anti-Gal3 antibody or binding fragment thereof, each unit dose comprising 1000 mg or about 1000 mg of the anti-Gal3 antibody or binding fragment thereof, the unit doses being administered every 7 days or about every 7 days, and each unit dose being administered over 1 hour or about 1 hour.

[0010] Also disclosed herein is a single-use, sealed glass injection vial containing 8 mL of 20 mg / mL anti-Gal3 antibody or binding fragment thereof.

[0011] Also disclosed herein is an IV infusion bag containing 1000 mg, or about 1000 mg, of an anti-Gal3 antibody or binding fragment thereof dissolved in 250 mL, or about 250 mL, of saline.

[0012] In some embodiments, the anti-Gal3 antibody or binding fragment is any one or more of the anti-Gal3 antibodies or binding fragments thereof disclosed herein, or any portion or component of any one or more of the anti-Gal3 antibodies or binding fragments thereof, including, but not limited to, one, two, three, four, five, or six CDRs, a heavy chain variable region, a light chain variable region, a heavy chain, or a light chain. [Brief explanation of the drawings]

[0013] In addition to the features described above, additional features and variations will be readily apparent from the following description of the drawings and illustrative embodiments. It should be understood that these drawings depict typical embodiments and are not intended to limit the scope. [Figure 1] FIG. 1 depicts an exemplary protein sequence of Gal3. [Figure 2] FIG. 2 depicts exemplary peptide sequences of Gal3 that were used to generate and analyze antibodies. [Figure 3A] 3A depicts an exemplary variable heavy chain complementarity-determining region (CDR) 1 for an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the variable heavy chain CDR1s provided herein. [Figure 3B] 3B depicts an exemplary variable heavy chain CDR2 for an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the variable heavy chain CDR2s provided herein. [Figure 3C] 3C depicts an exemplary variable heavy chain CDR3 for an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the variable heavy chain CDR3s provided herein. [Figure 4A]4A depicts an exemplary variable light chain CDR1 for an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the variable light chain CDR1s provided herein. [Figure 4B] 4B depicts an exemplary variable light chain CDR2 for an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the variable light chain CDR2s provided herein. [Figure 4C] 4C depicts an exemplary variable light chain CDR3 for an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the variable light chain CDR3s provided herein. [Figure 5-1] 5 depicts exemplary heavy chain variable region (VH) sequences for the anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the VH sequences provided herein. [Figure 5-2] 5 depicts exemplary heavy chain variable region (VH) sequences for the anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the VH sequences provided herein. [Figure 5-3] 5 depicts exemplary heavy chain variable region (VH) sequences for the anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the VH sequences provided herein. [Figure 5-4] 5 depicts exemplary heavy chain variable region (VH) sequences for the anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the VH sequences provided herein. [Figure 5-5]5 depicts exemplary heavy chain variable region (VH) sequences for the anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the VH sequences provided herein. [Figure 5-6] 5 depicts exemplary heavy chain variable region (VH) sequences for the anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the VH sequences provided herein. [Figure 5-7] 5 depicts exemplary heavy chain variable region (VH) sequences for the anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the VH sequences provided herein. [Figure 6-1] 6 depicts exemplary light chain variable region (VL) sequences for the anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the VL sequences provided herein. [Figure 6-2] 6 depicts exemplary light chain variable region (VL) sequences for the anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the VL sequences provided herein. [Figure 6-3] 6 depicts exemplary light chain variable region (VL) sequences for the anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the VL sequences provided herein. [Figure 6-4] 6 depicts exemplary light chain variable region (VL) sequences for the anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the VL sequences provided herein. [Figure 6-5]6 depicts exemplary light chain variable region (VL) sequences for the anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the VL sequences provided herein. [Figure 6-6] 6 depicts exemplary light chain variable region (VL) sequences for the anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the VL sequences provided herein. [Figure 7-1] 7 depicts exemplary combinations of heavy and light chain CDRs (CDR1, CDR2, and CDR3) of exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy and light chain CDR combinations provided herein. [Figure 7-2] 7 depicts exemplary combinations of heavy and light chain CDRs (CDR1, CDR2, and CDR3) of exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy and light chain CDR combinations provided herein. [Figure 7-3] 7 depicts exemplary combinations of heavy and light chain CDRs (CDR1, CDR2, and CDR3) of exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy and light chain CDR combinations provided herein. [Figure 8-1] 8 depicts exemplary combinations of heavy and light chain variable regions of exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy and light chain variable region combinations provided herein. [Figure 8-2]8 depicts exemplary combinations of heavy and light chain variable regions of exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy and light chain variable region combinations provided herein. [Figure 8-3] 8 depicts exemplary combinations of heavy and light chain variable regions of exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy and light chain variable region combinations provided herein. [Figure 9-1] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-2] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-3] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-4] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-5] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-6] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-7] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-8] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-9] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-10]9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-11] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-12] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-13] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-14] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-15]9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-16] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-17] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-18] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-19] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-20]9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 9-21] 9 depicts exemplary heavy chain (HC) and light chain (LC) sequences and possible pairings for exemplary anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the HC or LC, or HC and LC sequence pairs provided herein. [Figure 10-1] Figure 10 depicts peptides (according to the peptide nomenclature depicted in Figure 2 as discussed herein) found to bind to exemplary anti-Gal3 antibodies disclosed herein and the binning of these exemplary antibodies. [Figure 10-2] Figure 10 depicts peptides (according to the peptide nomenclature depicted in Figure 2 as discussed herein) found to bind to exemplary anti-Gal3 antibodies disclosed herein and the binning of these exemplary antibodies. [Figure 11A] FIG. 11A depicts the KD(M) values ​​of Gal3 binding for exemplary anti-Gal3 antibodies disclosed herein. [Figure 11B] FIG. 11B depicts the antibody affinity (KD) of anti-Gal3 humanized antibodies TB001 (IMT001) and TB006 (IMT006) for human, cynomolgus monkey, rat, and mouse Gal3. [Figure 12] Figure 12 depicts antibody names used throughout this disclosure to refer to the same antibody (exemplary peptide and nucleic acid sequences are provided elsewhere in this disclosure and are appropriately attributed to at least one of the depicted names), which may be used interchangeably. Names shown in a row correspond to the same antibody. [Figure 13-1]Figure 13 depicts an alignment of the hinge and constant heavy domain 2 (CH2) amino acid sequences of wild-type human immunoglobulin G1 (IgG1), IgG2, and IgG4, as well as their sigma variants. The alignment uses EU numbering. Residues identical to wild-type IgG1 are indicated as dots; gaps are indicated with hyphens. Sequences are given explicitly if they differ from the parent subtype for wild-type IgG1 or sigma variants. The open boxes below the alignment correspond to the chain definitions of the International Immunogenetics Information System (IMGT). The boxes below the alignment correspond to the chain and helix secondary structure assignments for wild-type IgG1. Residues 267-273 form the BC loop, and residues 322-332 form the FG loop. Also provided are exemplary constant regions for human IgG4 heavy (S228P mutant) and light (kappa) chains (SEQ ID NOs: 931-932) and mouse IgG2A (LALAPG and LALA mutants) (SEQ ID NOs: 933-934). In some embodiments, any one or more of the VH / VL and / or CDRs provided in other figures or otherwise disclosed herein can be paired with any one or more of the exemplary constant regions provided herein. [Figure 13-2]Figure 13 depicts an alignment of the hinge and constant heavy domain 2 (CH2) amino acid sequences of wild-type human immunoglobulin G1 (IgG1), IgG2, and IgG4, as well as their sigma variants. The alignment uses EU numbering. Residues identical to wild-type IgG1 are indicated as dots; gaps are indicated with hyphens. Sequences are given explicitly if they differ from the parent subtype for wild-type IgG1 or sigma variants. The open boxes below the alignment correspond to the chain definitions of the International Immunogenetics Information System (IMGT). The boxes below the alignment correspond to the chain and helix secondary structure assignments for wild-type IgG1. Residues 267-273 form the BC loop, and residues 322-332 form the FG loop. Also provided are exemplary constant regions for human IgG4 heavy (S228P mutant) and light (kappa) chains (SEQ ID NOs: 931-932) and mouse IgG2A (LALAPG and LALA mutants) (SEQ ID NOs: 933-934). In some embodiments, any one or more of the VH / VL and / or CDRs provided in other figures or otherwise disclosed herein can be paired with any one or more of the exemplary constant regions provided herein. [Figure 14-1] 14 depicts nucleic acid sequences encoding exemplary heavy chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chain variable regions encoded by the nucleic acids provided herein. [Figure 14-2] 14 depicts nucleic acid sequences encoding exemplary heavy chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chain variable regions encoded by the nucleic acids provided herein. [Figure 14-3]14 depicts nucleic acid sequences encoding exemplary heavy chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chain variable regions encoded by the nucleic acids provided herein. [Figure 14-4] 14 depicts nucleic acid sequences encoding exemplary heavy chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chain variable regions encoded by the nucleic acids provided herein. [Figure 14-5] 14 depicts nucleic acid sequences encoding exemplary heavy chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chain variable regions encoded by the nucleic acids provided herein. [Figure 14-6] 14 depicts nucleic acid sequences encoding exemplary heavy chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chain variable regions encoded by the nucleic acids provided herein. [Figure 14-7] 14 depicts nucleic acid sequences encoding exemplary heavy chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chain variable regions encoded by the nucleic acids provided herein. [Figure 14-8] 14 depicts nucleic acid sequences encoding exemplary heavy chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chain variable regions encoded by the nucleic acids provided herein. [Figure 14-9]14 depicts nucleic acid sequences encoding exemplary heavy chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chain variable regions encoded by the nucleic acids provided herein. [Figure 14-10] 14 depicts nucleic acid sequences encoding exemplary heavy chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chain variable regions encoded by the nucleic acids provided herein. [Figure 14-11] 14 depicts nucleic acid sequences encoding exemplary heavy chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chain variable regions encoded by the nucleic acids provided herein. [Figure 14-12] 14 depicts nucleic acid sequences encoding exemplary heavy chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chain variable regions encoded by the nucleic acids provided herein. [Figure 14-13] 14 depicts nucleic acid sequences encoding exemplary heavy chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chain variable regions encoded by the nucleic acids provided herein. [Figure 14-14] 14 depicts nucleic acid sequences encoding exemplary heavy chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chain variable regions encoded by the nucleic acids provided herein. [Figure 15-1]15 depicts nucleic acid sequences encoding exemplary light chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chain variable regions encoded by the nucleic acids provided herein. [Figure 15-2] 15 depicts nucleic acid sequences encoding exemplary light chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chain variable regions encoded by the nucleic acids provided herein. [Figure 15-3] 15 depicts nucleic acid sequences encoding exemplary light chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chain variable regions encoded by the nucleic acids provided herein. [Figure 15-4] 15 depicts nucleic acid sequences encoding exemplary light chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chain variable regions encoded by the nucleic acids provided herein. [Figure 15-5] 15 depicts nucleic acid sequences encoding exemplary light chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chain variable regions encoded by the nucleic acids provided herein. [Figure 15-6] 15 depicts nucleic acid sequences encoding exemplary light chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chain variable regions encoded by the nucleic acids provided herein. [Figure 15-7]15 depicts nucleic acid sequences encoding exemplary light chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chain variable regions encoded by the nucleic acids provided herein. [Figure 15-8] 15 depicts nucleic acid sequences encoding exemplary light chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chain variable regions encoded by the nucleic acids provided herein. [Figure 15-9] 15 depicts nucleic acid sequences encoding exemplary light chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chain variable regions encoded by the nucleic acids provided herein. [Figure 15-10] 15 depicts nucleic acid sequences encoding exemplary light chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chain variable regions encoded by the nucleic acids provided herein. [Figure 15-11] 15 depicts nucleic acid sequences encoding exemplary light chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chain variable regions encoded by the nucleic acids provided herein. [Figure 15-12] 15 depicts nucleic acid sequences encoding exemplary light chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chain variable regions encoded by the nucleic acids provided herein. [Figure 15-13]15 depicts nucleic acid sequences encoding exemplary light chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chain variable regions encoded by the nucleic acids provided herein. [Figure 15-14] 15 depicts nucleic acid sequences encoding exemplary light chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chain variable regions encoded by the nucleic acids provided herein. [Figure 16-1] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-2] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-3] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-4] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-5]16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-6] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-7] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-8] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-9] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-10] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-11] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-12] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-13] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-14] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-15] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-16] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-17] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-18]16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-19] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-20] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-21] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-22] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-23] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-24] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-25] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-26] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-27] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-28] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-29] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-30] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-31]16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 16-32] 16 depicts a nucleic acid sequence encoding an exemplary heavy chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein. [Figure 17-1] 17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 17-2] 17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 17-3] 17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 17-4] 17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 17-5] 17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 17-6] 17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 17-7] 17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 17-8] 17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 17-9] 17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 17-10] 17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 17-11] 17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 17-12]17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 17-13] 17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 17-14] 17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 17-15] 17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 17-16] 17 depicts a nucleic acid sequence encoding an exemplary light chain of an anti-Gal3 antibody disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein. [Figure 18A] 18A-B depict exemplary alignments of the heavy chain CDRs (FIG. 18A) and light chain CDRs (FIG. 18B) for an exemplary anti-Gal3 antibody disclosed herein. [Figure 18B] 18A-B depict exemplary alignments of the heavy chain CDRs (FIG. 18A) and light chain CDRs (FIG. 18B) for an exemplary anti-Gal3 antibody disclosed herein. [Figure 19A]19A-D each depict a table containing a subset of the anti-Gal3 antibodies disclosed herein. In some embodiments, sequences including heavy chain variable region CDRs, light chain variable region CDRs, heavy chain variable regions, light chain variable regions, heavy chains, and light chains, or combinations thereof, can be selected from any one or more of the anti-Gal3 antibodies provided as subsets in each table. [Figure 19B] 19A-D each depict a table containing a subset of the anti-Gal3 antibodies disclosed herein. In some embodiments, sequences including heavy chain variable region CDRs, light chain variable region CDRs, heavy chain variable regions, light chain variable regions, heavy chains, and light chains, or combinations thereof, can be selected from any one or more of the anti-Gal3 antibodies provided as subsets in each table. [Figure 19C] 19A-D each depict a table containing a subset of the anti-Gal3 antibodies disclosed herein. In some embodiments, sequences including heavy chain variable region CDRs, light chain variable region CDRs, heavy chain variable regions, light chain variable regions, heavy chains, and light chains, or combinations thereof, can be selected from any one or more of the anti-Gal3 antibodies provided as subsets in each table. [Figure 19D] 19A-D each depict a table containing a subset of the anti-Gal3 antibodies disclosed herein. In some embodiments, sequences including heavy chain variable region CDRs, light chain variable region CDRs, heavy chain variable regions, light chain variable regions, heavy chains, and light chains, or combinations thereof, can be selected from any one or more of the anti-Gal3 antibodies provided as subsets in each table. [Figure 20A] 20A-D each depict a table containing a subset of the anti-Gal3 antibodies disclosed herein. In some embodiments, sequences including heavy chain variable region CDRs, light chain variable region CDRs, heavy chain variable regions, light chain variable regions, heavy chains, and light chains, or combinations thereof, can be selected from any one or more of the anti-Gal3 antibodies provided as subsets in each table. [Figure 20B]20A-D each depict a table containing a subset of the anti-Gal3 antibodies disclosed herein. In some embodiments, sequences including heavy chain variable region CDRs, light chain variable region CDRs, heavy chain variable regions, light chain variable regions, heavy chains, and light chains, or combinations thereof, can be selected from any one or more of the anti-Gal3 antibodies provided as subsets in each table. [Figure 20C] 20A-D each depict a table containing a subset of the anti-Gal3 antibodies disclosed herein. In some embodiments, sequences including heavy chain variable region CDRs, light chain variable region CDRs, heavy chain variable regions, light chain variable regions, heavy chains, and light chains, or combinations thereof, can be selected from any one or more of the anti-Gal3 antibodies provided as subsets in each table. [Figure 20D] 20A-D each depict a table containing a subset of the anti-Gal3 antibodies disclosed herein. In some embodiments, sequences including heavy chain variable region CDRs, light chain variable region CDRs, heavy chain variable regions, light chain variable regions, heavy chains, and light chains, or combinations thereof, can be selected from any one or more of the anti-Gal3 antibodies provided as subsets in each table. [Figure 21A] Figures 21A-B depict quantification of motor activity in an intracerebral hemorrhage (ICH) stroke mouse model showing significantly shorter fall latency (Figure 21A) and smaller distance traveled (Figure 21B) compared to age-matched healthy control mice. [Figure 21B] Figures 21A-B depict quantification of motor activity in an intracerebral hemorrhage (ICH) stroke mouse model showing significantly shorter fall latency (Figure 21A) and smaller distance traveled (Figure 21B) compared to age-matched healthy control mice. [Figure 22] Figure 22 depicts an exemplary dosing regimen after inducing stroke (ICH). Mice were dosed with 8 doses of mTB001 or MOPC21 for 4 weeks (2 doses per week). [Figure 23A]Figures 23A-D depict quantification of motor activity in an ICH mouse model before and after treatment with mTB001 or MOPC21 compared to control wild-type mice. Treated mice were evaluated after 4 (Figure 23A), 6 (Figure 23B), and 8 doses. After 8 doses of treatment, stroke-induced mice treated with mTB001 showed significant improvements in terms of fall latency (Figure 23C) and distance traveled (Figure 23D), and motor performance was similar to that of age-matched healthy control mice. [Figure 23B] Figures 23A-D depict quantification of motor activity in an ICH mouse model before and after treatment with mTB001 or MOPC21 compared to control wild-type mice. Treated mice were evaluated after 4 (Figure 23A), 6 (Figure 23B), and 8 doses. After 8 doses of treatment, stroke-induced mice treated with mTB001 showed significant improvements in terms of fall latency (Figure 23C) and distance traveled (Figure 23D), and motor performance was similar to that of age-matched healthy control mice. [Figure 23C] Figures 23A-D depict quantification of motor activity in an ICH mouse model before and after treatment with mTB001 or MOPC21 compared to control wild-type mice. Treated mice were evaluated after 4 (Figure 23A), 6 (Figure 23B), and 8 doses. After 8 doses of treatment, stroke-induced mice treated with mTB001 showed significant improvements in terms of fall latency (Figure 23C) and distance traveled (Figure 23D), and motor performance was similar to that of age-matched healthy control mice. [Figure 23D] Figures 23A-D depict quantification of motor activity in an ICH mouse model before and after treatment with mTB001 or MOPC21 compared to control wild-type mice. Treated mice were evaluated after 4 (Figure 23A), 6 (Figure 23B), and 8 doses. After 8 doses of treatment, stroke-induced mice treated with mTB001 showed significant improvements in terms of fall latency (Figure 23C) and distance traveled (Figure 23D), and motor performance was similar to that of age-matched healthy control mice. [Figure 24A]Figures 24A-C depict the reduction in microhemorrhages in ICH model mice treated with mTB001 as quantified by Prussian Blue staining. Representative Prussian Blue-stained brain sections of mice treated with mTB001 showed significantly reduced microhemorrhages compared to mice treated with MOPC21 (Figure 24A). Healthy control mice showed no microhemorrhages (Figure 24B). Figure 24C is a quantification of the Prussian Blue-positive surface area of ​​the representative brain sections of Figures 24A-B. [Figure 24B] Figures 24A-C depict the reduction in microhemorrhages in ICH model mice treated with mTB001 as quantified by Prussian Blue staining. Representative Prussian Blue-stained brain sections of mice treated with mTB001 showed significantly reduced microhemorrhages compared to mice treated with MOPC21 (Figure 24A). Healthy control mice showed no microhemorrhages (Figure 24B). Figure 24C is a quantification of the Prussian Blue-positive surface area of ​​the representative brain sections of Figures 24A-B. [Figure 24C] Figures 24A-C depict the reduction in microhemorrhages in ICH model mice treated with mTB001 as quantified by Prussian Blue staining. Representative Prussian Blue-stained brain sections of mice treated with mTB001 showed significantly reduced microhemorrhages compared to mice treated with MOPC21 (Figure 24A). Healthy control mice showed no microhemorrhages (Figure 24B). Figure 24C is a quantification of the Prussian Blue-positive surface area of ​​the representative brain sections of Figures 24A-B. [Figure 25A] Figures 25A-B depict the reduction of activated microglia in ICH model mice treated with mTB001. Figure 25A shows brain sections from ICH mice and wild-type control mice treated with mTB001 or MOPC21 isotype control stained for the microglial marker Iba1. Figure 25B is a quantification of Iba1-positive staining in representative brain sections from Figure 24A. [Figure 25B]Figures 25A-B depict the reduction of activated microglia in ICH model mice treated with mTB001. Figure 25A shows brain sections from ICH mice and wild-type control mice treated with mTB001 or MOPC21 isotype control stained for the microglial marker Iba1. Figure 25B is a quantification of Iba1-positive staining in representative brain sections from Figure 24A. [Figure 26A] Figures 26A-B depict the reduction of activated astrocytes in ICH model mice treated with mTB001. Figure 26A shows brain sections from ICH mice and wild-type control mice treated with mTB001 or MOPC21 isotype control stained for the astrocyte marker GFAP. Figure 26B shows quantification of GFAP-positive staining in representative brain sections from Figure 26A. [Figure 26B] Figures 26A-B depict the reduction of activated astrocytes in ICH model mice treated with mTB001. Figure 26A shows brain sections from ICH mice and wild-type control mice treated with mTB001 or MOPC21 isotype control stained for the astrocyte marker GFAP. Figure 26B shows quantification of GFAP-positive staining in representative brain sections from Figure 26A. [Figure 27A]Figures 27A-F depict mouse models of TBI treated with the exemplary anti-Gal3 antibody mTB001, which exhibit reduced levels of activated microglia and astrocytes, as well as myeloid immune cells, in the affected brain. Brains from TBI models and wild-type mice were probed with antibodies against the activated microglia marker Iba1 (Figure 27A), the activated astrocyte marker GFAP (Figure 27C), and the myeloid cell marker CD68 (Figure 27E). Figure 27B shows quantification of Figure 27A, demonstrating that mTB001 significantly reduces activated microglia compared to the isotype control. Figure 27D shows quantification of Figure 27C, demonstrating that mTB001 significantly reduces activated astrocytes compared to the isotype control. Figure 27F shows quantification of Figure 27E, demonstrating that mTB001 significantly reduces myeloid cell levels, such as macrophages and microglia, compared to the isotype control. [Figure 27B] Figures 27A-F depict mouse models of TBI treated with the exemplary anti-Gal3 antibody mTB001, which exhibit reduced levels of activated microglia and astrocytes, as well as myeloid immune cells, in the affected brain. Brains from TBI models and wild-type mice were probed with antibodies against the activated microglia marker Iba1 (Figure 27A), the activated astrocyte marker GFAP (Figure 27C), and the myeloid cell marker CD68 (Figure 27E). Figure 27B shows quantification of Figure 27A, demonstrating that mTB001 significantly reduces activated microglia compared to the isotype control. Figure 27D shows quantification of Figure 27C, demonstrating that mTB001 significantly reduces activated astrocytes compared to the isotype control. Figure 27F shows quantification of Figure 27E, demonstrating that mTB001 significantly reduces myeloid cell levels, such as macrophages and microglia, compared to the isotype control. [Figure 27C]Figures 27A-F depict mouse models of TBI treated with the exemplary anti-Gal3 antibody mTB001, which exhibit reduced levels of activated microglia and astrocytes, as well as myeloid immune cells, in the affected brain. Brains from TBI models and wild-type mice were probed with antibodies against the activated microglia marker Iba1 (Figure 27A), the activated astrocyte marker GFAP (Figure 27C), and the myeloid cell marker CD68 (Figure 27E). Figure 27B shows quantification of Figure 27A, demonstrating that mTB001 significantly reduces activated microglia compared to the isotype control. Figure 27D shows quantification of Figure 27C, demonstrating that mTB001 significantly reduces activated astrocytes compared to the isotype control. Figure 27F shows quantification of Figure 27E, demonstrating that mTB001 significantly reduces myeloid cell levels, such as macrophages and microglia, compared to the isotype control. [Figure 27D] Figures 27A-F depict mouse models of TBI treated with the exemplary anti-Gal3 antibody mTB001, which exhibit reduced levels of activated microglia and astrocytes, as well as myeloid immune cells, in the affected brain. Brains from TBI models and wild-type mice were probed with antibodies against the activated microglia marker Iba1 (Figure 27A), the activated astrocyte marker GFAP (Figure 27C), and the myeloid cell marker CD68 (Figure 27E). Figure 27B shows quantification of Figure 27A, demonstrating that mTB001 significantly reduces activated microglia compared to the isotype control. Figure 27D shows quantification of Figure 27C, demonstrating that mTB001 significantly reduces activated astrocytes compared to the isotype control. Figure 27F shows quantification of Figure 27E, demonstrating that mTB001 significantly reduces myeloid cell levels, such as macrophages and microglia, compared to the isotype control. [Figure 27E]Figures 27A-F depict mouse models of TBI treated with the exemplary anti-Gal3 antibody mTB001, which exhibit reduced levels of activated microglia and astrocytes, as well as myeloid immune cells, in the affected brain. Brains from TBI models and wild-type mice were probed with antibodies against the activated microglia marker Iba1 (Figure 27A), the activated astrocyte marker GFAP (Figure 27C), and the myeloid cell marker CD68 (Figure 27E). Figure 27B shows quantification of Figure 27A, demonstrating that mTB001 significantly reduces activated microglia compared to the isotype control. Figure 27D shows quantification of Figure 27C, demonstrating that mTB001 significantly reduces activated astrocytes compared to the isotype control. Figure 27F shows quantification of Figure 27E, demonstrating that mTB001 significantly reduces myeloid cell levels, such as macrophages and microglia, compared to the isotype control. [Figure 27F] Figures 27A-F depict mouse models of TBI treated with the exemplary anti-Gal3 antibody mTB001, which exhibit reduced levels of activated microglia and astrocytes, as well as myeloid immune cells, in the affected brain. Brains from TBI models and wild-type mice were probed with antibodies against the activated microglia marker Iba1 (Figure 27A), the activated astrocyte marker GFAP (Figure 27C), and the myeloid cell marker CD68 (Figure 27E). Figure 27B shows quantification of Figure 27A, demonstrating that mTB001 significantly reduces activated microglia compared to the isotype control. Figure 27D shows quantification of Figure 27C, demonstrating that mTB001 significantly reduces activated astrocytes compared to the isotype control. Figure 27F shows quantification of Figure 27E, demonstrating that mTB001 significantly reduces myeloid cell levels, such as macrophages and microglia, compared to the isotype control. [Figure 28A]Figures 28A-D depict mouse models of TBI treated with the exemplary anti-Gal3 antibody mTB001, which exhibit reduced levels of hyperphosphorylated tau and microhemorrhage in affected brains. Brains from TBI models and wild-type mice were probed with antibody AT8, which binds to phosphorylated tau (Figure 28A), or stained with Prussian Blue (Figure 28C). Figure 28B shows quantification of Figure 28A, demonstrating that mTB001 significantly reduces levels of hyperphosphorylated tau compared to the isotype control. Figure 28D shows quantification of Figure 28C, demonstrating that mTB001 significantly reduces microhemorrhage compared to the isotype control. [Figure 28B] Figures 28A-D depict mouse models of TBI treated with the exemplary anti-Gal3 antibody mTB001, which exhibit reduced levels of hyperphosphorylated tau and microhemorrhage in affected brains. Brains from TBI models and wild-type mice were probed with antibody AT8, which binds to phosphorylated tau (Figure 28A), or stained with Prussian Blue (Figure 28C). Figure 28B shows quantification of Figure 28A, demonstrating that mTB001 significantly reduces levels of hyperphosphorylated tau compared to the isotype control. Figure 28D shows quantification of Figure 28C, demonstrating that mTB001 significantly reduces microhemorrhage compared to the isotype control. [Figure 28C] Figures 28A-D depict mouse models of TBI treated with the exemplary anti-Gal3 antibody mTB001, which exhibit reduced levels of hyperphosphorylated tau and microhemorrhage in affected brains. Brains from TBI models and wild-type mice were probed with antibody AT8, which binds to phosphorylated tau (Figure 28A), or stained with Prussian Blue (Figure 28C). Figure 28B shows quantification of Figure 28A, demonstrating that mTB001 significantly reduces levels of hyperphosphorylated tau compared to the isotype control. Figure 28D shows quantification of Figure 28C, demonstrating that mTB001 significantly reduces microhemorrhage compared to the isotype control. [Figure 28D]Figures 28A-D depict mouse models of TBI treated with the exemplary anti-Gal3 antibody mTB001, which exhibit reduced levels of hyperphosphorylated tau and microhemorrhage in affected brains. Brains from TBI models and wild-type mice were probed with antibody AT8, which binds to phosphorylated tau (Figure 28A), or stained with Prussian Blue (Figure 28C). Figure 28B shows quantification of Figure 28A, demonstrating that mTB001 significantly reduces levels of hyperphosphorylated tau compared to the isotype control. Figure 28D shows quantification of Figure 28C, demonstrating that mTB001 significantly reduces microhemorrhage compared to the isotype control. [Figure 28E] FIG. 28E depicts a mouse model of TBI treated with exemplary antibody mTB001, which exhibits reduced levels of neurofilament light chain (NF-L) in plasma after 48 hours of treatment. [Figure 29] FIG. 29 depicts exemplary anti-Gal3 antibodies evaluated for activity against fibrin oligomerization in Example 3. [Figure 30A] Figures 30A-B depict the time course of Gal3-mediated fibrin oligomerization over a 0-5 hour period. Figure 30A shows a dot blot in which fibrin was incubated with or without Gal3 (100 μg / mL each) for 0-5 hours and probed with the oligomer-specific conformational antibody A11. Figure 30B shows the quantification of Figure 30A. [Figure 30B] Figures 30A-B depict the time course of Gal3-mediated fibrin oligomerization over a 0-5 hour period. Figure 30A shows a dot blot in which fibrin was incubated with or without Gal3 (100 μg / mL each) for 0-5 hours and probed with the oligomer-specific conformational antibody A11. Figure 30B shows the quantification of Figure 30A. [Figure 31A]Figures 31A-B depict the time course of Gal3-mediated fibrin oligomerization over the course of 0-24 hours. Figure 31A shows a dot blot in which fibrin was incubated with or without Gal3 (100 μg / mL each) for 0-24 hours and probed with the oligomer-specific conformational antibody A11. Figure 31B shows the quantification of Figure 31A. [Figure 31B] Figures 31A-B depict the time course of Gal3-mediated fibrin oligomerization over the course of 0-24 hours. Figure 31A shows a dot blot in which fibrin was incubated with or without Gal3 (100 μg / mL each) for 0-24 hours and probed with the oligomer-specific conformational antibody A11. Figure 31B shows the quantification of Figure 31A. [Figure 32] Figure 32 depicts the ability of exemplary anti-Gal3 antibodies TB001 and TB006 to degrade fibrin oligomers. Fibrin and Gal3 at 100 μg / mL each were incubated for 24 hours prior to the addition of Gal3 antibody at concentrations of 0, 3, 10, or 100 μg / mL and incubated for 3 hours. Dot blots of the samples were probed with the A11 antibody. Degradation of fibrin oligomers was observed at all tested concentrations of antibody. [Figure 33A]Figures 33A-C depict the ability of additional exemplary anti-Gal3 antibodies to degrade fibrin oligomers. Figure 33A shows the time course of fibrin aggregation in a dot blot where samples of 100 μg / mL each of fibrin and Gal3 were incubated for 0, 2, 4, 6, or 24 hours and probed with the A11 antibody. Figure 33B shows a dot blot demonstrating the degradation of fibrin oligomers by exemplary anti-Gal3 antibodies, listed according to the assigned numbers shown in Figure 29. 100 μg / mL each of fibrin and Gal3 were incubated for 24 hours prior to the addition of 100 μg / mL of the listed anti-Gal3 antibody clone. The antibody incubation was performed for 24 hours, and samples were probed with the A11 antibody on the dot blot. The dot blot was performed in duplicate for each condition. Figure 33C shows quantification of Figures 33A-B (24 hour time point for fibrin or fibrin / Gal3 alone; and 24 hour fibrin / Gal3 incubation + 24 hour antibody incubation [one of the two duplicates in Figure 33B was quantified]). [Figure 33B] Figures 33A-C depict the ability of additional exemplary anti-Gal3 antibodies to degrade fibrin oligomers. Figure 33A shows the time course of fibrin aggregation in a dot blot where samples of 100 μg / mL each of fibrin and Gal3 were incubated for 0, 2, 4, 6, or 24 hours and probed with the A11 antibody. Figure 33B shows a dot blot demonstrating the degradation of fibrin oligomers by exemplary anti-Gal3 antibodies, listed according to the assigned numbers shown in Figure 29. 100 μg / mL each of fibrin and Gal3 were incubated for 24 hours prior to the addition of 100 μg / mL of the listed anti-Gal3 antibody clone. The antibody incubation was performed for 24 hours, and samples were probed with the A11 antibody on the dot blot. The dot blot was performed in duplicate for each condition. Figure 33C shows quantification of Figures 33A-B (24 hour time point for fibrin or fibrin / Gal3 alone; and 24 hour fibrin / Gal3 incubation + 24 hour antibody incubation [one of the two duplicates in Figure 33B was quantified]). [Figure 33C] Figures 33A-C depict the ability of additional exemplary anti-Gal3 antibodies to degrade fibrin oligomers. Figure 33A shows the time course of fibrin aggregation in a dot blot where samples of 100 μg / mL each of fibrin and Gal3 were incubated for 0, 2, 4, 6, or 24 hours and probed with the A11 antibody. Figure 33B shows a dot blot demonstrating the degradation of fibrin oligomers by exemplary anti-Gal3 antibodies, listed according to the assigned numbers shown in Figure 29. 100 μg / mL each of fibrin and Gal3 were incubated for 24 hours prior to the addition of 100 μg / mL of the listed anti-Gal3 antibody clone. The antibody incubation was performed for 24 hours, and samples were probed with the A11 antibody on the dot blot. The dot blot was performed in duplicate for each condition. Figure 33C shows quantification of Figures 33A-B (24 hour time point for fibrin or fibrin / Gal3 alone; and 24 hour fibrin / Gal3 incubation + 24 hour antibody incubation [one of the two duplicates in Figure 33B was quantified]). [Figure 34] Figure 34 depicts Gal3 induction of cytokine release by activated neutrophils (using an HL60 neutrophil-like cell line model) and inhibition of this effect by anti-Gal3 antibody. Expression of TNF-α, IL-6, and IL-8 was measured by ELISA. [Figure 35A] Figures 35A-C depict Gal3 induction of cytokine release by activated monocytes (using a THP-1 monocyte-like cell line model) and inhibition of this effect by anti-Gal3 antibodies. After 6 or 24 hours of cell incubation, expression of TNF-α (Figure 35A), IL-6 (Figure 35B), and IL-8 (Figure 35C) was measured by ELISA. IL-6 expression was not observed at the 6 hour time point. [Figure 35B]Figures 35A-C depict Gal3 induction of cytokine release by activated monocytes (using a THP-1 monocyte-like cell line model) and inhibition of this effect by anti-Gal3 antibodies. After 6 or 24 hours of cell incubation, expression of TNF-α (Figure 35A), IL-6 (Figure 35B), and IL-8 (Figure 35C) was measured by ELISA. IL-6 expression was not observed at the 6 hour time point. [Figure 35C] Figures 35A-C depict Gal3 induction of cytokine release by activated monocytes (using a THP-1 monocyte-like cell line model) and inhibition of this effect by anti-Gal3 antibodies. After 6 or 24 hours of cell incubation, expression of TNF-α (Figure 35A), IL-6 (Figure 35B), and IL-8 (Figure 35C) was measured by ELISA. IL-6 expression was not observed at the 6 hour time point. [Figure 36] FIG. 36 depicts an exemplary dosing and follow-up diagram for treating acute ischemic stroke (AIS) using TB006 as described in Example 12. DETAILED DESCRIPTION OF THE INVENTION

[0014] Detailed Description of the Disclosure Galectin-3 (Gal3, GAL3) plays a role in cell proliferation, adhesion, differentiation, angiogenesis, and apoptosis. This activity is due, at least in part, to its immunomodulatory properties and binding affinity for other immunomodulatory proteins, signaling proteins, and other cell surface markers.

[0015] Gal3 functions through distinct N- and C-terminal domains. The N-terminal domain (amino acids 1-111 in isoform 1, amino acids 1-125 in isoform 3) contains a tandem repeat domain (TRD, amino acids 36-109 in isoform 1, amino acids 50-123 in isoform 3) and is primarily responsible for Gal3 oligomerization. The C-terminal domain (amino acids 112-250 in isoform 1, amino acids 126-264 in isoform 3) contains a carbohydrate recognition binding domain (CRD) that binds β-galactosides.

[0016] An exemplary sequence of isoform 1 of human Gal3 (NCBI reference number NP_002297.2) is shown in SEQ ID NO: 1. An exemplary sequence of isoform 3 of human Gal3 (NCBI reference number NP_001344607.1) is shown in SEQ ID NO: 2.

[0017] Disclosed herein are methods for inhibiting, reducing, preventing, and / or treating stroke in a subject in need thereof. The method includes administering an anti-Gal3 antibody or binding fragment thereof to the subject, thereby inhibiting, reducing, preventing, and / or treating the stroke. In some embodiments, the stroke is ischemic stroke, thrombotic stroke, embolic stroke, transient ischemic attack, hemorrhagic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage.

[0018] Also disclosed herein are methods for inhibiting, reducing, preventing, and / or treating traumatic brain injury (TBI) in a subject in need thereof. The method includes administering an anti-Gal3 antibody or binding fragment thereof to the subject, thereby inhibiting, reducing, preventing, and / or treating TBI. In some embodiments, TBI is associated with concussion, edema, diffuse axonal injury, spinal cord injury, coma, neuroinflammation, microhemorrhage, astrocytosis, activated microglia, and / or hematoma.

[0019] Also disclosed herein are methods for inhibiting, reducing, preventing, and / or treating a disorder associated with fibrin activity or dysfunction in a subject in need thereof. The method includes administering an anti-Gal3 antibody or binding fragment thereof to the subject, thereby inhibiting, reducing, preventing, and / or treating the disorder associated with fibrin activity or dysfunction. In some embodiments, the disorder associated with fibrin activity or dysfunction includes atherosclerosis, thrombosis, thromboembolism, carotid artery disease, coronary artery disease, peripheral artery disease, myocardial infarction, heart failure, heart attack, hypertension, chronic kidney disease, coagulation disorders, or thrombocytopathy.

[0020] Any and all of the methods provided herein are also contemplated for use in the preparation of a medicament for the treatment of the described disorders and / or as a corresponding composition for use in the treatment of the described disorders.

[0021] In some embodiments, the anti-Gal3 antibody or binding fragment is any one or more of the anti-Gal3 antibodies or binding fragments thereof disclosed herein, or any portion or component of any one or more of the anti-Gal3 antibodies or binding fragments thereof, including, but not limited to, one, two, three, four, five, or six CDRs, a heavy chain variable region, a light chain variable region, a heavy chain, or a light chain.

[0022] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is or comprises any one or more of the sequences set forth in Figures 3A-C, 4A-C, 5, 6, 7, 8, or 9, and comprises any one, two, three, four, five, or six of the CDRs in SEQ ID NOs: 27-538, 801-865, and / or one or both of the VH / VL in SEQ ID NOs: 297-447, 803-865, 926-929. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 in SEQ ID NOs: 27, 71, 112, 170, 221, or 248. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 31, 72, 113, 171, 222, or 249. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 30, 86, 130, 189, 230, or 263. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 34, 74, 116, 174, 225, or 252. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 32, 84, 119, 186, 228, or 255. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 37, 77, 118, 178, 229, 256.In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 34, 74, 126, 187, 225, or 252. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 66, 108, 164, 215, 225, or 291.

[0023] definition In the following detailed description, reference is made to the accompanying drawings, which form a part of this application. In the drawings, like symbols typically identify like components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein and illustrated in the figures, can be arranged, substituted, combined, separated, and designed in a variety of different configurations, all of which are expressly contemplated herein.

[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of any claimed subject matter.

[0025] The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.

[0026] In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. In this application, the use of "or" means "and / or" unless stated otherwise. Furthermore, the use of the term "including" as well as other forms such as "include," "includes," and "included" is not limiting.

[0027] By "about" is meant an amount, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by up to 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1% of the referenced amount, level, value, number, frequency, percentage, dimension, size, amount, weight or length.

[0028] Throughout this specification, unless the context requires otherwise, the words "comprise," "comprises," and "comprising" are understood to imply the inclusion of a recited step or element or group of steps or elements, but not the exclusion of any other step or element or group of steps or elements. By "consisting of," is meant including and limited to whatever precedes the phrase "consisting of." Thus, the phrase "consisting of" indicates that the recited elements are required or mandatory, and that no other elements may be present. By "consisting essentially of," is meant including any elements recited before the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in this disclosure for the recited elements. Thus, the phrase "consisting essentially of" indicates that the recited elements are required or mandatory, but that other elements are optional and may or may not be present depending on whether they substantially affect the activity or action of the recited elements.

[0029] As used herein, the terms "individual," "subject," and "patient" refer to any mammal. In some embodiments, the mammal is a human. In some embodiments, the mammal is a non-human. None of these terms require or are limited to situations characterized by the supervision (e.g., constant or intermittent) of a medical professional (e.g., a doctor, registered nurse, nurse practitioner, physician's assistant, orderly, or hospice worker).

[0030] The terms " polypeptide ", " peptide " and " protein " are used interchangeably herein to refer to any length of amino acid polymer.Polymer may be linear, cyclic or branched, may contain modified amino acids, and may be interleaved with non-amino acids.The term also encompasses the amino acid polymer that has been modified, for example, by sulfation, glycosylation, lipidation, acetylation, phosphorylation, iodination, methylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, transfer RNA-mediated addition of amino acids to protein, for example, arginylation, ubiquitination, or any other manipulation, for example, by conjugation with a labeling component.

[0031] As used herein, the term "amino acid" refers to natural and / or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.

[0032] A polypeptide or amino acid sequence "derived from" a specified protein refers to the origin of the polypeptide. Preferably, the polypeptide has an amino acid sequence that is essentially identical to, or immunologically identifiable with, the polypeptide encoded in the sequence, or a portion thereof consisting of at least 10-20 amino acids, or at least 20-30 amino acids, or at least 30-50 amino acids. This term also includes polypeptides expressed from a specified nucleic acid sequence.

[0033] As used herein, the term "antibody" refers to the meaning ascribed to it by those of skill in the art, and is further intended to include any polypeptide chain-containing molecular structure having a specific shape that fits and recognizes an epitope, where one or more non-covalent binding interactions stabilize the complex between the molecular structure and the epitope. Although antibodies may be polyclonal, monoclonal antibodies may be preferred, because This is because monoclonal antibodies can be reproduced by cell culture or recombinantly and can be modified to reduce their antigenicity.

[0034] In addition to whole immunoglobulins (or their recombinant counterparts), immunoglobulin fragments or "binding fragments" (e.g., Fab', F(ab')2, single-chain variable fragments (scFv), diabodies, minibodies, nanobodies, single-domain antibodies (sdAb), or other fragments) containing the epitope-binding site are useful as antibody portions in the present invention. Such antibody fragments may be generated from whole immunoglobulins by ricin, pepsin, papain, or other protease cleavage. Minimal immunoglobulins may also be engineered using recombinant immunoglobulin technology. For example, "Fv" immunoglobulins for use in the present invention may be produced by linking the light chain variable region to the heavy chain variable region via a peptide linker (e.g., polyglycine or another sequence that does not form an alpha-helix or beta-sheet motif). Nanobodies or single-domain antibodies can also be derived from alternative organisms, such as dromedaries, camels, llamas, alpacas, or sharks. In some embodiments, the antibody can be a conjugate, such as a pegylated antibody, a drug, a radioisotope, or a toxin conjugate. Monoclonal antibodies directed against a specific epitope or a combination of epitopes can target and / or deplete cell populations that express markers. A variety of techniques are available that use monoclonal antibodies to screen cell populations that express markers, including magnetic separation using antibody-coated magnetic beads, "panning" with antibodies attached to a solid matrix (i.e., plate), and flow cytometry (e.g., U.S. Pat. No. 5,985,660, the entire contents of which are expressly incorporated herein by reference).

[0035] As known in the art, the term "Fc region" is used to define the C-terminal region of an immunoglobulin heavy chain. The "Fc region" may be a native sequence Fc region or a variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain can vary, the human IgG heavy chain Fc region is usually defined as extending from the amino acid residue at position Cys226 or Pro230 to its carboxyl terminus. The numbering of residues in the Fc region is that of the EU index as in Kabat. Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991. The Fc region of an immunoglobulin generally contains two constant domains, CH2 and CH3. As known in the art, the Fc region can exist in a dimeric or monomeric form.

[0036] As known in the art, a "constant region" of an antibody refers to the constant region of the antibody light chain or the constant region of the antibody heavy chain, either alone or in combination.

[0037] The "variable region" of an antibody refers to the variable region of the antibody light chain or the variable region of the antibody heavy chain, either alone or in combination. As is known in the art, each of the variable regions of the heavy and light chains consists of four framework regions (FRs) connected by three complementarity-determining regions (CDRs), also known as hypervariable regions, and contributes to the formation of the antigen-binding site of the antibody. When a variant of a target variable region is desired, particularly a variant having a substitution at an amino acid residue outside the CDR region (i.e., in the framework region), appropriate amino acid substitutions, preferably conservative amino acid substitutions, can be identified by comparing the target variable region with the variable regions of other antibodies containing the CDR1 and CDR2 sequences of the same canonical class as the target variable region (Chothia and Lesk, J Mol Biol 196(4): 901-917, 1987).

[0038] In some embodiments, definitive delineation of CDRs and identification of the residues that constitute the antibody binding site are achieved by solving the structure of the antibody and / or the structure of the antibody-ligand complex. In certain embodiments, this can be achieved by any of a variety of techniques known to those skilled in the art, such as X-ray crystallography. In certain embodiments, various methods of analysis can be used to identify or approximate CDR regions. In certain embodiments, various methods of analysis can be used to identify or approximate CDR regions. Examples of such methods include, but are not limited to, the Kabat definition, the Chothia definition, the IMGT approach (Lefranc et al., 2003, Dev Comp Immunol. 27:55-77), computer programs such as Paratome (Kunik et al., 2012, Nucl Acids Res. W521-4), the AbM definition, and conformational definition.

[0039] The Kabat definition is a standard for numbering residues in antibodies and is typically used to identify CDR regions. See, for example, Johnson & Wu, 2000, Nucleic Acids Res., 28: 214-8. The Chothia definition is similar to the Kabat definition, but takes into account the location of certain structural loop regions. See, for example, Chothia et al., 1986, J. Mol. Biol., 196: 901-17; Chothia et al., 1989, Nature, 342: 877-83. The AbM definition uses a unified set of computer programs produced by the Oxford Molecular Group to model antibody structure. See, e.g., Martin et al., 1989, Proc Natl Acad Sci (USA), 86:9268-9272; 'AbM.TM., A Computer Program for Modeling Variable Regions of Antibodies,' Oxford, UK; Oxford Molecular, Ltd. The AbM definition models the tertiary structure of antibodies from primary sequence using a combination of knowledge databases and ab initio methods, such as those described by Samudrala et al., 1999, 'Ab Initio Protein Structure Prediction Using a Combined Hierarchical Approach,' PROTEINS, Structure, Function and Genetics Suppl., 3:194-198. The contact definition is based on an analysis of available complex crystal structures. See, e.g., MacCallum et al., 1996, J. Mol. Biol., 5:732-45. In another approach, referred to herein as the "conformational definition" of CDRs, the positions of the CDRs may be identified as residues that contribute enthalpic- ically to antigen binding.See, e.g., Makabe et al., 2008, Journal of Biological Chemistry, 283:1156-1166. Still other CDR boundary definitions may not strictly adhere to one of the above approaches, but nevertheless overlap with at least a portion of the Kabat CDRs, provided that they may be shortened or extended in light of predictions or experimental findings that particular residues or groups of residues do not significantly affect antigen binding. As used herein, CDR may refer to CDRs defined by any approach known in the art, including combinations of approaches. The methods used herein may utilize CDRs defined according to any of these approaches. For any given embodiment containing more than one CDR, the CDRs may be defined according to any of the Kabat, Chothia, extended, IMGT, Paratome, AbM, and / or conformational definitions, or any combination thereof.

[0040] As disclosed herein, sequences having a certain percent identity to any of the sequences disclosed herein are contemplated and may be used. The term "% identity" refers to the percentage of units (i.e., amino acids or nucleotides) that are identical between two or more sequences relative to the length of the sequences. If the two or more sequences being compared are the same length, the percent identity is for each of those lengths. If the two or more sequences being compared are of different lengths, deletions and / or insertions may be introduced to achieve the best alignment. In some embodiments, these sequences may include peptide sequences, nucleic acid sequences, CDR sequences, variable region sequences, or heavy or light chain sequences. In some embodiments, any sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any of the sequences disclosed herein may be used. In some embodiments, any sequence having at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 substitutions, deletions, or additions compared to any of the sequences disclosed herein may be used. Changes in sequence may apply to, for example, single amino acids, single nucleic acid bases, or nucleic acid codons; although differences in longer stretches of sequence are also contemplated. When applied to antibody sequences, these differences in sequence may apply to antigen-binding regions (e.g., CDRs) or to regions that do not bind to antigen or are only secondary to antigen binding (e.g., framework regions).

[0041] As disclosed herein, sequences having a certain percent homology to any of the sequences disclosed herein are contemplated and may be used. The term "% homology" refers to the degree of conservation between two sequences when considering three-dimensional structure. For example, homology between two protein sequences may depend on structural motifs, such as beta-strands, alpha-helices, and other folds, as well as their distribution throughout the sequences. Homology may be determined through structural determination, either empirically or in silico. In some embodiments, any sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence homology to any of the sequences disclosed herein may be used. In some embodiments, any sequence with at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 substitutions, deletions, or additions compared to any of the sequences disclosed herein, which may or may not affect the overall % homology, may be used.

[0042] As applied herein, sequences having a certain percentage of similarity to any of the sequences disclosed herein are contemplated and may be used. In some embodiments, these sequences may include peptide sequences, nucleic acid sequences, CDR sequences, variable region sequences, or heavy or light chain sequences. As understood in the art with respect to peptide sequences, "similarity" refers to a comparison of amino acids based on their properties, including, but not limited to, size, polarity, charge, pK, aromaticity, hydrogen-bonding properties, or the presence of functional groups (e.g., hydroxyl, thiol, amine, carboxyl, etc.). The term "% similarity" refers to the percentage of units (i.e., amino acids) that are identical between two or more sequences relative to the length of the sequences. If the two or more sequences being compared are the same length, the % similarity is their respective lengths. If the two or more sequences being compared are different lengths, deletions and / or insertions may be introduced to achieve optimal alignment. The similarity of two amino acids may define whether a particular substitution is conservative or non-conservative. Methods for determining the conservatism of amino acid substitutions are generally known in the art and may involve substitution matrices. Commonly used substitution matrices include BLOSUM45, BLOSUM62, BLOSUM80, PAM100, PAM120, PAM160, PAM200, and PAM250, although other substitution matrices or approaches may be used as deemed appropriate by those skilled in the art. Certain substitution matrices may be preferred over others when considering factors such as stringency, conservation and / or differences of related sequences (e.g., within the same or broader species), and the length of the sequence in question. As used herein, a peptide sequence having a certain percentage of similarity to another sequence has a maximum percentage of amino acids that are identical or allowable substitutions as governed by the method of determining similarity used.In some embodiments, sequences having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity to any of the sequences disclosed herein may be used. In some embodiments, any sequence having at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 similar substitutions compared to any of the sequences disclosed herein may be used. When applied to antibody sequences, these similar substitutions may be applied to antigen-binding regions (i.e., CDRs) or to regions that do not bind antigen or are only secondary to antigen binding (i.e., framework regions).

[0043] The term "consensus sequence," as used herein with respect to a sequence, refers to a generalized sequence that represents all of the different combinations of allowable amino acids at each position in a group of sequences. Consensus sequences can provide insight into conserved regions of related sequences, where units (e.g., amino acids or nucleotides) are the same in most or all of the sequences, and regions that exhibit differences between sequences. In the case of antibodies, consensus sequences for CDRs can indicate important or essential amino acids for antigen binding. It is contemplated that consensus sequences can be prepared using any of the sequences provided herein, and that the resulting various sequences derived from the consensus sequence can be verified to have similar effects as the template sequence.

[0044] The term "compete," as used herein with respect to antibodies, means that a first antibody, or antigen-binding portion thereof, binds to an epitope in a manner sufficiently similar to that of a second antibody, or antigen-binding portion thereof, such that the binding of the first antibody to its cognate epitope is detectably reduced in the presence of the second antibody compared to the binding of the first antibody in the absence of the second antibody. The option of the second antibody also being detectably reduced in the presence of the first antibody is also possible, but not necessarily true. That is, a first antibody can inhibit the binding of a second antibody to its epitope without the second antibody inhibiting the binding of the first antibody to its respective epitope. However, if each antibody detectably inhibits binding of the other antibody to its cognate epitope or ligand, whether to the same, greater, or lesser extent, the antibodies are said to "cross-compete" with each other for binding of their respective epitopes. Both competing and cross-competing antibodies are encompassed by the present invention. Regardless of the mechanism by which such competition or cross-competition occurs (e.g., steric hindrance, conformational change, or binding to a common epitope, or portion thereof), one of skill in the art will be able to determine, based on the teachings provided herein, the nature of the antibodies that such competing and / or cross-competing antibodies encompass. It is understood that such methods may be useful for the methods disclosed herein.

[0045] An antibody that "preferentially binds" or "specifically binds" (used interchangeably herein) to an epitope is a term well understood in the art, and methods for determining such specific or preferential binding are also well known in the art. A molecule is said to exhibit "specific binding" or "preferential binding" if it reacts or associates with a particular cell or substance more frequently, more rapidly, and / or with a longer duration and / or with a higher affinity than with alternative cells or substances. An antibody "specifically binds" or "preferentially binds" to a target if it binds with higher affinity, and / or avidity, and / or more readily and / or with a longer duration than it binds to other substances. For example, an antibody that specifically or preferentially binds to a target epitope is an antibody that binds to this epitope with higher affinity, and / or avidity, and / or more readily and / or with a longer duration than it binds to other target epitopes or non-target epitopes. It is understood by reading this definition that, for example, an antibody (or portion or epitope) that specifically or preferentially binds to a first target may or may not also specifically or preferentially bind to a second target. Thus, "specific binding" or "preferential binding" does not necessarily require (although can include) exclusive binding. Generally, although not necessarily, reference to binding means preferential binding.

[0046] The term "blocking" or "interfering" as used herein with respect to an antibody refers to the ability of an antibody to interfere with a biological process, including, but not limited to, the activity of an enzyme, the binding of two or more biological molecules (e.g., two or more proteins, peptides, nucleic acids, and lipids, etc.), or the progression of a signal transduction cascade. Generally, interference with a biological process involves the antibody binding to its target or its epitope, thereby interfering with the normal function of the target, for example, by blocking the active site of the target, blocking another region of the target that is important for its function, or altering the localization and / or transport of the target. Blocking or interfering with the activity of an antibody may be quantified in terms of the reduction of the biological process compared to a control condition in which the biological process in question is not interfered with. In other cases, blocking or interfering with the activity of an antibody may be quantified in terms of the modulation of another biological process known to be associated with the target biological process, whether directly or inversely related. In some embodiments, blocking or preventing activity may result in a change of at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, or any percentage within a range defined by any two of the above values, compared to control conditions. In some embodiments provided herein, the interaction between Gal3 and fibrin is a biological process that can be disrupted by anti-Gal3 antibodies. It is contemplated that the interaction between Gal3 and fibrin may or may not be a direct interaction between Gal3 and fibrin, and that anti-Gal3 antibodies may interfere with some other aspect of the activity of Gal3 and / or fibrin.

[0047] As used herein, the term "antigen-binding molecule" refers to a molecule comprising an antigen-binding portion that binds to an antigen and, optionally, a scaffold or framework portion that allows the antigen-binding portion to adopt a conformation that facilitates binding of the antigen-binding portion or provides some additional property to the antigen-binding molecule. In some embodiments, the antigen is Gal3. In some embodiments, the antigen-binding portion comprises at least one CDR from an antibody that binds to the antigen. In some embodiments, the antigen-binding portion comprises all three CDRs from the heavy chain of the antibody that binds the antigen or from the light chain of the antibody that binds the antigen. In some embodiments, the antigen-binding portion comprises all six CDRs (three from the heavy chain and three from the light chain) from an antibody that binds the antigen. In some embodiments, In embodiments, the antigen-binding portion is an antibody fragment.

[0048] Non-limiting examples of antigen-binding molecules include antibodies, antibody fragments (e.g., antigen-binding fragments of antibodies), antibody derivatives, and antibody analogs. Further specific examples include, but are not limited to, single-chain variable fragments (scFv), nanobodies (e.g., VH domains of camelid heavy chain antibodies; VHH fragments, see Cortez-Retamozo et al., Cancer Research, Vol. 64:2853-57, 2004), Fab fragments, Fab' fragments, F(ab')2 fragments, Fv fragments, Fd fragments, and complementarity-determining region (CDR) fragments. These molecules can be derived from any mammalian source, such as humans, mice, rats, rabbits, pigs, dogs, cats, horses, donkeys, guinea pigs, goats, or camelids. Antibody fragments may compete with intact antibodies for target antigen binding, and fragments may be produced by modifying intact antibodies (e.g., enzymatic or chemical cleavage) or by de novo synthesis using recombinant DNA technology or peptide synthesis. Antigen-binding molecules can include, for example, alternative protein scaffolds or artificial scaffolds with grafted CDRs or CDR derivatives. Such scaffolds include, but are not limited to, antibody-derived scaffolds containing introduced mutations to stabilize the three-dimensional structure of the antigen-binding molecule, as well as entirely synthetic scaffolds, including, for example, biocompatible polymers. See, for example, Korndorfer et al., 2003, Proteins: Structure, Function, and Bioinformatics, Volume 53, Issue 1:121-129 (2003); Roque et al., Biotechnol. Prog. 20:639-654 (2004). Additionally, besides peptide antibody mimics ("PAMs"), antibody mimic-based scaffolds that utilize a fibronectin component as the scaffold can be used.

[0049] Antigen-binding molecules can also include proteins comprising one or more antibody fragments incorporated into a single polypeptide chain or into multiple polypeptide chains. For example, antigen-binding molecules can include diabodies (see, e.g., EP 404,097; WO 93 / 11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, Vol. 90:6444-6448, 1993); intrabodies; domain antibodies (a single VL or VH domain or two or more VH domains joined by a peptide linker; see Ward et al., Nature, Vol. 341:544-546, 1989); maxibodies (two scFvs fused to an Fc region; see Fredericks et al., Protein Engineering, Design & Selection, Vol. 17:95-106, 2004 and Powers et al., Journal of Immunological Methods, Vol. 251:123-135, 2001); triabodies; tetrabodies; minibodies (scFvs fused to a CH3 domain; see Olafsen et al., Protein Eng Des Sel., Vol. 17:315-23, 2004); peptibodies (one or more peptides attached to an Fc region, see WO 00 / 24782); linear antibodies (a pair of tandem Fd segments, VH-CH1-VH-CH1, which, together with complementary light chain polypeptides, form a pair of antigen-binding regions, see Zapata et al., Protein Eng., Vol. 8:1057-1062, 1995); small modular immunopharmaceuticals (see U.S. Patent Application Publication No. 20030133939); and immunoglobulin fusion proteins (e.g., IgG-scFv, IgG-Fab, 2scFv-IgG, 4scFv-IgG, VH-IgG, IgG-VH, and Fab-scFv-Fc).

[0050] In certain embodiments, the antigen-binding molecule can have the structure of, for example, an immunoglobulin. An "immunoglobulin" is a tetrameric molecule, with each tetramer containing two identical pairs of polypeptide chains, each pair having one "light" chain (approximately 25 kDa) and one "heavy" chain (approximately 50-70 kDa). The amino-terminal portion of each chain contains a variable region of approximately 100-110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.

[0051] Unless otherwise specified, the complementarity defining regions disclosed herein are according to the IMGT definition. In some embodiments, any of the CDRs disclosed herein may alternatively be interpreted according to Kabat, Chothia, or other definitions accepted by those of skill in the art.

[0052] The term "humanized" when applied to non-human (e.g., rodent or primate) antibodies is a hybrid immunoglobulin, immunoglobulin chain or fragment thereof that contains minimal sequence derived from non-human immunoglobulin.

[0053] As used herein, the term "cytokine" refers to a small protein, polypeptide, or peptide involved in inflammatory signaling, or a protein released by one cell population to act as an intercellular mediator in another cell or that has an autocrine effect in the cell that produces the protein.Cytokines include chemokines, interferons, interleukins, lymphokines, monokines, tumor necrosis factors, CCL1, CCl2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, and CCL22. , CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8 , CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL17, CX3CL1, XCL1, XCL2, INFα , INFβ, INFγ, IL-1, IL-1α, IL-1β, IL-1Ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL- 11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-17A-F, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, IL-36, IL-36R a, IL-36α, IL-36β, IL-36γ, IL-37, IL-38, adesleukin, GM-CSF, TNFα, TNFβ, TNFγ, TGF-I-3 including, but not limited to, TNFSF4, TNFSF5, TNFSF6, TNFSF7, TNFSF8, TNFSF9, TNFSF10, TNFSF11, TNFSF12, TNFSF13, TNFSF13B, TNFSF14, TNFSF15, TNFSF18, or TNFSF19, leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), CNTF-like cytokine (CLC), cardiotrophin (CT), Kit ligand (KL), or any combination thereof.

[0054] As used herein, the terms "treat" or "treatment," as well as related terms such as "inhibit," "reduce," and "prevent" (as well understood in the art), refer to an approach for obtaining beneficial or desired results in a subject's condition, including clinical results. Beneficial or desired clinical results may be partial or total, and may be detectable or undetectable. "Prevention" can include, but is not limited to, alleviation or amelioration of one or more symptoms or conditions, reduction in the extent of the disease, stabilization of the disease state (i.e., not worsening), prevention of the spread or spread of the disease, delay or slowing of disease progression, remission or palliation of the disease state, reduction in disease recurrence, and remission. As provided herein, "prevention" may include one or more of "inhibition" or "reduction." "Treating" and "treatment," as used herein, may include therapeutic treatment (e.g., in response to an existing disease state) and / or prophylactic treatment (e.g., to prevent the onset or severity of an anticipated disease state). A method of treatment involves administering a therapeutically effective amount of an active agent to a subject. The administering step may consist of a single administration or may include a series of administrations. The composition is administered to the subject in an amount and for a duration sufficient to treat the subject. The length of the treatment period depends on various factors, such as the severity of the condition, the age and genetic profile of the subject, the concentration of the active agent, the activity of the composition used in the treatment, or a combination thereof. It is also understood that the effective dosage of an agent used for treatment or prevention may increase or decrease over the course of a particular treatment or prevention regime. Variations in dosage may be effected and revealed by standard diagnostic assays known in the art. In some cases, chronic administration may be required.

[0055] The term "effective amount" or "effective dose," as used herein, has its plain and ordinary meaning as understood in light of the present specification and refers to the amount of the described composition or compound that results in an observable, specified effect. The actual dosage level of the active ingredient in the active composition of the presently disclosed subject matter can be varied to administer an amount of the active composition or compound that is effective to achieve the specified response for a specific subject and / or application. The selected dosage level can be varied based on various factors, including, but not limited to, the activity of the composition, formulation, route of administration, combination with other drugs or treatments, the severity of the condition being treated, and the physical condition and past medical history of the subject being treated. In some embodiments, a minimum dose is administered, and the dose is titrated to the minimum effective amount in the absence of dose-limiting toxicity. In addition to determining and adjusting the effective dose, evaluation of the time and method for making such adjustments is contemplated herein.

[0056] In some non-limiting embodiments, an effective amount or dose of a composition or compound may refer to an amount or dose that provides a significant, measurable, or sufficient therapeutic effect toward the treatment of any one or more of the diseases provided herein, such as cardiovascular disease, e.g., stroke, traumatic brain injury, cerebral amyloid angiopathy, atherosclerosis, myocardial infarction, and / or diseases associated with fibrin activity or dysfunction, or cancer. In some embodiments, an effective amount or dose of a composition or compound may treat, ameliorate, or prevent the progression of any one or more symptoms of the diseases provided herein.

[0057] The term "administering" includes oral administration, topical contact, administration as a suppository, intravenous, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal, or subcutaneous administration to a subject, or implantation of a delayed-release device, such as a mini-osmotic pump. Administration can be by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration can include, for example, intravenous, intramuscular, intraarteriolar, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, and the like. By "co-administering" is meant that a first compound described herein is administered simultaneously with, immediately before, or immediately after the administration of a second compound described herein.

[0058] As used herein, the term "therapeutic target" refers to a target whose activity, modulation of which (e.g., by modulation of expression, biological activity, etc.) results in a phenotype that is highly susceptible to disease. "Modulation" refers to a gene or gene product that can provide modulation. As used throughout, "modulation" is meant to refer to an increase or decrease in the phenomenon referred to (e.g., modulation of biological activity refers to an increase in biological activity or a decrease in biological activity).

[0059] As used herein, "pharmaceutically acceptable" refers to a carrier, excipient, and / or stabilizer that has its plain and ordinary meaning as understood in light of the present specification and that is non-toxic or has an acceptable level of toxicity to cells or mammals exposed thereto at the dosages and concentrations employed. "Pharmaceutically acceptable," "diluent," "excipient," and / or "carrier," as used herein, has its plain and ordinary meaning as understood in light of the present specification and is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, that are compatible with administration to humans, felines, dogs, or other vertebrate hosts. Typically, pharmaceutically acceptable diluents, excipients, and / or carriers are those that have been approved by federal, state, or other regulatory agencies or are listed in the U.S. Pharmacopoeia or other generally recognized pharmacopeia for use in animals, including non-human mammals such as cats and dogs, in addition to humans. The terms diluent, excipient, and / or carrier can refer to a diluent, adjuvant, vehicle, or vehicle with which a pharmaceutical formulation is administered. Such pharmaceutical diluents, excipients, and / or carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin. Water, saline solution, and aqueous dextrose and glycerol solutions can be used as liquid diluents, excipients, and / or carriers, particularly for injectable solutions. Suitable pharmaceutical diluents and / or excipients include sugar, starch, glucose, fructose, lactose, sucrose, maltose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, salt, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, and ethanol. A non-limiting example of a physiologically acceptable carrier is an aqueous pH-buffered solution.Physiologically acceptable carriers may also contain one or more of the following: antioxidants, such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, such as serum albumin, gelatin, immunoglobulins, hydrophilic polymers, such as polyvinylpyrrolidone, amino acids, carbohydrates, such as glucose, mannose, or dextrin, chelating agents, such as EDTA, sugar alcohols, such as glycerol, erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, isomalt, maltitol, or lactitol, salt-forming counterions, such as sodium, and nonionic surfactants, such as TWEEN®, polyethylene glycol (PEG), and PLURONICS®. Preparations may also contain minor amounts of wetting agents, bulking agents, emulsifiers, or pH buffering agents, if desired. These preparations may take the form of solutions, suspensions, emulsions, sustained-release formulations, and the like. The formulation should suit the mode of administration.

[0060] The term "pharmaceutically acceptable salts" has its plain and ordinary meaning as understood in light of this specification and includes relatively non-toxic, inorganic and organic acid or base addition salts of compositions or excipients, including, but not limited to, analgesics, therapeutic agents, and other materials. Examples of pharmaceutically acceptable salts include those derived from mineral acids, such as hydrochloric acid and sulfuric acid, and those derived from organic acids, such as ethanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid. Examples of suitable inorganic bases for the formation of salts include hydroxides, carbonates, and bicarbonates of ammonia, sodium, lithium, potassium, calcium, magnesium, aluminum, zinc, and the like. Salts are also non-toxic and The salts may be formed with suitable organic bases, including organic bases strong enough to form such salts. For example, classes of such organic bases may include, but are not limited to, mono-, di-, and tri-alkylamines, including methylamine, dimethylamine, and triethylamine; mono-, di-, or trihydroxyalkylamines, including mono-, di-, and triethanolamine; amino acids, including glycine, arginine, and lysine; guanidine; N-methylglucosamine; N-methylglucamine; L-glutamine; N-methylpiperazine; morpholine; ethylenediamine; N-benzylphenethylamine; and trihydroxymethylaminoethane.

[0061] As used herein, "carrier" refers to a compound, particle, solid, semi-solid, liquid, or diluent that facilitates the passage, delivery, and / or incorporation of a compound into cells, tissues, and / or body organs. For example, but not limited to, lipid nanoparticles (LNPs) are a type of carrier that can encapsulate oligonucleotides, thereby protecting them from degradation during bloodstream passage and / or facilitating delivery to a desired organ, such as the lung.

[0062] As used herein, "diluent" refers to an ingredient in a pharmaceutical composition that lacks pharmacological activity but may be pharmaceutically necessary or desirable. For example, a diluent may be used to increase the bulk of a potent drug whose mass is too small for production and / or administration. It may also be a liquid for dissolving a drug to be administered by injection, ingestion, or inhalation. A common form of diluent in the art is a buffered aqueous solution, such as, but not limited to, phosphate-buffered saline, which mimics the composition of human blood.

[0063] The term "excipient" has its ordinary meaning as understood in light of the present specification and refers to an inert substance, compound, or material added to a pharmaceutical composition to provide the composition with, but not limited to, bulk, consistency, stability, binding capacity, lubrication, disintegration capacity, etc. Excipients with desirable properties include preservatives, adjuvants, stabilizers, solvents, buffers, diluents, solubilizers, detergents, surfactants, chelating agents, antioxidants, alcohols, ketones, aldehydes, ethylenediaminetetraacetic acid (EDTA), citric acid, salts, sodium chloride, sodium bicarbonate, sodium phosphate, sodium borate, sodium citrate, potassium chloride, potassium phosphate, magnesium sulfate, sugars, dextrose, dextran, fructose, mannose, lactose, galactose, sucrose, sorbitol, cellulose, methylcellulose, etc. The additives and / or additives may include, but are not limited to, cellulose, hydroxypropyl methylcellulose (hypromellose), glycerin, polyvinyl alcohol, povidone, propylene glycol, serum, amino acids, polyethylene glycol, polysorbate 20, polysorbate 80, sodium deoxycholate, sodium taurodeoxycholate, magnesium stearate, octylphenol ethoxylate, benzethonium chloride, thimerosal, gelatin, esters, ethers, 2-phenoxyethanol, urea, or vitamins, or any combination thereof. The amount of excipient may be found in the pharmaceutical composition in a percentage of 0%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100% w / w or any weight percentage within a range defined by any two of the aforementioned numbers.

[0064] Additional excipients with desirable properties include preservatives, adjuvants, stabilizers, solvents, buffers, diluents, solubilizers, detergents, surfactants, chelating agents, antioxidants, alcohols, ketones, aldehydes, ethylenediaminetetraacetic acid (EDTA), tris(hydroxymethyl)aminomethane (Tris), citric acid, ascorbic acid, acetic acid, salts, phosphates, and citrates. , acetate, succinate, chloride, bicarbonate, borate, sulfate, sodium chloride, sodium bicarbonate, sodium phosphate, sodium borate, sodium citrate, potassium chloride, potassium phosphate, magnesium sulfate, sugar, dextrose, dextran 40, fructose, mannose, lactose, trehalose, galactose, sucrose, sorbitol, mannitol, cellulose, serum, amino acids, alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, Examples of excipients include, but are not limited to, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, poloxamer, poloxamer 188, sodium deoxycholate, sodium taurodeoxycholate, magnesium stearate, octylphenol ethoxylate, benzethonium chloride, thimerosal, gelatin, esters, ethers, 2-phenoxyethanol, urea, or vitamins, or any combination thereof. Some excipients may be in residual quantities or contaminants from the production process, including, but not limited to, serum, albumin, ovalbumin, antibiotics, inactivators, formaldehyde, glutaraldehyde, β-propiolactone, gelatin, cell debris, nucleic acids, peptides, amino acids, or growth medium components, or any combination thereof. The amount of excipient may be found in the formulation in a percentage that is at least 0%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100% w / w or any weight percentage within a range defined by any two of the aforementioned numbers.

[0065] The term "purity" of any given substance, compound, or material, as used herein, refers to the actual amount of the substance, compound, or material present compared to the expected amount. For example, the substance, compound, or material may be at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% pure, including all decimal points in between. Purity may be affected by undesired impurities, including, but not limited to, by-products, isomers, enantiomers, degradation products, solvents, carriers, media, or contaminants, or any combination thereof. Purity may be measured by techniques, including, but not limited to, chromatography, liquid chromatography, gas chromatography, spectroscopy, UV-visible spectroscopy, infrared spectroscopy, mass spectrometry, nuclear magnetic resonance, gravimetry, or titration, or any combination thereof.

[0066] As used herein, the terms "standard of care," "best practice," and "standard therapy" refer to a treatment that is accepted by physicians as being appropriate, reasonable, effective, and / or widely used for a particular disease. The standard of care for a particular disease depends on many different factors, including the biological effectiveness of the treatment, the area or location in the body, the patient's condition (e.g., age, weight, sex, genetic risk, other disorders, secondary conditions), toxicity, metabolism, bioaccumulation, therapeutic index, dosage, and other factors known in the art. Determining the standard of care for a disease also depends on establishing safety and efficacy in clinical trials as standardized by regulatory agencies, such as the U.S. Food and Drug Administration, the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Health Canada, the European Medicines Agency, the Australian Therapeutic Goods Administration, the Central Drugs Standards Administration of India, the National Medical Products Administration of China, the Pharmaceuticals and Medical Devices Agency, the Korea Food and Drug Safety Agency, and the World Health Organization. Standard treatments for a disease may include, but are not limited to, surgery, radiation, chemotherapy, targeted therapy, or immunotherapy.

[0067] As used herein, the term "inhibit" refers to a decrease or reduction in an expected activity, e.g., cellular activity. A decrease or reduction can be at least 5%, 10%, 20%, or more. The reduction or decrease in expected activity may be 30%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, or any percentage within a range defined by any two of the above values, with a 100% reduction or decrease indicating complete inhibition and any lower percentage indicating partial inhibition. The reduction or decrease in expected activity may be observed in a direct or indirect manner.

[0068] As used herein, the term "stroke" refers to a medical disorder that involves the interruption of the normal blood flow that supplies the brain. Generally, stroke has two categories: ischemic stroke (including thrombotic stroke, embolic stroke, or transient ischemic attack), which is caused by blood clot, blood vessel compression, or blockage due to atherosclerotic plaque, and blood vessel blockage leads to bleeding in the brain, and hemorrhagic stroke (including intracerebral hemorrhage or subarachnoid hemorrhage), which can be caused by aneurysm rupture or physical trauma, which is caused by blood vessel blockage leading to bleeding in the brain. Stroke symptoms include neurological problems, such as paralysis, loss of sensation, loss of vision, dizziness, difficulty speaking, or problems with cognitive ability. Patients who have stroke or are at risk of developing stroke can be selected by evaluating causative factors, such as high blood pressure, smoking, obesity, high blood cholesterol, diabetes, kidney disease, or cardiac dysfunction. As disclosed herein, the compositions disclosed herein may be used for the treatment or prevention of stroke or symptoms thereof, including those provided herein or otherwise known in the art.

[0069] As used herein, the term "traumatic brain injury (TBI)" refers to a medical condition involving damage to the brain caused by external forces, such as blunt trauma, a fall, a collision, a sudden change in acceleration, or an explosion. External forces exerted on the brain can result in damage to brain tissue and consequent loss of function in the affected area. Symptoms, which may vary in severity based on the severity of the TBI, can include dizziness, headache, vomiting, lethargy, increased intracranial pressure, edema, loss of consciousness, and problems with cognitive ability. Patients with traumatic brain injury may be evaluated by medical examination after the traumatic injury. Individuals at risk of developing traumatic brain injury may be evaluated based on their lifestyle, such as occupation, hobbies, age, or behavioral trends. As disclosed herein, the compositions disclosed herein may be used for the treatment or prevention of TBI or its symptoms, including those provided herein or otherwise known in the art.

[0070] As used herein, the term "fibrin" refers to a protein involved in blood clotting and also known as "factor Ia." In vascular obstruction, circulating fibrinogen is proteolytically processed by thrombin to form fibrin, which polymerizes to form an insoluble network that, among other functions, traps platelets to block vascular injury, preventing additional blood leakage, as well as preventing the entry of foreign substances, such as pathogens. Activity of fibrin and other components of the coagulation cascade can lead to harmful clots and thrombosis. As disclosed herein, the compositions disclosed herein may be used for the treatment or prevention of disorders or symptoms associated with fibrin activity or dysfunction, including those provided herein or otherwise known in the art.

[0071] The terms "% w / w" or "% wt / wt" refer to the percentage expressed by the weight of a component or agent relative to the total weight of the composition, multiplied by 100.

[0072] It is understood that antibodies having an antibody name described herein may be referred to using a shortened version of the antibody name, provided there is no conflict with another antibody described herein. For example, F846C.1B2 may also be referred to as 846C.1B2, or 846.1B2. This also applies to fragments of antibodies (e.g., fragments having the same one, three, or six CDRs). It can refer to

[0073] Exemplary Methods of Treatment and / or Use Any of the anti-Gal3 antibodies or binding fragments thereof, or antigen-binding molecules, and formulations thereof provided herein may be used in the methods provided herein.

[0074] Disclosed herein in some embodiments are methods for inhibiting, reducing, preventing, and / or treating stroke in a subject in need thereof. The methods include administering an anti-Gal3 antibody or binding fragment thereof to the subject, thereby inhibiting, reducing, preventing, and / or treating stroke. In some embodiments, any of the methods disclosed herein involving an anti-Gal3 antibody or binding fragment may be carried out using an antigen-binding molecule that binds to Gal3.

[0075] In some embodiments, methods are disclosed for inhibiting, reducing, preventing, and / or treating traumatic brain injury (TBI) in a subject in need thereof. In some embodiments, the method comprises administering an anti-Gal3 antibody or binding fragment thereof to the subject, thereby inhibiting, reducing, preventing, and / or treating TBI.

[0076] In some embodiments, methods are disclosed for inhibiting, reducing, preventing, and / or treating a disorder associated with fibrin activity or dysfunction in a subject in need thereof. In some embodiments, the method comprises administering an anti-Gal3 antibody or binding fragment thereof to the subject, thereby inhibiting, reducing, preventing, and / or treating the disorder associated with fibrin activity or dysfunction.

[0077] In some embodiments, a method for administering an anti-Gal3 antibody or binding fragment thereof is disclosed. In some embodiments, the method includes administering 5 unit doses of an anti-Gal3 antibody or binding fragment thereof, each unit dose containing 1000 mg or about 1000 mg of the anti-Gal3 antibody or binding fragment thereof, the unit doses being administered every 7 days or about every 7 days, and each unit dose being administered over 1 hour or about 1 hour.

[0078] In some embodiments, a single-use sealed glass vial for injection is disclosed. In some embodiments, the single-use sealed glass vial for injection contains 8 mL of 20 mg / mL anti-Gal antibody or binding fragment thereof.

[0079] In some embodiments, an IV infusion bag is disclosed, in some embodiments, the IV infusion bag comprises 1000 mg or about 1000 mg of an anti-Gal3 antibody or binding fragment thereof dissolved in 250 mL or about 250 mL of saline.

[0080] In some embodiments, the method further comprises selecting the subject as having or at risk of having a stroke prior to the administering step. In some embodiments, selecting the subject as having or at risk of having a stroke comprises evaluating the subject according to the National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), Fugl-Meyer Assessment (FMA), Montreal Cognitive Assessment (MoCA), neuroimaging (e.g., CT or MRI), and / or detecting stroke biomarkers (including, but not limited to, S100 calcium-binding protein B (S100B), glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), and / or matrix metalloproteinase-9 (MMP9)). In some embodiments, the method further comprises detecting amelioration of symptoms associated with stroke after the administering step. In some embodiments, stroke is ischemic stroke, thrombotic stroke, embolic stroke, transient ischemic attack, hemorrhagic stroke, intracerebral hemorrhage or subarachnoid hemorrhage.In some embodiments, stroke is intracerebral hemorrhage (ICH).In some embodiments, ICH is associated with amyloid aggregate deposition and / or cerebral amyloid angiopathy (CAA).

[0081] In some embodiments, the method of inhibiting, reducing, preventing, and / or treating stroke in a subject comprises detecting a decrease in motor function loss deficits, a decrease in the incidence of microhemorrhages, a decrease in the level of activated microglia, a decrease in the level of activated astrocytes, a decrease in circulating pro-inflammatory immune cells, a decrease in circulating pro-inflammatory cytokines, or any combination thereof in the subject.

[0082] In some embodiments, the reduction in motor dysfunction is assessed by the Hugelmeyer Assessment (FMA), the Motor Assessment Scale (MAS), and / or the Chedoke-McMaster Stroke Assessment (CMSA).

[0083] In some embodiments, the reduction in motor dysfunction in the subject is at least 50%. In some embodiments, the reduction in motor dysfunction in the subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the above reductions. For example, in some embodiments, the reduction in motor dysfunction in the subject is at least 5% to 95%, 5% to 90%, 5% to 75%, 5% to 50%, 5% to 25%, 5% to 10%, 5% to 7%, 7% to 95%, 7% to 90%, 7% to 75%, 7% to 50%, 7% to 25%, 7% to 10%, 10% to 95%, 10% to 90%, 10% to 75%, 10% to 50%, 10% to 25%, 25% to 95%, 25% to 90%, 25% to 75%, 25% to 50%, 50% to 95%, 50% to 90%, 50% to 75%, 75% to 95%, 75% to 90%, and 90% to 95%.

[0084] In some embodiments, the reduction in microhemorrhage is assessed by neuroimaging, MRI, and / or Prussian blue staining.

[0085] In some embodiments, the reduction in microbleeds in the subject is at least 50%. In some embodiments, the reduction in microbleeds in the subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the above reductions. For example, in some embodiments, the reduction in microhemorrhage is at least 5% to 95%, 5% to 90%, 5% to 75%, 5% to 50%, 5% to 25%, 5% to 10%, 5% to 7%, 7% to 95%, 7% to 90%, 7% to 75%, 7% to 50%, 7% to 25%, 7% to 10%, 10% to 95%, 10% to 90%, 10% to 75%, 10% to 50%, 10% to 25%, 25% to 95%, 25% to 90%, 25% to 75%, 25% to 50%, 50% to 95%, 50% to 90%, 50% to 75%, 75% to 95%, 75% to 90%, and 90% to 95%.

[0086] In some embodiments, the reduction in levels of activated microglia is achieved by detecting markers of microglial activation, optionally from the cerebrospinal fluid of the subject, such as ionized calcium-binding adaptor molecule 1 (Iba1), monocyte chemoattractant protein-1 (mon chemoattractant protein-1 (MCP-1), or the like. This is assessed by detection of cytocyte chemoattractant protein-1 (MCP-1), chitinase-3-like protein 1 (YKL-40), and / or soluble CD14 (sCD14).

[0087] In some embodiments, the reduction in the level of activated microglia in the subject is at least 20%. In some embodiments, the reduction in the level of activated microglia, the reduction in the level of activated astrocytes, the reduction in the level of circulating pro-inflammatory cytokines in the subject, or any combination thereof, is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the foregoing reductions. For example, in some embodiments, the reduction in levels of activated microglia in a subject is at least 5% to 95%, 5% to 90%, 5% to 75%, 5% to 50%, 5% to 25%, 5% to 10%, 5% to 7%, 7% to 95%, 7% to 90%, 7% to 75%, 7% to 50%, 7% to 25%, 7% to 10%, 10% to 95%, 10% to 90%, 10% to 75%, 10% to 50%, 10% to 25%, 25% to 95%, 25% to 90%, 25% to 75%, 25% to 50%, 50% to 95%, 50% to 90%, 50% to 75%, 75% to 95%, 75% to 90%, and 90% to 95%.

[0088] In some embodiments, the reduction in the level of activated astrocytes is assessed by detection of astrocyte activation markers, optionally GFAP and / or S100B, optionally from the cerebrospinal fluid of the subject.

[0089] In some embodiments, the reduction in the level of activated astrocytes in the subject is at least 30%, hi some embodiments, the reduction in the level of activated astrocytes in the subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the foregoing reductions. For example, in some embodiments, the reduction in levels of activated astrocytes in a subject is at least 5% to 95%, 5% to 90%, 5% to 75%, 5% to 50%, 5% to 25%, 5% to 10%, 5% to 7%, 7% to 95%, 7% to 90%, 7% to 75%, 7% to 50%, 7% to 25%, 7% to 10%, 10% to 95%, 10% to 90%, 10% to 75%, 10% to 50%, 10% to 25%, 25% to 95%, 25% to 90%, 25% to 75%, 25% to 50%, 50% to 95%, 50% to 90%, 50% to 75%, 75% to 95%, 75% to 90%, and 90% to 95%.

[0090] In some embodiments, the reduction in the level of circulating pro-inflammatory cytokines in the subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the foregoing reductions. For example, in some embodiments, the reduction in levels of circulating pro-inflammatory cytokines in a subject is at least 5% to 95%, 5% to 90%, 5% to 75%, 5% to 50%, 5% to 25%, 5% to 10%, 5% to 7%, 7% to 95%, 7% to 90%, 7% to 75%, 7% to 50%, 7% to 25%, 7% to 10%, 10% to 95%, 10% to 90%, 10% to 75%, 10% to 50%, 10% to 25%, 25% to 95%, 25% to 90%, 25% to 75%, 25% to 50%, 50% to 95%, 50% to 90%, 50% to 75%, 75% to 95%, 75% to 90%, and 90% to 95%.

[0091] In some embodiments, the reduction in levels of circulating pro-inflammatory immune cells in a subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or a range defined by any two of the foregoing reductions. It is any percentage within For example, in some embodiments, the reduction in motor dysfunction, reduction in microhemorrhage, reduction in circulating pro-inflammatory immune cells in a subject is at least 5% to 95%, 5% to 90%, 5% to 75%, 5% to 50%, 5% to 25%, 5% to 10%, 5% to 7%, 7% to 95%, 7% to 90%, 7% to 75%, 7% to 50%, 7% to 25%, 7% to 10%, 10% to 95%, 10% to 90%, 10% to 75%, 10% to 50%, 10% to 25%, 25% to 95%, 25% to 90%, 25% to 75%, 25% to 50%, 50% to 95%, 50% to 90%, 50% to 75%, 75% to 95%, 75% to 90%, and 90% to 95%.

[0092] In some embodiments, methods are disclosed for inhibiting, reducing, preventing, and / or treating traumatic brain injury (TBI) in a subject in need thereof. In some embodiments, TBI is associated with concussion, edema, diffuse axonal injury, spinal cord injury, coma, neuroinflammation, microhemorrhage, astrocytosis, activated microglia, and / or hematoma.

[0093] In some embodiments, administration of the anti-Gal3 antibody or binding fragment thereof prevents elevated levels of activated microglia, prevents elevated levels of activated astrocytes, prevents elevated levels of macrophages, prevents elevated levels of hyperphosphorylated tau, prevents the incidence of microhemorrhages, prevents neuroinflammation, prevents elevated levels of circulating pro-inflammatory cytokines, or any combination thereof in a subject.

[0094] In some embodiments, administration of the anti-Gal3 antibody or binding fragment thereof improves the patient's level of consciousness, memory loss, and / or Glasgow Coma Scale; and / or reduces the level of activated microglia, reduces the level of activated astrocytes, reduces the level of macrophages, reduces the level of hyperphosphorylated tau, reduces microhemorrhages, reduces neuroinflammation, reduces the level of circulating pro-inflammatory cytokines, or any combination thereof, in the subject.

[0095] In some embodiments, administration of the anti-Gal3 antibody results in a reduction in the level of activated microglia, a reduction in the level of activated astrocytes, a reduction in the level of macrophages, a reduction in the level of hyperphosphorylated tau, a reduction in microhemorrhages, a reduction in neuroinflammation, a reduction in the level of circulating pro-inflammatory cytokines, or any combination thereof in the subject.

[0096] In some embodiments, the reduction in the level of activated microglia in the subject is at least 70%. In some embodiments, the reduction in the level of activated microglia in the subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the above reductions. For example, in some embodiments, the reduction in levels of activated microglia in a subject is at least 5% to 95%, 5% to 90%, 5% to 75%, 5% to 50%, 5% to 25%, 5% to 10%, 5% to 7%, 7% to 95%, 7% to 90%, 7% to 75%, 7% to 50%, 7% to 25%, 7% to 10%, 10% to 95%, 10% to 90%, 10% to 75%, 10% to 50%, 10% to 25%, 25% to 95%, 25% to 90%, 25% to 75%, 25% to 50%, 50% to 95%, 50% to 90%, 50% to 75%, 75% to 95%, 75% to 90%, and 90% to 95%.

[0097] In some embodiments, the reduction in levels of activated astrocytes is achieved by detecting a marker of astrocyte activation, optionally GFAP, from the cerebrospinal fluid of the subject. It is evaluated by the detection of

[0098] In some embodiments, the reduction in the level of activated astrocytes in the subject is at least 90%, hi some embodiments, the reduction in the level of activated astrocytes in the subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the foregoing reductions. For example, in some embodiments, the reduction in levels of activated astrocytes in a subject is at least 5% to 95%, 5% to 90%, 5% to 75%, 5% to 50%, 5% to 25%, 5% to 10%, 5% to 7%, 7% to 95%, 7% to 90%, 7% to 75%, 7% to 50%, 7% to 25%, 7% to 10%, 10% to 95%, 10% to 90%, 10% to 75%, 10% to 50%, 10% to 25%, 25% to 95%, 25% to 90%, 25% to 75%, 25% to 50%, 50% to 95%, 50% to 90%, 50% to 75%, 75% to 95%, 75% to 90%, and 90% to 95%.

[0099] In some embodiments, the reduction in macrophage levels is assessed by detection of a macrophage activation marker, optionally CD68, optionally from the cerebrospinal fluid of the subject.

[0100] In some embodiments, the reduction in macrophage levels in the subject is at least 70%, hi some embodiments, the reduction in macrophage levels in the subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the foregoing reductions. For example, in some embodiments, the reduction in macrophage levels in a subject is at least 5% to 95%, 5% to 90%, 5% to 75%, 5% to 50%, 5% to 25%, 5% to 10%, 5% to 7%, 7% to 95%, 7% to 90%, 7% to 75%, 7% to 50%, 7% to 25%, 7% to 10%, 10% to 95%, 10% to 90%, 10% to 75%, 10% to 50%, 10% to 25%, 25% to 95%, 25% to 90%, 25% to 75%, 25% to 50%, 50% to 95%, 50% to 90%, 50% to 75%, 75% to 95%, 75% to 90%, and 90% to 95%.

[0101] In some embodiments, the reduction in the level of hyperphosphorylated tau in the subject is at least 80%. In some embodiments, the reduction in the level of hyperphosphorylated tau in the subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the above reductions. For example, in some embodiments, the reduction in the level of hyperphosphorylated tau in a subject is at least 5% to 95%, 5% to 90%, 5% to 75%, 5% to 50%, 5% to 25%, 5% to 10%, 5% to 7%, 7% to 95%, 7% to 90%, 7% to 75%, 7% to 50%, 7% to 25%, 7% to 10%, 10% to 95%, 10% to 90%, 10% to 75%, 10% to 50%, 10% to 25%, 25% to 95%, 25% to 90%, 25% to 75%, 25% to 50%, 50% to 95%, 50% to 90%, 50% to 75%, 75% to 95%, 75% to 90%, and 90% to 95%.

[0102] In some embodiments, the reduction in the level of microhemorrhage is assessed by neuroimaging, MRI, and / or Prussian blue staining.

[0103] In some embodiments, the reduction in microbleeds in the subject is at least 80%. In some embodiments, the reduction in microbleeds in the subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the aforementioned reductions. For example, in some embodiments, the reduction in microhemorrhage in a subject is at least 5% to 95%, 5% to 90%, 5% to 75%, 5% to 50%, 5% to 25%, 5% to 10%, 5% to 7%, 7% to 95%, 7% to 90%, 7% to 75%, 7% to 50%, 7% to 25%, 7% to 10%, 10% to 95%, 10% to 90%, 10% to 75%, 10% to 50%, 10% to 25%, 25% to 95%, 25% to 90%, 25% to 75%, 25% to 50%, 50% to 95%, 50% to 90%, 50% to 75%, 75% to 95%, 75% to 90%, and 90% to 95%.

[0104] In some embodiments, the reduction in neuroinflammation in the subject is at least 70%. In some embodiments, the reduction in neuroinflammation in the subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the above reductions. For example, in some embodiments, the reduction in neuroinflammation in the subject is at least 5% to 95%, 5% to 90%, 5% to 75%, 5% to 50%, 5% to 25%, 5% to 10%, 5% to 7%, 7% to 95%, 7% to 90%, 7% to 75%, 7% to 50%, 7% to 25%, 7% to 10%, 10% to 95%, 10% to 90%, 10% to 75%, 10% to 50%, 10% to 25%, 25% to 95%, 25% to 90%, 25% to 75%, 25% to 50%, 50% to 95%, 50% to 90%, 50% to 75%, 75% to 95%, 75% to 90%, and 90% to 95%.

[0105] In some embodiments, methods are disclosed for inhibiting, reducing, preventing, and / or treating a disorder associated with fibrin activity or dysfunction in a subject in need thereof. In some embodiments, amelioration of one or more symptoms associated with the disorder associated with fibrin activity or dysfunction is detected after the administering step. In some embodiments, the one or more symptoms include neuroinflammation and / or fibrin oligomerization. In some embodiments, administering an anti-Gal3 antibody or binding fragment thereof to a subject reduces neuroinflammation and / or fibrin oligomerization in the subject.

[0106] In some embodiments, the reduction in fibrin oligomerization in the subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the above reductions. For example, in some embodiments, the reduction in fibrin oligomerization in a subject is at least 5% to 95%, 5% to 90%, 5% to 75%, 5% to 50%, 5% to 25%, 5% to 10%, 5% to 7%, 7% to 95%, 7% to 90%, 7% to 75%, 7% to 50%, 7% to 25%, 7% to 10%, 10% to 95%, 10% to 90%, 10% to 75%, 10% to 50%, 10% to 25%, 25% to 95%, 25% to 90%, 25% to 75%, 25% to 50%, 50% to 95%, 50% to 90%, 50% to 75%, 75% to 95%, 75% to 90%, and 90% to 95%.

[0107] The exemplary standardized approach for assessing the severity of neurological problems, such as stroke and TBI, is described herein.It should be understood that these and other approaches are recognized in the art for their usefulness in quantifying the neurological capacity of patients.Other approaches that are used in common knowledge are also envisioned as alternatives to the approach provided herein.

[0108] NIH Stroke Scale (NIHSS): The NIHSS provides an objective quantification of disability caused by stroke. The NIHSS was designed to be a standardized and repeatable assessment of stroke patients for use in large, multicenter clinical trials. It is It has good inter-rater and test-retest reliability. The NIHSS has also been used to predict 3-month outcomes (e.g., hospitalization, mortality) in patients after stroke.

[0109] The NIHSS consists of 11 items, each of which rates a specific parameter of ability or function. Each item is rated from 0 to 4. A score of 0 indicates normal function, and higher scores indicate greater degrees of impairment. Individual item scores are added to calculate the NIHSS total score. The maximum possible score is 42 (death), and the minimum score is 0 (no impairment). Items scored include level of consciousness, horizontal eye movements, visual fields, facial paresis, motor arm, motor leg, limb ataxia, sensation, language, speech, and extinction and inattention.

[0110] In some embodiments, the NIHSS assessment can be assessed 7, 35, and / or 75 days after administering the anti-Gal3 antibody or binding fragment thereof.

[0111] The modified Rankin Scale (mRS) is another scale commonly used in stroke clinical trials to measure the degree of disability or dependency in daily activities in patients who have suffered a stroke. It consists of well-defined and easily understood grades that describe the extent of global disability. The mRS exhibits strong correlations with clinical measures of stroke severity in addition to other disability and outcome endpoints.

[0112] Scoring of the mRS involves a semi-structured interview between the patient and a trained facilitator. Scores range from "0" (asymptomatic) to "6" (death). It also has good inter-rater and test-retest reliability.

[0113] The Hugel-Meyer Assessment: FMA scale is an assessment of sensorimotor impairment in patients who have had a stroke. It is widely used in stroke clinical trials for the clinical evaluation of motor function. The FMA score has been found to have excellent consistency, responsiveness, and good accuracy.

[0114] Each item in the FMA is scored on a 3-point scale: 0 = unable to perform, 1 = task partially performed, 2 = task fully performed. The maximum possible score on the FMA scale is 226, which corresponds to complete recovery. The five domains in the FMA are motor function, sensory function, balance, range of motion, and joint pain.

[0115] The Montreal Cognitive Assessment (MoCA) is a brief screening instrument designed to assess mild cognitive impairment in a variety of patient conditions. Scores on the MoCA range from 0 to 30, with lower scores indicating greater impairment. The MoCA takes approximately 10 minutes to administer. The MoCA assesses eight cognitive domains: visuospatial ability, executive function, short-term memory recall, attention, concentration, working memory, language, and temporal and spatial orientation. The MoCA is particularly useful for patients with impairments due to vascular conditions, primarily due to the assessment of executive function and the presence of more demanding visuoconstructive tasks. The MoCA is one of the most commonly used cognitive assessments used in stroke studies.

[0116] Validation studies indicated that the sensitivity and specificity of the MoCA in detecting mild cognitive impairment was 90% and 97%, respectively, which was superior to that of the Mini Mental Status Examination.

[0117] In addition to the exemplary assessments described herein, other standardized assessments known in the art can be used to assess improvement and / or remission of stroke or stroke-associated symptoms in a subject. It can be used to determine. In some embodiments, detecting the amelioration of symptoms associated with stroke after the administering step includes detecting improvement by the subject according to the NIHSS, mRS, FMA, or MoCA, which may be at an endpoint determined by a physician. In some embodiments, after the administering step, a) improvement by the subject according to the NIHSS includes a decrease of at least 4 points in the NIHSS; b) improvement by the subject according to the mRS includes a decrease of at least 1 point in the mRS; c) improvement by the subject according to the FMA includes an increase of at least 1 point in the FMA; and / or d) improvement by the subject according to the MoCA includes an increase of at least 1 point in the MoCA. In some embodiments, improvement by the subject is assessed 7, 35, and / or 75 days after the administering step.

[0118] In some embodiments, any of the endpoints delineated in Table 1 may be achieved or is the goal of any one of the suitable methods provided herein. In some embodiments, the method is performed to achieve any one, two, three, or four of the objectives and / or is determined by any one, two, three, or four of the endpoints delineated in Table 1.

[0119] In some embodiments, any one of the suitable methods provided herein is performed to include assessing the subject with the NIHSS at baseline (day 1 upon initial administration), and is further assessed at 15, 36, 64, and 104 days after the initial intervention. In some embodiments, any one of the suitable methods provided herein is performed to include assessing the subject with the NIHSS at baseline (day 1 upon initial administration), and is further assessed at about 10-20, 31-41, 59-69, and 99-109 days after the initial intervention. In some embodiments, the subject's NIHSS is assessed at about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after the initial administration, or at a time point within a range defined by any two of the preceding values. For example, in some embodiments, the subject's NIHSS is assessed at about 1 to 12, 1 to 8, 1 to 6, 1 to 4, 1 to 3, 3 to 12, 3 to 8, 3 to 6, 3 to 4, 4 to 12, 4 to 8, 4 to 6, 6 to 12, 6 to 8, or 8 to 12 months after the initial intervention. In some embodiments, any one of the suitable methods provided herein is performed to include assessing the subject with the NIHSS at baseline (day 1 of initial administration) and further assessing at one or more time points after the initial intervention. For example, the subject's NIHSS may be assessed at baseline (day 1 of initial administration) and further assessed at 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more time points after the initial intervention, or at a number of time points defined by any two of the preceding values. For example, in some embodiments, the subject's NIHSS is assessed at about 1 to 10, 1 to 7, 1 to 5, 1 to 4, 1 to 3, 3 to 10, 3 to 7, 3 to 5, 5 to 10, or 5 to 7 time points after the initial intervention. In some embodiments, the subject's NIHSS is assessed more than 1 year after the initial intervention.

[0120] In some embodiments, the subject's NIHSS is reduced from baseline (Day 1 at the time of initial administration) by Day 36 after the initial intervention. In some embodiments, the subject's NIHSS is reduced from baseline (Day 1 at the time of initial administration) by about Day 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 after the initial intervention, or by a time point within a range defined by any two of the preceding values. For example, in some embodiments, the subject's NIHSS is reduced from baseline (Day 1 at the time of initial administration) by about Days 31-41, 31-38, 31-36, 31-33, 33-41, 33-38, 33-36, 34-41, 34-37, or 37-41. In some embodiments, the reduction in the subject's NIHSS is sustained from Days 36 to 64 after the initial intervention. In some embodiments, the reduction in the subject's NIHSS is sustained from Days 36 to 104 after the initial intervention. In some embodiments, the reduction in the subject's NIHSS score is sustained from about 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 days after the initial intervention to about 99, 100, 101, 102, 103, 104, 105, 105, 107, 108, or 109 days after the initial intervention. In some embodiments, the reduction in the subject's NIHSS score is sustained from about 1 month to about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after the initial intervention, or for a period defined by any two of the preceding values. In some embodiments, the reduction in the subject's NIHSS score is sustained within one month of the initial intervention. In some embodiments, the reduction in the subject's NIHSS score is sustained for more than about 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after the initial intervention. In some embodiments, the reduction in the subject's NIHSS score is sustained for more than 12 months. For example, in some embodiments, the subject's reduction in NIHSS score is sustained for greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 years, or a range defined by any two of the preceding values. For example, in some embodiments, the subject's reduction in NIHSS score is sustained for greater than about 1-20, 1-15, 1-10, 1-7, 1-5, 1-3, 3-20, 3-15, 3-10, 3-7, 3-5, 5-20, 5-15, 5-10, 5-7, 7-20, 7-15, 7-10, 10-20, 10-15, or 15-20 years.

[0121] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's NIHSS score by 1, 2, 3, and / or 4 points. In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's NIHSS score by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 points, or a range defined by any two of the preceding values. For example, in some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's NIHSS score by about 1-12, 1-10, 1-8, 1-6, 1-4, 2-12, 2-10, 2-8, 2-6, 2-4, 4-12, 4-10, 4-8, 8-12, or 8-10 points. In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's NIHSS by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 75, 80, 90, 100, 200, 250, 300, 400, 500, 600, 700, 750, 800, 900, or 1000%, or by a range defined by any two of the preceding values. For example, in some embodiments, the administration of an anti-Gal3 antibody or binding fragment thereof to a subject is at least about 1-1000, 1-750, 1-500, 1-250, 1-100, 1-75, 1-50, 1-25, 1-10, 1-5, 5-1000, 5-750, 5-500, 5-250, 5-100, 5-75, 5-50, 5-10, 10-1000, 10-750, 10-500, 10-250, 10-100, 10-75, 10-50, 1 Decrease the subject's NIHSS by 0-25, 25-1000, 25-750, 25-500, 25-250, 25-100, 25-75, 25-50, 50-1000, 50-750, 50-500, 50-250, 50-100, 100-1000, 100-750, 100-500, 100-250, 250-1000, 250-750, 250-500, 500-1000, 500-750, or 750-1000%.

[0122] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's level of consciousness score on the NIHSS by about 1, 2, 3, 4, 5, 6, or 7 points, or by a range defined by any two of the preceding values. For example, in some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's level of consciousness score on the NIHSS by about 1-7, 1-5, 1-3, 3-7, or 5-7 points.

[0123] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject comprises administering to the subject at least about Decrease the subject's horizontal extraocular movement score on the NIHSS by 1 or 2 points.

[0124] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's visual field score on the NIHSS by about 1, 2, or 3 points.

[0125] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's facial paralysis score on the NIHSS by about 1, 2, or 3 points.

[0126] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's left arm motor drift score on the NIHSS by about 1, 2, 3, or 4 points.

[0127] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's right arm motor drift score on the NIHSS by about 1, 2, 3, or 4 points.

[0128] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's left leg motor drift score on the NIHSS by about 1, 2, 3, or 4 points.

[0129] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's right leg motor drift score on the NIHSS by about 1, 2, 3, or 4 points.

[0130] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's limb ataxia score on the NIHSS by about 1 or 2 points.

[0131] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's language / aphasia score on the NIHSS by about 1, 2, or 3 points.

[0132] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's dysarthria score on the NIHSS by about 1 or 2 points.

[0133] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's extinction / neglect score on the NIHSS by about 1 or 2 points.

[0134] In some embodiments, any one of the suitable methods provided herein is performed to include assessing the subject with the modified Rankin Scale (mRS) at baseline (day 1 upon initial administration), and is further assessed at 15, 36, 64, and 104 days after the initial intervention. In some embodiments, any one of the suitable methods provided herein is performed to include assessing the subject with the mRS at baseline (day 1 upon initial administration), and is further assessed at about 10-20, 31-41, 59-69, and 99-109 days after the initial intervention. In some embodiments, the subject's mRS is assessed at about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after the initial administration, or at a time point within a range defined by any two of the preceding values. For example, in some embodiments, the subject's mRS is assessed at about 1 to 12, 1 to 8, 1 to 6, 1 to 4, 1 to 3, 3 to 12, 3 to 8, 3 to 6, 3 to 4, 4 to 12, 4 to 8, 4 to 6, 6 to 12, 6 to 8, or 8 to 12 months after the initial intervention. In some embodiments, any one of the suitable methods provided herein is performed to include assessing the subject with the mRS at baseline (day 1 of initial administration) and further assessing at one or more time points after the initial intervention. For example, the subject's mRS may be assessed at baseline (day 1 of initial administration) and further assessed at 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more time points after the initial intervention, or at a number of time points defined by any two of the preceding values. For example, in some embodiments, the subject's mRS is assessed at about 1-10, 1-7, 1-5, 1-4, 1-3, 3-10, 3-7, 3-5, 5-10, or 5-7 time points after the initial intervention. In some embodiments, the subject's mRS is assessed more than 1 year after the initial intervention.

[0135] In some embodiments, the subject's mRS is reduced from baseline (Day 1 of initial administration) by Day 36 after the initial intervention. In some embodiments, the subject's mRS is reduced from baseline (Day 1 of initial administration) by about Day 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 after the initial intervention, or by a time point within a range defined by any two of the preceding values. For example, in some embodiments, the subject's mRS is reduced from baseline (Day 1 of initial administration) by about Days 31-41, 31-38, 31-36, 31-33, 33-41, 33-38, 33-36, 34-41, 34-37, or 37-41. In some embodiments, the reduction in the subject's mRS is sustained from Day 36 to Day 64 after the initial intervention. In some embodiments, the reduction in the subject's mRS is sustained from Day 36 to Day 104 after the initial intervention. In some embodiments, the reduction in the subject's mRS is sustained from about 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 days after the initial intervention to about 99, 100, 101, 102, 103, 104, 105, 105, 107, 108, or 109 days after the initial intervention. In some embodiments, the reduction in the subject's mRS is sustained from about 1 month to about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after the initial intervention, or for a period defined by any two of the preceding values. In some embodiments, the reduction in the subject's mRS is sustained within 1 month after the initial intervention. In some embodiments, the reduction in the subject's mRS is sustained for more than about 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after the initial intervention.

[0136] In some embodiments, administering an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's mRS by 1 point. In some embodiments, administering an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's mRS by about 1, 2, 3, 4, 5, or 6 points, or by a range defined by any two of the preceding values. In some embodiments, administering an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's mRS by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 75, 80, 90, 100, 200, 250, 300, 400, 500, 600, 700, 750, 800, 900, or 1000%, or by a range defined by any two of the preceding values. For example, in some embodiments, the administration of an anti-Gal3 antibody or binding fragment thereof to a subject is at least about 1-1000, 1-750, 1-500, 1-250, 1-100, 1-75, 1-50, 1-25, 1-10, 1-5, 5-1000, 5-750, 5-500, 5-250, 5-100, 5-75, 5-50, 5-10, 10-1000, 10-750, 10-500, 10-250, 10-100, 10-75, 10-50, Decrease the subject's mRS by 10-25, 25-1000, 25-750, 25-500, 25-250, 25-100, 25-75, 25-50, 50-1000, 50-750, 50-500, 50-250, 50-100, 100-1000, 100-750, 100-500, 100-250, 250-1000, 250-750, 250-500, 500-1000, 500-750, or 750-1000%.

[0137] In some embodiments, any one of the suitable methods provided herein comprises: The method is performed to include assessing the subject by Hugel-Meyer assessment (FMA) at baseline (day 1 upon initial administration), and further assessed at 15, 36, 64, and 104 days after the initial intervention. In some embodiments, any one of the suitable methods provided herein is performed to include assessing the subject by FMA at baseline (day 1 upon initial administration), and further assessed at about 10-20, 31-41, 59-69, and 99-109 days after the initial intervention. In some embodiments, the subject's mRS is assessed at about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after the initial administration, or at a time point within a range defined by any two of the preceding values. For example, in some embodiments, the subject's FMA is assessed at about 1-12, 1-8, 1-6, 1-4, 1-3, 3-12, 3-8, 3-6, 3-4, 4-12, 4-8, 4-6, 6-12, 6-8, or 8-12 months after the initial intervention. In some embodiments, any one of the suitable methods provided herein is performed to include assessing the subject using the mRS at baseline (day 1 of initial administration) and further assessed at one or more time points after the initial intervention. For example, the subject's FMA may be assessed at baseline (day 1 of initial administration) and further assessed at 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more time points after the initial intervention, or at a number of time points defined by any two of the preceding values. For example, in some embodiments, the subject's FMA is assessed at about 1-10, 1-7, 1-5, 1-4, 1-3, 3-10, 3-7, 3-5, 5-10, or 5-7 time points after the initial intervention, hi some embodiments, the subject's FMA is assessed more than 1 year after the initial intervention.

[0138] In some embodiments, the subject's FMA is increased from baseline (Day 1 of initial administration) by Day 36 after the initial intervention. In some embodiments, the subject's FMA is increased from baseline (Day 1 of initial administration) by about Day 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 after the initial intervention, or by a time within a range defined by any two of the preceding values. For example, in some embodiments, the subject's FMA is increased from baseline (Day 1 of initial administration) by about Days 31-41, 31-38, 31-36, 31-33, 33-41, 33-38, 33-36, 34-41, 34-37, or 37-41. In some embodiments, the increase in the subject's FMA is sustained from Day 36 to Day 64 after the initial intervention. In some embodiments, the decrease in the subject's FMA is sustained from Day 36 to Day 104 after the initial intervention. In some embodiments, the increase in subject's FMA is sustained from about 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 days after initial intervention to about 99, 100, 101, 102, 103, 104, 105, 105, 107, 108, or 109 days after initial intervention. In some embodiments, the increase in subject's FMA is sustained from about 1 month to about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after initial intervention, or for a period defined by any two of the preceding values. In some embodiments, the increase in subject's FMA is sustained within 1 month after initial intervention. In some embodiments, the increase in subject's FMA is sustained for more than about 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after initial intervention.

[0139] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's FMA by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 225, or 226 points, or by a range defined by any two of the preceding values. For example, in some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject is within the scope of the present invention, and may be administered in an amount of about 1-226, 1-200, 1-150, 1-100, 1-75, 1-50, 1-25, 1-10, 1-5, 5-226, 5-200, 5-150, 5-100, 5-75, 5-50, 5-25, 5-10, 10-226, 10-200, 10-150, 10-100, 10-75, 10-50 , increase the target FMA by 10-25, 25-226, 25-200, 25-150, 25-100, 25-75, 25-50, 50-226, 50-200, 50-150, 50-100, 50-75, 75-226, 75-200, 75-150, 75-100, 100-226, 100-200, 100-150, 150-226, 150-200, or 200-226 points. In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the subject's FMA by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 75, 80, 90, 100, 200, 250, 300, 400, 500, 600, 700, 750, 800, 900, or 1000%, or by a range defined by any two of the preceding values.For example, in some embodiments, the administration of an anti-Gal3 antibody or binding fragment thereof to a subject is at least about 1-1000, 1-750, 1-500, 1-250, 1-100, 1-75, 1-50, 1-25, 1-10, 1-5, 5-1000, 5-750, 5-500, 5-250, 5-100, 5-75, 5-50, 5-10, 10-1000, 10-750, 10-500, 10-250, 10-100, 10-75, 10-50, Increases the target FMA by 10-25, 25-1000, 25-750, 25-500, 25-250, 25-100, 25-75, 25-50, 50-1000, 50-750, 50-500, 50-250, 50-100, 100-1000, 100-750, 100-500, 100-250, 250-1000, 250-750, 250-500, 500-1000, 500-750, or 750-1000%.

[0140] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's motility score on the FMA by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 points, or by a range defined by any two of the preceding values. For example, in some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's motility score on the FMA by about 1-100, 1-75, 1-50, 1-25, 1-10, 1-5, 5-100, 5-75, 5-50, 5-25, 5-10, 10-100, 10-75, 10-50, 10-25, 25-100, 25-75, 25-50, 50-100, 50-75, or 75-100 points.

[0141] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's upper limb mobility score on the FMA by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 40, 50, 60, 65, or 66 points, or by a range defined by any two of the preceding values. For example, in some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's upper limb mobility score on the FMA by about 1-66, 1-50, 1-25, 1-10, 1-5, 5-66, 5-50, 5-25, 5-10, 10-66, 10-50, 10-25, 25-66, 25-50, or 50-66 points.

[0142] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's lower limb mobility score on the FMA by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, or 34 points, or by a range defined by any two of the preceding values. For example, in some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's lower limb mobility score on the FMA by about 1-34, 1-25, 1-10, 1-5, 5-34, 5-25, 5-10, 10-34, 10-25, or 25-34 points.

[0143] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject comprises administering to the subject at least about The subject's sensory score on the FMA increases by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, or 24 points, or by a range defined by any two of the preceding values. For example, in some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's sensory score on the FMA by about 1-24, 1-10, 1-5, 5-24, 5-10, or 10-24 points.

[0144] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's light touch sensation score on the FMA by about 1, 2, 3, 4, 5, 6, 7, or 8 points, or by a range defined by any two of the preceding values. For example, in some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's light touch sensation score on the FMA by about 1-8, 1-6, 1-4, 4-8, or 6-8 points.

[0145] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's position sense score on the FMA by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 points, or by a range defined by any two of the preceding values. For example, in some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's position sense score on the FMA by about 1-16, 1-10, 1-5, 5-16, 5-10, or 10-16 points.

[0146] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's balance score on the FMA by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 points, or by a range defined by any two of the preceding values. For example, in some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's balance score on the FMA by about 1-14, 1-10, 1-5, 5-14, 5-10, or 10-14 points.

[0147] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's locomotion balance score on the FMA by about 1, 2, 3, 4, 5, or 6 points, or by a range defined by any two of the preceding values. For example, in some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's balance score on the FMA by about 1-6, 1-3, or 3-6 points.

[0148] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's standing balance score on the FMA by about 1, 2, 3, 4, 5, 6, 7, or 8 points, or by a range defined by any two of the preceding values. For example, in some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's balance score on the FMA by about 1-8, 1-6, 1-4, 4-8, 4-6, or 6-8 points.

[0149] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's joint range of motion score on the FMA by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 40, or 44 points, or by a range defined by any two of the preceding values. For example, in some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's joint range of motion score on the FMA by about 1-44, 1-30, 1-25, 1-10, 1-5, 5-44, 5-30, 5-25, 5-10, 10-44, 10-30, 10-25, 25-44, 25-30, or 30-44 points.

[0150] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject comprises administering to the subject at least about The subject's joint pain score on the FMA increases by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 40, or 44 points, or by a range defined by any two of the preceding values. For example, in some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's joint pain score on the FMA by about 1 to 44, 1 to 30, 1 to 25, 1 to 10, 1 to 5, 5 to 44, 5 to 30, 5 to 25, 5 to 10, 10 to 44, 10 to 30, 10 to 25, 25 to 44, 25 to 30, or 30 to 44 points.

[0151] In some embodiments, any one of the suitable methods provided herein is performed to include assessing the subject with the Montreal Cognitive Assessment (MoCA) at baseline (day 1 upon initial administration), and is further assessed at 15, 36, 64, and 104 days after the initial intervention. In some embodiments, any one of the suitable methods provided herein is performed to include assessing the subject with the MoCA at baseline (day 1 upon initial administration), and is further assessed at about 10-20, 31-41, 59-69, and 99-109 days after the initial intervention. In some embodiments, the subject's MoCA is assessed at about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after the initial administration, or at a time point within a range defined by any two of the preceding values. For example, in some embodiments, the subject's MoCA is assessed at about 1-12, 1-8, 1-6, 1-4, 1-3, 3-12, 3-8, 3-6, 3-4, 4-12, 4-8, 4-6, 6-12, 6-8, or 8-12 months after the initial intervention. In some embodiments, any one of the suitable methods provided herein is performed to include assessing the subject with the MoCA at baseline (day 1 of initial administration) and further assessing at one or more time points after the initial intervention. For example, the subject's MoCA may be assessed at baseline (day 1 of initial administration) and further assessed at 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more time points after the initial intervention, or at a number of time points defined by any two of the preceding values. For example, in some embodiments, the subject's MoCA is assessed at about 1-10, 1-7, 1-5, 1-4, 1-3, 3-10, 3-7, 3-5, 5-10, or 5-7 time points after the initial intervention. In some embodiments, the subject's MoCA is assessed more than 1 year after the initial intervention.

[0152] In some embodiments, the subject's MoCA increases from baseline (day 1 upon initial administration) by day 36 after the initial intervention. In some embodiments, the subject's MoCA increases from baseline (day 1 upon initial administration) by about day 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 after the initial intervention, or by a time within a range defined by any two of the preceding values. For example, in some embodiments, the subject's MoCA increases from baseline (day 1 upon initial administration) by about days 31-41, 31-38, 31-36, 31-33, 33-41, 33-38, 33-36, 34-41, 34-37, or 37-41. In some embodiments, the increase in the subject's MoCA is sustained from day 36 to day 64 after the initial intervention. In some embodiments, the increase in the subject's MoCA is sustained from day 36 to day 104 after the initial intervention. In some embodiments, the increase in the subject's MoCA is sustained from about 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 days after the initial intervention to about 99, 100, 101, 102, 103, 104, 105, 105, 107, 108, or 109 days after the initial intervention. In some embodiments, the increase in the subject's MoCA is sustained from about 1 month to about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after the initial intervention, or for a period defined by any two of the preceding values. In some embodiments, the increase in the subject's MoCA is sustained within 1 month after the initial intervention. In some embodiments, the increase in the subject's MoCA is sustained for more than about 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after the initial intervention.

[0153] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's MoCA by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 points, or a range defined by any two of the preceding values. For example, in some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's MoCA by about 1-30, 1-20, 1-15, 1-10, 1-5, 5-30, 5-20, 5-15, 5-10, 10-30, 10-15, 15-30, 15-20, or 20-30 points. In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject increases the subject's MoCA by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 75, 80, 90, 100, 200, 250, 300, 400, 500, 600, 700, 750, 800, 900, or 1000%, or a range defined by any two of the preceding values. For example, in some embodiments, the administration of an anti-Gal3 antibody or binding fragment thereof to a subject is at least about 1-1000, 1-750, 1-500, 1-250, 1-100, 1-75, 1-50, 1-25, 1-10, 1-5, 5-1000, 5-750, 5-500, 5-250, 5-100, 5-75, 5-50, 5-10, 10-1000, 10-750, 10-500, 10-250, 10-100, 10-75, 10-50, Increase the subject's MoCA by 10-25, 25-1000, 25-750, 25-500, 25-250, 25-100, 25-75, 25-50, 50-1000, 50-750, 50-500, 50-250, 50-100, 100-1000, 100-750, 100-500, 100-250, 250-1000, 250-750, 250-500, 500-1000, 500-750, or 750-1000%.

[0154] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject prevents a stroke (which may also be accompanied by a reduction in the severity of any stroke that occurs). In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof prevents motor function loss disorders, prevents the incidence of microhemorrhages, prevents elevated levels of activated microglia, prevents elevated levels of activated astrocytes, prevents elevated circulating pro-inflammatory immune cells, prevents elevated circulating pro-inflammatory cytokines, or any combination thereof in a subject.

[0155] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the likelihood of stroke or reduces the likelihood of severe stroke by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or any percentage within a range defined by any two of the aforementioned reductions. In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the likelihood of stroke or reduces the likelihood of severe stroke by at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more, or any percentage within a range defined by any two of the aforementioned reductions.

[0156] In some embodiments, administering an anti-Gal3 antibody or binding fragment thereof to a subject treats stroke. In some embodiments, administering an anti-Gal3 antibody or binding fragment thereof reduces motor dysfunction, reduces microhemorrhage, reduces levels of activated microglia, reduces levels of activated astrocytes, reduces levels of circulating pro-inflammatory immune cells, reduces levels of circulating pro-inflammatory cytokines, or any combination thereof in the subject.

[0157] In some embodiments, the subject is provided with a reduction in motor dysfunction, a reduction in microhemorrhages, The reduction in motor dysfunction, the reduction in activated microglia levels, the reduction in activated astrocyte levels, the reduction in circulating pro-inflammatory cytokine levels, or any combination thereof, is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more, or any percentage within a range defined by any two of the aforementioned reductions. In some embodiments, the reduction in motor dysfunction in the subject is at least 50%. In some embodiments, the reduction in motor dysfunction is assessed by the Hugel-Meyer Assessment (FMA), the Motor Assessment Scale (MAS), and / or the Chedok-McMaster Stroke Assessment (CMSA). In some embodiments, the reduction in microhemorrhage in the subject is at least 50%. In some embodiments, the reduction in microhemorrhage is assessed by neuroimaging, MRI, and / or Prussian blue staining. In some embodiments, the reduction in activated microglia levels in the subject is at least 20%. In some embodiments, the reduction in the level of activated microglia is assessed by detecting a microglia activation marker. In some embodiments, the microglia activation marker includes, but is not limited to, ionized calcium-binding adaptor molecule 1 (Iba1), monocyte chemoattractant protein-1 (MCP-1), chitinase-3-like protein 1 (YKL-40), and / or soluble CD14 (sCD14). In some embodiments, the microglia activation marker is detected in the cerebrospinal fluid of the subject. In some embodiments, the reduction in the level of activated astrocytes in the subject is at least 30%. In some embodiments, the reduction in the level of activated astrocytes is assessed by detecting an astrocyte activation marker. In some embodiments, the astrocyte activation marker includes, but is not limited to, GFAP. In some embodiments, the astrocyte activation marker is detected in the cerebrospinal fluid of the subject. In some embodiments, the pro-inflammatory immune cells include NK cells, monocytes, and / or lymphocytes.In some embodiments, pro-inflammatory cytokines include, but are not limited to, IL-6 and / or IL1β.

[0158] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered together with one or more additional therapeutic compositions, for example, one or more additional therapeutic compositions for the treatment of stroke. In some embodiments, the stroke is ischemic stroke, thrombotic stroke, embolic stroke, or transient ischemic attack, and the one or more additional therapeutic compositions comprise a thrombolytic agent, tissue plasminogen activator (tPA), alteplase, reteplase, tenecteplase, desmoteplase, an anticoagulant, an ACE inhibitor, an antihypertensive agent, nicardipine, or any combination thereof. In some embodiments, the stroke is hemorrhagic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage, and the one or more additional therapeutic compositions comprise an antihypertensive agent, nicardipine, or any combination thereof. The administration of the anti-Gal3 antibody or binding fragment thereof may also be accompanied by surgery.

[0159] In addition to methods of selecting subjects as having or at risk of having a stroke and / or detecting remission of symptoms associated with stroke, alternative approaches may also be used. These approaches include the Action Research Arm Test, Barthel Index, Berg Balance Scale, Box and Block Test, Chedoke McMaster Stroke Assessment Scale, Chedoke Arm and Hand Activity Inventory, Clinical Outcome Variables Scale, Functional Ambulation Categories, Functional Independence Measure, Frenchay Activities Index, Motor Assessment Scale, Motricity Test, Nine-hole Peg Test, Rankin Handicap Scale, and Rivermead Mobility Scale. Other approaches may involve the analysis of inflammatory components from blood or cerebrospinal fluid samples from patients. These inflammatory components may include immune cells, such as leukocytes, NK cells, monocytes, and lymphocytes, or pro-inflammatory cytokines.The use of any one or more of these approaches to assess the incidence or risk of stroke may be at the discretion of a trained medical professional.

[0160] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is or comprises any one or more of the sequences set forth in Figures 3A-C, 4A-C, 5, 6, 7, 8, or 9, and comprises any one, two, three, four, five, or six of the CDRs in SEQ ID NOs: 27-538, 801-865, and / or one or both of the VH / VL in SEQ ID NOs: 297-447, 803-865, 926-929. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 in SEQ ID NOs: 27, 71, 112, 170, 221, or 248. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 31, 72, 113, 171, 222, or 249. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 30, 86, 130, 189, 230, or 263. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 34, 74, 116, 174, 225, or 252. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 32, 84, 119, 186, 228, or 255. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 37, 77, 118, 178, 229, 256.In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 34, 74, 126, 187, 225, or 252. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 66, 108, 164, 215, 225, or 291.

[0161] Also disclosed herein are methods for inhibiting, reducing, preventing, and / or treating traumatic brain injury (TBI) in a subject in need thereof, comprising administering to the subject an anti-Gal3 antibody or binding fragment thereof, thereby inhibiting, reducing, preventing, and / or treating TBI.

[0162] In some embodiments, the method further comprises selecting the subject as having or at risk of suffering from a TBI prior to the administering step. In some embodiments, selecting the subject as having a TBI comprises evaluating the subject for level of consciousness, memory loss, and / or Glasgow Coma Scale, neuroimaging (e.g., CT or MRI), and / or detection of TBI biomarkers (including, but not limited to, GFAP and / or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)). In some embodiments, the method further comprises detecting amelioration of symptoms associated with the TBI after the administering step. In some embodiments, TBI is associated with concussion, edema, diffuse axonal injury, spinal cord injury, coma, neuroinflammation, microhemorrhage, astrocytosis, activated microglia, and / or hematoma. In some embodiments, any of the methods disclosed herein involving an anti-Gal3 antibody or binding fragment may be performed using an antigen-binding molecule that binds to Gal3.

[0163] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject prevents TBI, concussion, edema, diffuse axonal injury, spinal cord injury, coma, neuroinflammation, microhemorrhage, astrocytosis, activated microglia, and / or hematoma. This may also involve reducing the severity of TBI, concussion, edema, diffuse axonal injury, spinal cord injury, coma, neuroinflammation, microhemorrhage, astrocytosis, activated microglia, and / or hematoma. In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof prevents elevated levels of activated microglia, elevated levels of activated astrocytes, elevated levels of macrophages, elevated levels of hyperphosphorylated tau, reduced incidence of microhemorrhage, neuroinflammation, elevated levels of circulating pro-inflammatory cytokines, or any combination thereof in a subject.

[0164] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the likelihood of TBI, concussion, edema, diffuse axonal injury, spinal cord injury, coma, neuroinflammation, microhemorrhage, astrocytosis, activated microglia, and / or hematoma, or reduces the likelihood of severe forms of said conditions, by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the above reductions. In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject reduces the likelihood of TBI, concussion, edema, diffuse axonal injury, spinal cord injury, coma, neuroinflammation, microhemorrhage, astrocytosis, activated microglia, and / or hematoma, or reduces the likelihood of severe forms of said conditions, by at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more, or any percentage within a range defined by any two of the above reductions.

[0165] In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof to a subject treats TBI, concussion, edema, diffuse axonal injury, spinal cord injury, coma, neuroinflammation, microhemorrhage, astrocytosis, activated microglia, and / or hematoma. In some embodiments, administration of an anti-Gal3 antibody or binding fragment thereof improves the patient's level of consciousness, memory loss, and / or Glasgow Coma Scale; and / or reduces the level of activated microglia, the level of activated astrocytes, the level of macrophages, the level of hyperphosphorylated tau, the level of microhemorrhage, the neuroinflammation, the level of circulating pro-inflammatory cytokines, or any combination thereof, in the subject.

[0166] In some embodiments, the subject has a reduction in the level of activated microglia, a reduction in the level of activated astrocytes, a reduction in the level of macrophages, a reduction in the level of hyperphosphorylated tau, a reduction in microhemorrhage, a reduction in neuroinflammation, a reduction in the level of circulating pro-inflammatory cytokines, or any combination thereof, of at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more, or any percentage within a range defined by any two of the above reductions. In some embodiments, the reduction in the level of activated microglia in the subject is at least 70%. In some embodiments, the reduction in the level of activated microglia is assessed by detecting a microglial activation marker. In some embodiments, the microglial activation marker includes, but is not limited to, ionized calcium-binding adaptor molecule 1 (Iba1), monocyte chemoattractant protein-1 (MCP-1), chitinase-3-like protein 1 (YKL-40), and / or soluble CD14 (sCD14). In some embodiments, the microglial activation marker is detected in the subject's cerebrospinal fluid. In some embodiments, the reduction in the level of activated astrocytes in the subject is at least 90%. In some embodiments, the reduction in the level of activated astrocytes is assessed by detection of an astrocyte activation marker. In some embodiments, the astrocyte activation marker includes, but is not limited to, GFAP. In some embodiments, the astrocyte activation marker is detected in the subject's cerebrospinal fluid. In some embodiments, the reduction in the level of macrophages in the subject is at least 70%. In some embodiments, the reduction in the level of macrophages is assessed by detection of a macrophage activation marker. In some embodiments, the macrophage activation marker includes, but is not limited to, CD68. In some embodiments, the macrophage activation marker is detected in the subject's cerebrospinal fluid.In some embodiments, the reduction in the level of hyperphosphorylated tau in the subject is at least 80%. In some embodiments, the reduction in the level of microhemorrhage in the subject is at least 80%. In some embodiments, the reduction in the level of microhemorrhage is assessed by neuroimaging, MRI, and / or Prussian blue staining. In some embodiments, the reduction in neuroinflammation in the subject is at least 70%. In some embodiments, the pro-inflammatory cytokines include IL-6, IL-10, and / or TNF-α.

[0167] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered together with one or more additional therapeutic compositions, for example, one or more additional therapeutic compositions for the treatment of TBI. In some embodiments, the one or more additional therapeutic compositions include levodopa, bromocriptine, an NMDA receptor antagonist, amantadine, memantine, a cholinesterase inhibitor, tacrine, rivastigmine, galantamine, donepezil, or any combination thereof. The administration of the anti-Gal3 antibody or binding fragment thereof may also be accompanied by surgery.

[0168] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is or comprises any one or more of the sequences set forth in Figures 3A-C, 4A-C, 5, 6, 7, 8, or 9, and comprises any one, two, three, four, five, or six of the CDRs in SEQ ID NOs: 27-538, 801-865, and / or one or both of the VH / VL in SEQ ID NOs: 297-447, 803-865, 926-929. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 in SEQ ID NOs: 27, 71, 112, 170, 221, or 248. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 31, 72, 113, 171, 222, or 249. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 30, 86, 130, 189, 230, or 263. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 34, 74, 116, 174, 225, or 252. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 32, 84, 119, 186, 228, or 255. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 37, 77, 118, 178, 229, 256.In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 34, 74, 126, 187, 225, or 252. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 66, 108, 164, 215, 225, or 291.

[0169] Also disclosed herein are methods for inhibiting, reducing, preventing, and / or treating a disorder associated with fibrin activity or dysfunction in a subject in need thereof, comprising administering to the subject an anti-Gal3 antibody or binding fragment thereof, thereby inhibiting, reducing, preventing, and / or treating the disorder associated with fibrin activity or dysfunction.

[0170] In some embodiments, the disorder associated with fibrin activity or dysfunction comprises atherosclerosis, thrombosis, thromboembolism, carotid artery disease, coronary artery disease, peripheral artery disease, myocardial infarction, heart failure, heart attack, hypertension, chronic kidney disease, coagulation disorders, or thrombocytosis. In some embodiments, the disorder associated with fibrin activity or dysfunction is atherosclerosis. In some embodiments, the disorder associated with fibrin activity or dysfunction is thrombosis. In some embodiments, the disorder associated with fibrin activity or dysfunction is thromboembolism. In some embodiments, the disorder associated with fibrin activity or dysfunction is carotid artery disease. In some embodiments, the disorder associated with fibrin activity or dysfunction is coronary artery disease. In some embodiments, the disorder associated with fibrin activity or dysfunction is peripheral artery disease. In some embodiments, the disorder associated with fibrin activity or dysfunction is myocardial infarction. In some embodiments, the disorder associated with fibrin activity or dysfunction is heart failure. In some embodiments, the disorder associated with fibrin activity or dysfunction is chronic kidney disease. In some embodiments, the disorder associated with fibrin activity or dysfunction is a coagulation disorder. In some embodiments, the disorder associated with fibrin activity or dysfunction is a thrombocytosis. In some embodiments, the method further comprises, prior to the administering step, selecting the subject as having or at risk of developing a disorder associated with fibrin activity or dysfunction. In some embodiments, selecting the subject as having a disorder associated with fibrin activity or dysfunction comprises detecting a thrombus biomarker. In some embodiments, the thrombus biomarker includes, but is not limited to, fibrinogen, C-reactive protein (CRP), and / or plasminogen activator inhibitor-1 (PAI-1). In some embodiments, the method further comprises, after the administering step, detecting amelioration of symptoms associated with the disorder associated with fibrin activity or dysfunction.In some embodiments, any of the methods disclosed herein involving anti-Gal3 antibodies or binding fragments can be performed using an antigen-binding molecule that binds to Gal3.

[0171] In some embodiments, administering an anti-Gal3 antibody or binding fragment thereof to a subject prevents neuroinflammation and / or fibrin oligomerization in the subject. In some embodiments, administering an anti-Gal3 antibody or binding fragment thereof to a subject reduces neuroinflammation and / or fibrin oligomerization in the subject.

[0172] In some embodiments, the reduction in neuroinflammation and / or reduction in fibrin oligomerization in a subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the above reductions.

[0173] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered with one or more additional therapeutic compositions, such as one or more additional therapeutic compositions used to treat disorders associated with fibrin activity or dysfunction, atherosclerosis, thrombosis, thromboembolism, carotid artery disease, coronary artery disease, peripheral artery disease, myocardial infarction, heart failure, heart attack, hypertension, chronic kidney disease, coagulation disorders, or thrombocytopathy. In some embodiments, the one or more additional therapeutic compositions comprise an anticoagulant, aspirin, statin, antihypertensive, diuretic, calcium channel blocker, ACE inhibitor, angiotensin II receptor antagonist, adrenergic receptor antagonist, vasodilator, renin inhibitor, aldosterone receptor antagonist, endothelial receptor blocker, or any combination thereof. The administration of the anti-Gal3 antibody or binding fragment thereof may also be accompanied by surgery.

[0174] In addition to the indications provided herein, it is contemplated that anti-Gal3 antibodies and binding fragments thereof are also effective for related indications, such as inflammation-related indications in which a subject would benefit from a reduction in pro-inflammatory cytokines. In some embodiments, methods are provided for inhibiting, reducing, preventing, and / or treating disorders associated with inflammation and elevated pro-inflammatory cytokines in a subject in need thereof. The methods include administering an anti-Gal3 antibody or binding fragment thereof to the subject, thereby treating the disorder associated with inflammation. In some embodiments, the administration reduces pro-inflammatory cytokines, such as circulating cytokines, in the subject.

[0175] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is or comprises any one or more of the sequences set forth in Figures 3A-C, 4A-C, 5, 6, 7, 8, or 9, and comprises any one, two, three, four, five, or six of the CDRs in SEQ ID NOs: 27-538, 801-865, and / or one or both of the VH / VL in SEQ ID NOs: 297-447, 803-865, 926-929. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 in SEQ ID NOs: 27, 71, 112, 170, 221, or 248. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 31, 72, 113, 171, 222, or 249. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 30, 86, 130, 189, 230, or 263. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 34, 74, 116, 174, 225, or 252. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 32, 84, 119, 186, 228, or 255. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 37, 77, 118, 178, 229, 256.In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 34, 74, 126, 187, 225, or 252. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 66, 108, 164, 215, 225, or 291.

[0176] When applied to any of the methods disclosed herein comprising administering an anti-Gal3 antibody or binding fragment thereof to a subject, in some embodiments, administering the anti-Gal3 antibody or binding fragment thereof to a subject comprises administering one or more unit doses of the anti-Gal3 antibody or binding fragment thereof, optionally 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 unit doses. In some embodiments, 5, 6, 7, 8, 9, or 10 unit doses are administered. In some embodiments, 5 unit doses are administered. In some embodiments, 8 unit doses are administered. In some embodiments, one or more unit doses comprise 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500, or 5000 mg of anti-Gal3 antibody or binding fragment thereof per unit dose, or any amount per unit dose within a range defined by any two of the above amounts per unit dose. In some embodiments, one or more unit doses are 70-5000 mg of anti-Gal3 antibody or binding fragment thereof per unit dose. In some embodiments, one or more unit doses comprise 800, 900, 1000, 1100, 1200, 1300, 1400, or 1500 mg of anti-Gal3 antibody or binding fragment thereof per unit dose, or any amount per unit dose within a range defined by any two of the above amounts per unit dose. In some embodiments, one or more unit doses comprise 1000 mg or about 1000 mg of anti-Gal3 antibody or binding fragment thereof per unit dose.In some embodiments, one or more unit doses comprise 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 mg per kg of subject body weight, or any amount per unit dose within a range defined by any two of the above amounts per unit dose. In some embodiments, one or more unit doses comprise 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mg per kg of subject body weight, or any amount per unit dose within a range defined by any two of the above-mentioned amounts per unit dose. In some embodiments, one or more unit doses comprise 10 mg or about 10 mg per kg of subject body weight. In some embodiments, a combined total of 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, or 10000 mg of anti-Gal3 antibodies or binding fragments thereof is administered to a subject. In some embodiments, a combined total of 4000, 4500, 5000, 5500, or 6000 mg of anti-Gal3 antibodies or binding fragments thereof is administered to a subject. In some embodiments, a combined total of 5000 mg of anti-Gal3 antibodies or binding fragments thereof is administered to a subject. In some embodiments, one or more unit doses are administered every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, or 4 weeks, or any interval within a range defined by any two of the above intervals. In some embodiments, one or more unit doses are administered every 7 days or about every 7 days. In some embodiments, one or more unit doses comprise 1000 mg or about 1000 mg of an anti-Gal3 antibody or binding fragment thereof per unit dose, and the unit doses are administered every 7 days or about every 7 days. In some embodiments, five unit doses comprise 1000 mg or about 1000 mg of an anti-Gal3 antibody or binding fragment thereof per unit dose, and the unit doses are administered every 7 days or about every 7 days.In some embodiments, the one or more unit doses are administered over 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 minutes, or any amount of time within a range defined by any two of the aforementioned durations. In some embodiments, the one or more unit doses are administered over 60 minutes or about 60 minutes. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered enterally, orally, intranasally, parenterally, intracranially, subcutaneously, intramuscularly, intradermally, or intravenously, or any combination thereof, optionally intravenously.

[0177] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is or comprises any one or more of the sequences set forth in Figures 3A-C, 4A-C, 5, 6, 7, 8, or 9, and comprises any one, two, three, four, five, or six of the CDRs in SEQ ID NOs: 27-538, 801-865, and / or one or both of the VH / VL in SEQ ID NOs: 297-447, 803-865, 926-929. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 in SEQ ID NOs: 27, 71, 112, 170, 221, or 248. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 31, 72, 113, 171, 222, or 249. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 30, 86, 130, 189, 230, or 263. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 34, 74, 116, 174, 225, or 252. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 32, 84, 119, 186, 228, or 255. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 37, 77, 118, 178, 229, 256.In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 34, 74, 126, 187, 225, or 252. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one, two, three, four, five, or six of the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and / or VL-CDR3 of SEQ ID NOs: 66, 108, 164, 215, 225, or 291.

[0178] When applied to any of the methods comprising administering an anti-Gal3 antibody or binding fragment thereof, in some embodiments, the anti-Gal3 antibody or binding fragment thereof selectively binds to the N-terminal domain of Gal3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to peptide 1 (SEQ ID NO: 3), peptide 6 (SEQ ID NO: 8), or peptide 7 (SEQ ID NO: 9), or any combination thereof. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises: (1) a heavy chain variable region comprising VH-CDR1, VH-CDR2, and VH-CDR3; and (2) a light chain variable region comprising VL-CDR1, VL-CDR2, and VL-CDR3. In some embodiments, VH-CDR1 comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any one of the amino acid sequences of SEQ ID NOs: 27 to 70. In some embodiments, VH-CDR2 comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any one of the amino acid sequences of SEQ ID NOs: 71 to 111, 801. In some embodiments, VH-CDR3 comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any one of the amino acid sequences of SEQ ID NOs: 112-169, 802. In some embodiments, VL-CDR1 comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any one of the amino acid sequences of SEQ ID NOs: 170-220.In some embodiments, VL-CDR2 comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any one of the amino acid sequences of SEQ ID NOs: 221 to 247. In some embodiments, VL-CDR3 comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any one of the amino acid sequences of SEQ ID NOs: 248 to 296. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a combination of VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 shown in Figure 7. In some embodiments, the heavy chain variable region comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 297-373, 803, 806-820. In some embodiments, the light chain variable region comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 374-447, 821-835. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain, wherein the heavy chain is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a sequence selected from SEQ ID NOs: 448-494, 804, 836-850. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a light chain, wherein the light chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 495-538, 805, and 851-865. In some embodiments, any of the methods disclosed herein involving an anti-Gal3 antibody or binding fragment may be performed using an antigen-binding molecule that binds to Gal3.

[0179] When applied to any of the methods disclosed herein comprising administering an anti-Gal3 antibody or binding fragment thereof, in some embodiments, the anti-Gal3 antibody or binding fragment thereof is selected from the group consisting of TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6 H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5, 23B10.2B1 2, 24D12.2H9, F846C.1B2, F846C.1F5, F846C.1H12, F846C.1H5, F846C.2H3, F846TC.14A2, F846TC.14E4, F846TC.16B5, F846TC.7F10, F847C.10B9, F84 7C.11B1, F847C.12F12, F847C.26F5, F847C.4B10, F849C.8D10, F849C.8H3, 846.2B11, 846.4D5, 846T.1H2, 847.14H4, 846.2D4, 846.2F11, 846T.10B1, 846T.2E3, 846T.4C9, 846T.4E11, 846T.4F5, 846T.8D1, 847.10C9, 847.11D6 , 847.15D12, 847.15F9, 847.15H11, 847.20H7, 847.21B11, 847.27B9, 847. 28D1, 847.2B8, 847.3B3, 849.1D2, 849.2D7, 849.2F12, 849.4B2, 849.4F12, 849.4F2, 849.5C2, 849.8D12, F847C.21H6, 849.5H1, 847.23F11, 847.16D1 0, 847.13E2-mH0mL1, 847.13E2-mH0mL2, 847.12C4, 847.4D3, 2D10-VH0-VL0 , 2D10-hVH4-HVL1, 2D10-hVH4-HVL2, 2D10-hVH4-HVL3, 2D10-hVH4-HVL4, 2D 10-hVH3-HVL1, 2D10-hVH3-HVL2, 2D10-hVH3-HVL3, 2D10-hVH3-HVL4, 20H5.

[0023] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is selected from the group consisting of 20H5.A3-VH3VL1, 20H5.A3-VH3VL3, 20H5.A3-VH4VL1, 20H5.A3-VH5VL1, 20H5.A3-VH5VL3, 20H5.A3-VH6VL1, 20H5.A3-VH6VL3, or a binding fragment thereof. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one or more of TB001, TB006, F846C.1F5, F846TC.16B5, 14H10.2C9, 15G7.2A7, 20H5.A3, 19D9.2E5, 19B5.2E6, or F847C.21H6. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises TB001. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises TB006. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises F846C.1F5. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises F846TC.16B5. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises 14H10.2C9. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises 15G7.2A7. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises 20H5.A3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises 19D9.2E5. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises 19B5.2E6. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises F847C.21H6. In some embodiments, any of the methods disclosed herein involving anti-Gal3 antibodies or binding fragments can be performed using an antigen-binding molecule that binds to Gal3.

[0180] When applied to any of the methods of use disclosed herein, in some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to one or more peptides set forth in SEQ ID NOs: 3-26. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to an epitope present within a region of Gal3 defined by peptide 1 (ADNFSLHDALSGSGNPNPQG; SEQ ID NO: 3), peptide 4 (GAGGYPGASYPGAYPGQAPP; SEQ ID NO: 6), peptide 6 (GAYPGQAPPGAYPGAPGAYP; SEQ ID NO: 8), peptide 7 (AYPGAPGAYPGAPAPGVYPG; SEQ ID NO: 9), or a combination thereof. In some embodiments, any of the methods disclosed herein involving an anti-Gal3 antibody or binding fragment may be performed using an antigen-binding molecule that binds to Gal3.

[0181] When applied to any of the methods of use disclosed herein, in some embodiments, an anti-Gal3 antibody or binding fragment thereof binds to an epitope of Gal3 containing a GxYPG motif (where x is the amino acid alanine (A), glycine (G), or valine (V)). In some embodiments, an anti-Gal3 antibody described herein binds to an epitope of Gal3 containing two GxYPG motifs (where x is A, G, or V) separated by three amino acids. In some embodiments, any of the methods disclosed herein involving an anti-Gal3 antibody or binding fragment may be performed using an antigen-binding molecule that binds to Gal3.

[0182] When applied to any of the methods of use disclosed herein, in some embodiments, an exemplary VH-CDR1 sequence is depicted in Figure 3A. In some embodiments, an exemplary VH-CDR2 sequence is depicted in Figure 3B. In some embodiments, an exemplary VH-CDR3 sequence is depicted in Figure 3C. In some embodiments, an exemplary VL-CDR1 sequence is depicted in Figure 4A. In some embodiments, an exemplary VL-CDR2 sequence is depicted in Figure 4B. In some embodiments, an exemplary VL-CDR3 sequence is depicted in Figure 4C. In some embodiments, any of the methods disclosed herein involving anti-Gal3 antibodies or binding fragments may be performed using an antigen-binding molecule that binds to Gal3.

[0183] When applied to any of the methods of use disclosed herein, in some embodiments, the heavy chain variable region of any of the anti-Gal3 antibodies or binding fragments thereof disclosed herein comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 100% sequence identity to any sequence according to SEQ ID NOs: 297-373, 803, 806-82. In some embodiments, the heavy chain variable region of any of the anti-Gal3 antibodies or binding fragments thereof disclosed herein is selected from the group consisting of SEQ ID NOs: 297-373, 803, 806-82. In some embodiments, exemplary VH sequences are depicted in Figure 5. In some embodiments, any of the methods disclosed herein involving anti-Gal3 antibodies or binding fragments may be performed using an antigen-binding molecule that binds to Gal3.

[0184] When applied to any of the methods of use disclosed herein, in some embodiments, the light chain variable region of any of the anti-Gal3 antibodies or binding fragments thereof disclosed herein comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 100% sequence identity to any sequence according to SEQ ID NOs: 374-447, 821-835. In some embodiments, the light chain variable region of any of the anti-Gal3 antibodies or binding fragments thereof disclosed herein comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, or 100% sequence identity to any sequence according to SEQ ID NOs: 374-447, 821-835. In some embodiments, an exemplary VL sequence is depicted in Figure 6. In some embodiments, any of the methods disclosed herein involving an anti-Gal3 antibody or binding fragment may be performed using an antigen-binding molecule that binds to Gal3.

[0185] When applied to any of the methods of use disclosed herein, in some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises the heavy chain sequence of any one of SEQ ID NOs: 448-494, 804, 836-850. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises the light chain sequence of any one of SEQ ID NOs: 495-538, 805, 851-865. In some embodiments, any of the methods disclosed herein involving an anti-Gal3 antibody or binding fragment may be performed using an antigen-binding molecule that binds to Gal3.

[0186] When applied to any of the methods of use disclosed herein, in some embodiments, the anti-Gal3 antibody or binding fragment thereof excludes a subset of the listed anti-Gal3 antibodies or binding fragments thereof depicted in any one of Figures 19A-D. In some embodiments, CDRs (including heavy and light chain CDRs), heavy chain variable regions, light chain variable regions, heavy chains, and / or light chains are excluded from the sequences associated with the subset of listed anti-Gal3 antibodies or binding fragments thereof depicted in any one of Figures 19A-D. In some embodiments, a combination of CDRs (including heavy and light chain CDRs), heavy chain variable regions, light chain variable regions, heavy chains, and / or light chains is excluded from the sequences associated with the subset of listed anti-Gal3 antibodies or binding fragments thereof depicted in any one of Figures 19A-D, or excludes any one or more of its CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof excludes one selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 19A, or excludes any one or more of their CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof excludes one selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 19B, or excludes any one or more of their CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof excludes one selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 19C, or excludes any one or more of their CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof excludes one selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 19D, or excludes any one or more of its CDRs, VH, VL, HC, and / or LC.

[0187] When applied to any of the methods of use disclosed herein, in some embodiments, the anti-Gal3 antibody or binding fragment thereof is selected from the subset of listed anti-Gal3 antibodies or binding fragments thereof depicted in any one of Figures 20A-D. In some embodiments, the CDRs (including heavy and light chain CDRs), heavy chain variable region, light chain variable region, heavy chain, and / or light chain are selected from sequences associated with the subset of listed anti-Gal3 antibodies or binding fragments thereof depicted in any one of Figures 20A-D. In some embodiments, the combination of CDRs (including heavy and light chain CDRs), heavy chain variable region, light chain variable region, heavy chain, and / or light chain is selected from sequences associated with the subset of listed anti-Gal3 antibodies or binding fragments thereof depicted in any one of Figures 20A-D. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 20A, or comprises any one or more of their CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 20B, or comprises any one or more of their CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 20C, or comprises any one or more of their CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 20D, or comprises any one or more of their CDRs, VH, VL, HC, and / or LC.

[0188] In some embodiments, when applied to any of the methods of use disclosed herein, the anti-Gal3 antibody or its binding fragment comprises a payload. In some embodiments, the payload is conjugated to the anti-Gal3 antibody or its binding fragment. In some embodiments, the payload is a cytotoxic payload, a microtubule-disrupting agent, a DNA-modifying agent, an Akt inhibitor, a polymerase inhibitor, a detectable moiety, an immunomodulator, an immunotoxin, a nucleic acid polymer, an aptamer, a peptide, or any combination thereof. In some embodiments, the payload is a detectable moiety. In some embodiments, any of the methods disclosed herein involving an anti-Gal3 antibody or binding fragment can be performed using an antigen-binding molecule that binds to Gal3.

[0189] When applied to any of the methods of use disclosed herein, in some embodiments, the anti-Gal3 antibody or binding fragment thereof is or comprises a humanized antibody. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is or comprises a full-length antibody or binding fragment thereof. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is or comprises a bispecific antibody or binding fragment thereof. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is or comprises a monovalent Fab', a bivalent Fab2, a single-chain variable fragment (scFv), a diabody, a minibody, a nanobody, a single-domain antibody (sdAb), or a camelid antibody or binding fragment thereof. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is or comprises an IgG framework. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is or comprises an IgG1, IgG2, or IgG4 framework. In some embodiments, any of the methods disclosed herein involving an anti-Gal3 antibody or binding fragment may be performed using an antigen-binding molecule that binds to Gal3.

[0190] When applied to any of the therapeutic methods disclosed herein, in some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered enterally, orally, intranasally, parenterally, intracranially, subcutaneously, intramuscularly, intradermally, or intravenously, or any combination thereof.

[0191] When applied to any of the methods of treatment disclosed herein, subjects are administered TB006 sterile drug product supplied in 8 mL glass vials sealed with rubber stoppers and aluminum flip tops, at a strength of 160 mg of TB006 drug product per vial (20 mg / mL, 8 mL).

[0192] When applied to any of the methods of treatment disclosed herein, subjects will receive TB006 sterile drug product via IV infusion over 60 minutes after dilution in 0.9% Sodium Chloride Injection, USP (normal saline) to a final volume of 250 mL.

[0193] When applied to any of the therapeutic methods disclosed herein, in some embodiments, the anti-Gal3 antibody or binding fragment thereof is formulated for systemic administration. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is formulated for parenteral administration. In some embodiments, more than one anti-Gal3 antibody or binding fragment is administered. In some embodiments, when more than one anti-Gal3 antibody or binding fragment is administered, the more than one anti-Gal3 antibody or binding fragment thereof may be selected from the anti-Gal3 antibodies or binding fragments thereof disclosed herein. In some embodiments, any of the methods disclosed herein involving an anti-Gal3 antibody or binding fragment may be performed using an antigen-binding molecule that binds to Gal3.

[0194] When applied to any of the uses or treatment methods disclosed herein, the subject is a mammal.In some embodiments, the mammal is a human, cat, dog, mouse, rat, hamster, rodent, pig, cow, horse, sheep or goat.In some embodiments, the mammal is a human.

[0195] Treatment regimen In some embodiments, the anti-Gal3 antibody or binding fragment thereof disclosed herein is administered for therapeutic purposes. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered once daily, twice daily, three or more times daily. The anti-Gal3 antibody or binding fragment thereof is administered daily, every other day, five days a week, once a week, every two weeks, two weeks a month, three weeks a month, once a month, twice a month, three or more times a month. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 18 months, two years, three years or more.

[0196] If the patient's condition improves, at the physician's discretion, administration of the anti-Gal3 antibody or binding fragment thereof may be given continuously; alternatively, the dose of the anti-Gal3 antibody or binding fragment thereof being administered may be temporarily reduced or temporarily discontinued for a certain length of time (i.e., a "drug holiday"). In some cases, the length of the drug holiday may vary from 2 days to 1 year, and may include, by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. Dose reductions between drug holidays range from 10% to 100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

[0197] In an exemplary treatment regimen, the anti-Gal3 antibody or binding fragment thereof is administered in 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 unit doses. In some embodiments, 5, 6, 7, 8, 9, or 10 unit doses are administered. In some embodiments, 5 unit doses are administered. In some embodiments, 8 unit doses are administered. In some embodiments, each unit dose contains 1000 mg or about 1000 mg of the anti-Gal3 antibody or binding fragment thereof, the unit doses are administered every 7 days or about 7 days, and each unit dose is administered over 1 hour or about 1 hour. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is TB006 or a binding fragment thereof. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered enterally, orally, intranasally, parenterally, intracranially, or subcutaneously. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered intravenously.

[0198] In an exemplary treatment regimen, the anti-Gal3 antibody or binding fragment thereof is administered in 5 unit doses. In some embodiments, each unit dose contains 50, The anti-Gal3 antibody or binding fragment thereof may be present in an amount of 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500, or 5000 mg per unit dose, or any amount per unit dose within a range defined by any two of the above-mentioned amounts per unit dose. In some embodiments, each unit dose contains 800, 900, 1000, 1100, 1200, 1300, 1400, or 1500 mg of anti-Gal3 antibody or binding fragment thereof per unit dose, or any amount per unit dose within a range defined by any two of the above amounts per unit dose. In some embodiments, each unit dose contains 1000 mg or about 1000 mg of anti-Gal3 antibody or binding fragment thereof per unit dose. The unit doses are administered every 7 days or about every 7 days, and each unit dose is administered over 1 hour or about 1 hour. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is TB006 or a binding fragment thereof. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered enterally, orally, intranasally, parenterally, intracranially, or subcutaneously. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered intravenously.

[0199] In an exemplary treatment regimen, the anti-Gal3 antibody or binding fragment thereof is administered in 5 unit doses, each unit dose containing 1000 mg or about 1000 mg of the anti-Gal3 antibody or binding fragment thereof per unit dose. In some embodiments, the unit dose is administered every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, or 4 weeks, or any interval within a range defined by any two of the above intervals. In some embodiments, the unit dose is administered every 7 days or about every 7 days. Each unit dose is administered over 1 hour or about 1 hour. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is TB006 or a binding fragment thereof. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered enterally, orally, intranasally, parenterally, intracranially, or subcutaneously. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered intravenously.

[0200] In an exemplary treatment regimen, the anti-Gal3 antibody or binding fragment thereof is administered in 5 unit doses, each unit dose containing 1000 mg or about 1000 mg of the anti-Gal3 antibody or binding fragment thereof per unit dose, and the unit doses are administered every 7 days or about every 7 days. In some embodiments, each unit dose is administered over 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 minutes, or any amount of time within a range defined by any two of the above durations. In some embodiments, each unit dose is administered over 1 hour or about 1 hour. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is TB006 or a binding fragment thereof. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered enterally, orally, intranasally, parenterally, intracranially, or subcutaneously. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered intravenously.

[0201] In an exemplary treatment regimen, the anti-Gal3 antibody or binding fragment thereof is administered in 5 unit doses, each unit dose containing 1000 mg or about 1000 mg of the anti-Gal3 antibody or binding fragment thereof, the unit doses being administered every 7 days or about every 7 days, and each unit dose being administered over 1 hour or about 1 hour. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is TB006 or a binding fragment thereof. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered enterally, orally, intranasally, parenterally, intracranially, or subcutaneously. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is administered intravenously.

[0202] In some embodiments, the anti-Gal3 antibody or binding fragment thereof, e.g., TB006, is supplied in 8 mL glass vials sealed with rubber stoppers and aluminum flip tops at a strength of 160 mg of anti-Gal3 antibody or binding fragment per vial (20 mg / mL, 8 mL).

[0203] In some embodiments, the anti-Gal3 antibody or binding fragment thereof, e.g., TB006, is administered via IV infusion over 60 minutes after dilution in 0.9% Sodium Chloride Injection, USP (normal saline) to a final volume of 250 mL.

[0204] Once improvement of the patient's condition has occurred, a maintenance dose is administered if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced as a function of symptoms to a level at which treatment of the disease, disorder, or condition is maintained.

[0205] In some embodiments, any one of the suitable regimens provided herein is carried out to include administering to a subject 5 unit doses of 1000 mg or about 1000 mg of an anti-Gal3 antibody or binding fragment thereof, e.g., TB006, every 7 days or about every 7 days, and assessing the subject using the NIHSS at baseline (day 1 at the time of initial administration), and further assessing at days 15, 36, 64, and 104 after the initial intervention.

[0206] In some embodiments, the amount of a given agent that corresponds to such an amount will vary depending on factors such as the particular compound, the severity of the disease, and the identity (e.g., body weight) of the subject or host requiring treatment, but will nevertheless be routinely determined in a manner known in the art according to the particular circumstances surrounding the case, including, for example, the particular agent being administered, the route of administration, and the subject or host being treated. In some cases, the desired dose is conveniently provided in a single dose or as divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, for example, as two, three, four, or more partial doses per day.

[0207] The above ranges are only suggestive, as the number of variables associated with any particular treatment regime is large, and significant deviations from these recommended values ​​are not uncommon. Such dosages will vary depending on a number of variables, including but not limited to, the activity of the compound being used, the disease or condition being treated, the mode of administration, the needs of the particular subject, the severity of the disease or condition being treated, and the judgment of the physician.

[0208] In some embodiments, the toxicity and therapeutic efficacy of such treatment regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LD50 and ED50. Compounds that exhibit high therapeutic indices are preferred. Data obtained from cell culture assays and animal studies are used in formulating a dosage range for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that includes the ED50 with minimal toxicity. Dosages vary within this range depending on the dosage form employed and the route of administration utilized.

[0209] Exemplary Anti-Gal3 Antibodies and Binding Fragments Thereof Anti-Gal3 antibodies or binding fragments thereof are disclosed herein and can be used in any of the methods or uses disclosed herein. In some embodiments, the anti-Gal3 antibodies or binding fragments thereof bind to the N-terminal domain of Gal3, the N-terminus of Gal3, or the tandem repeat domain (TRD) of Gal3. In some embodiments, the anti-Gal3 antibodies or binding fragments thereof do not bind to the N-terminus of Gal3, the N-terminal domain of Gal3, or the TRD of Gal3. In some embodiments, the anti-Gal3 antibodies or binding fragments thereof bind to the C-terminus of Gal3, the C-terminal domain of Gal3, or the CRD of Gal3. In some embodiments, the anti-Gal3 antibodies or binding fragments thereof do not bind to the C-terminus of Gal3, the C-terminal domain of Gal3, or the CRD of Gal3. In some embodiments, any of the anti-Gal3 antibodies or binding fragments thereof, or any configuration of any of the anti-Gal3 antibodies or binding fragments thereof provided herein, may be replaced with an antigen-binding molecule that binds to Gal3.

[0210] In some embodiments, an antibody or a binding fragment thereof is provided. In some embodiments, the antibody is an anti-Gal3 antibody or a binding fragment thereof. In some embodiments, the anti-Gal3 antibody or a binding fragment thereof comprises a heavy chain variable region comprising VH-CDR1, VH-CDR2, and VH-CDR3. In some embodiments, the anti-Gal3 antibody or a binding fragment thereof comprises a light chain variable region comprising VL-CDR1, VL-CDR2, and VL-CDR3. In some embodiments, VH-CDR1 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity or similarity to any amino acid sequence according to SEQ ID NOs: 27-70. In some embodiments, VH-CDR2 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity or similarity to any amino acid sequence according to SEQ ID NOs: 71-111, 801. In some embodiments, the VH-CDR3 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity or similarity to any amino acid sequence according to SEQ ID NOs: 112-169, 802.In some embodiments, VL-CDR1 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity or similarity to any amino acid sequence according to SEQ ID NOs: 170-220. In some embodiments, the VL-CDR2 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity or similarity to any amino acid sequence according to SEQ ID NOs:221-247. In some embodiments, the VL-CDR3 is at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any amino acid sequence according to SEQ ID NOs: 248-296. 9, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity or similarity to a set of VL sequences, VH sequences, VL / VH pairings, and / or VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, VL-CDR3 (comprising 1, 2, 3, 4, or 5 amino acid substitutions in any one or more of these CDRs) from the heavy and light chain sequences depicted in FIG.

[0211] In some embodiments, an antibody or binding fragment thereof is provided. In some embodiments, the antibody or binding fragment thereof is an anti-Gal3 antibody or binding fragment thereof. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain variable region comprising VH-CDR1, VH-CDR2, and VH-CDR3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a light chain variable region comprising VL-CDR1, VL-CDR2, and VL-CDR3. In some embodiments, VH-CDR1 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions compared to any amino acid sequence according to SEQ ID NOs: 27-70. In some embodiments, VH-CDR2 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions compared to any amino acid sequence according to SEQ ID NOs: 71-111, 801. In some embodiments, VH-CDR3 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions compared to any amino acid sequence according to SEQ ID NOs: 112-169, 802. In some embodiments, VL-CDR1 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions compared to any amino acid sequence according to SEQ ID NOs: 170-220. In some embodiments, VL-CDR2 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions compared to any amino acid sequence according to SEQ ID NOs: 221-247. In some embodiments, VL-CDR3 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions compared to any amino acid sequence according to SEQ ID NOs: 248-296.

[0212] In some embodiments, the antibody or binding fragment thereof comprises a combination of VL-CDR1, VL-CDR2, VL-CDR3, VH-CDR1, VH-CDR2, and VH-CDR3 shown in Figure 7.

[0213] In some embodiments, an antibody or binding fragment thereof comprises a combination of VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, where one or more of these CDRs are defined by a consensus sequence. The consensus sequences provided herein are derived from an alignment of the CDRs depicted in Figures 18A-B. However, it is contemplated that alternative alignments may be performed (e.g., using global or local alignments, or using different algorithms, such as hidden Markov models, seeded guide trees, the Needleman-Wunsch algorithm, or the Smith-Waterman algorithm), and thus alternative consensus sequences may be derived.

[0214] In some embodiments, the VH-CDR1 has the formula X1X2X3X4X5X6X7X8X9X10 (SEQ ID NO: 935), where X1 is E, G, or R; X2 is F, N, or Y; X3 is A, I, K, N, S, or T; X4 is F, I, or L; X5 is I, K, N, R, S, or T; X6 is D, G, I, N, S, or T; X7 is F, G, H, S, or Y; and X8 is no amino acid, A, D, G, X9 is I, M, N, T, V, W, or Y; X10 is no amino acid, M, or Y; and X10 is no amino acid or G; in some embodiments, VH-CDR1 comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence. In some embodiments, VH-CDR1 comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence (SEQ ID NO: 935).

[0215] In some embodiments, the VH-CDR2 is defined by the formula X1X2X3X4X5X6X7X8X9X10 (SEQ ID NO: 936) (wherein X1 is no amino acid, I, or L; X2 is no amino acid or R; X3 is no amino acid, F, I, L, or V; X4 is A, D, F, H, K, L, N, S, W, or Y; X5 is A, D, P, S, T, W, or Y; X6 is D, E, G, H, K, N, S, V, or Y; X7 is D, E, G, N, S, or T; X8 is D, G, I, K, N, Q, R, S, V, or Y; X9 is A, D, E, G, I, K, N, P, S, T, V, or Y; and X10 is no amino acid, I, P, S, or T). In some embodiments, VH-CDR2 comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence. In some embodiments, VH-CDR2 comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence (SEQ ID NO: 936).

[0216] In some embodiments, the VH-CDR3 has the formula X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20X21X22X23X24X25 (SEQ ID NO: 937), where X1 is no amino acid or A; X2 is no amino acid, A, R, or Y; X3 is no amino acid, A, F, H, K, L, R, S, or V; X4 is no amino acid, A, D, K, N, R, S, or T; and X5 is an amino acid. X6 is no amino acid, A, D, G, H, I, L, N, P, R, S, T, V, or Y; X7 is no amino acid, D, F, G, H, P, R, S, W, or Y; X8 is no amino acid, A, D, E, G, I, R, or S; X9 is no amino acid, A, C, D, E, F, G, I, N, R, S, T, V, or Y; X10 is no amino acid, A, D, M, P, R, S, T, V, or Y; X11 is no amino acid, A, D, E, F, L, T, V, or Y; X12 is no amino acid, A, G, L, M, R, or T; X13 is no amino acid, A, D, E, F, G, R, S, T, or V; X14 is no amino acid, A, D, G, L, P, Q, R, S, T, V, or Y; X15 is no amino acid, A, D, G, N, S, V, W, or Y; X16 is no amino acid, A, D, E, F, L, P, T, V, W, or Y; X17 is no amino acid, F, I, L, M, R, or Y; X18 is no amino acid, A, D, G, N, or T; X19 is no amino acid, F, N, S, T, V, or Y; X20 is no amino acid or L; X21 is no amino acid or A; X22 is no amino acid or W; X23 is no amino acid or F; X24 is no amino acid or A; and X25 is no amino acid or Y). In some embodiments, the VH-CDR3 comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence.In some embodiments, the VH-CDR3 is 0, 1, 2, 3 from this consensus sequence (SEQ ID NO: 937). , 4, 5, or 6 substitutions.

[0217] In some embodiments, the VL-CDR1 has the formula X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17 (SEQ ID NO: 938), where X1 is no amino acid or R; X2 is no amino acid or S; X3 is no amino acid, S, or T; X4 is no amino acid, E, G, K, Q, or R; X5 is no amino acid, A, D, G, I, N, or S; X6 is no amino acid, I, L, or V; X7 is no amino acid, F, L, S, or V; X8 is no amino acid, D, E, H, N, S, T, or Y; and X9 is , no amino acids, D, E, I, K, N, R, S, T, or V; X10 is no amino acids, D, H, N, R, S, or Y; X11 is no amino acids, A, G, N, S, T, or V; X12 is no amino acids, A, I, K, N, Q, T, V, or Y; X13 is no amino acids, D, G, H, K, N, S, T, or Y; X14 is no amino acids, C, F, I, N, S, T, V, or Y; X15 is no amino acids, D, L, N, W, or Y; X16 is no amino acids, N, or D; and X17 is no amino acid or D). In some embodiments, VL-CDR1 comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence (SEQ ID NO: 938). In some embodiments, VL-CDR1 comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence.

[0218] In some embodiments, the VL-CDR2 is defined by the formula X1X2X3X4X5X6X7X8 (SEQ ID NO: 939) (wherein X1 is no amino acid, K, L, N, Q, or R; X2 is no amino acid, A, L, M, or V; X3 is no amino acid, C, K, or S; X4 is no amino acid or T; X5 is no amino acid, A, E, F, G, H, K, Q, R, S, W, or Y; X6 is no amino acid, A, G, or T; X7 is no amino acid, I, K, N, S, or T; and X8 is no amino acid, N, or S). In some embodiments, VL-CDR2 comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence. In some embodiments, VL-CDR2 comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence (SEQ ID NO: 939).

[0219] In some embodiments, the VL-CDR3 has the formula X1X2X3X4X5X6X7X8X9X10 (SEQ ID NO: 940), where X1 is no amino acid, A, E, F, H, L, M, Q, S, V, or W; X2 is A, H, or Q; X3 is D, F, G, H, L, M, N, Q, S, T, W, or Y; X4 is no amino acid or W; and X5 is X is A, D, I, K, L, N, Q, R, S, T, V, or Y; X is D, E, H, I, K, L, N, Q, S, or T; X is D, F, K, L, N, P, S, T, V, W, or Y; X is H, P, or S; X is F, L, P, Q, R, T, W, or Y; and X is no amino acid, T, or V. In some embodiments, the VL-CDR3 comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence. In some embodiments, the VL-CDR3 comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence (SEQ ID NO: 940).

[0220] In some embodiments, the heavy chain variable region of the anti-Gal3 antibody or binding fragment thereof comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity or similarity to a sequence selected from SEQ ID NOs: 297-373, 803, 806-820, and 926. In some embodiments, the light chain variable region of the antibody or binding fragment thereof comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity or similarity to a sequence selected from SEQ ID NOs: 374-447, 821-835, 927-929. In some embodiments, the antibody or binding fragment thereof is an anti-Gal3 antibody or binding fragment thereof.

[0221] In some embodiments, the antibody comprises one or more sequences having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity or similarity to a set of VL sequences, VH sequences, VL / VH pairings, and / or VL-CDR1, VL-CDR2, VL-CDR3, VH-CDR1, VH-CDR2, VH-CDR3 (comprising 1, 2, 3, 4, or 5 amino acid substitutions in any one or more of these CDRs) from the heavy and light chain sequences depicted in Figure 9.

[0222] In some embodiments, an antibody or a binding fragment thereof is provided. In some embodiments, the antibody is an anti-Gal3 antibody or a binding fragment thereof. In some embodiments, the anti-Gal3 antibody or a binding fragment thereof comprises a heavy chain variable region comprising VH-CDR1, VH-CDR2, and VH-CDR3. In some embodiments, the anti-Gal3 antibody or a binding fragment thereof comprises a light chain variable region comprising VL-CDR1, VL-CDR2, and VL-CDR3. In some embodiments, VH-CDR1 comprises one of the amino acid sequences of SEQ ID NOs: 27 to 70, VH-CDR2 comprises one of the amino acid sequences of SEQ ID NOs: 71 to 111, 801, VH-CDR3 comprises one of the amino acid sequences of SEQ ID NOs: 112 to 169, 802, VL-CDR1 comprises one of the amino acid sequences of SEQ ID NOs: 170 to 220, VL-CDR2 comprises one of the amino acid sequences of SEQ ID NOs: 211 to 247, VL-CDR3 comprises one of the amino acid sequences of SEQ ID NOs: 248 to 296, and the heavy chain variable region comprises one of the amino acid sequences of SEQ ID NOs: 297 to 373, 803, 806 to 820, 926. and the light chain variable region has a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to one of the amino acid sequences of SEQ ID NOs: 374-447, 821-835, and 927-929.

[0223] In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain, wherein the heavy chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity or similarity to a sequence selected from SEQ ID NOs: 448-494, 804, 836-850. In some embodiments, the antibody or binding fragment thereof comprises a light chain, wherein the light chain has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity or similarity to a sequence selected from SEQ ID NOs: 495-538, 805, 851-865. 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity to the sequence of any of the sequences of the present invention. In some embodiments, the antibody or binding fragment thereof is an anti-Gal3 antibody or binding fragment thereof.

[0224] In some embodiments, an antibody or a binding fragment thereof is provided. In some embodiments, the antibody is an anti-Gal3 antibody or a binding fragment thereof. In some embodiments, the anti-Gal3 antibody or a binding fragment thereof comprises a heavy chain variable region and a light chain variable region. In some embodiments, the heavy chain variable region is paired with an IgG4 heavy chain constant domain or an IgG2 heavy chain constant domain. In some embodiments, the IgG4 heavy chain constant domain or the IgG2 heavy chain constant domain is human or mouse. In some embodiments, the IgG4 heavy chain constant domain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 931. In some embodiments, the IgG4 heavy chain constant domain is an S228P mutant. In some embodiments, the IgG2 heavy chain constant domain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 933 or SEQ ID NO: 934. In some embodiments, the IgG2 heavy chain constant domain is a LALAPG or LALA mutant. In some embodiments, the light chain variable region is paired with an IgG4 kappa chain constant domain. In some embodiments, the IgG4 kappa chain constant domain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 932. In some embodiments, the light chain variable region and / or heavy chain variable region may be selected from the light chain variable regions and / or heavy chain variable regions depicted in Figures 5 and 6 and / or combinations of light chain variable regions and heavy chain variable regions depicted in Figure 8.In some embodiments, the light chain variable region and / or the heavy chain variable region comprises one or more CDRs depicted in Figures 3A-C, 4A-C and / or a combination of the CDRs depicted in Figure 7.

[0225] In some embodiments, the antibody or binding fragment thereof is selected from the group consisting of TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D 3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5, 23B10.2B12, 24D12.2H9, F846C.1B2, F846C.1F 5, F846C.1H12, F846C.1H5, F846C.2H3, F846TC.14A2, F846TC.14E4, F846TC.16B5, F846TC.7F10, F847C.10B9, F84 7C.11B1, F847C.12F12, F847C.26F5, F847C.4B10, F849C.8D10, F849C.8H3, 846.2B11, 846.4D5, 846T.1H2, 847.14 H4, 846.2D4, 846.2F11, 846T.10B1, 846T.2E3, 846T.4C9, 846T.4E11, 846T.4F5, 846T.8D1, 847.10C9, 847.11D6, 8 47.15D12, 847.15F9, 847.15H11, 847.20H7, 847.21B11, 847.27B9, 847.28D1, 847.2B8, 847.3B3, 849.1D2, 849.2D 7, 849.2F12, 849.4B2, 849.4F12, 849.4F2, 849.5C2, 849.8D12, F847C.21H6, 849.5H1, 847.23F11, 847.16D10, 847 .13E2-mH0mL1, 847.13E2-mH0mL2, 847.12C4, 847.4D3, 2D10-VH0-VL0, 2D10-hVH4-HVL1, 2D 10-hVH4-HVL2, 2D10-hVH4-HVL3, 2D10-hVH4-HVL4, 2D10-hVH3-HVL1, 2D10-hVH3-HVL2, 2D10 - selected from the group consisting of: 2D10-hVH3-HVL3, 2D10-hVH3-HVL4, 20H5.A3-VH3VL1, 20H5.A3-VH3VL3, 20H5.A3-VH4VL1, 20H5.A3-VH5VL1, 20H5.A3-VH5VL3, 20H5.A3-VH6VL1, 20H5.A3-VH6VL3, or a binding fragment thereof.

[0226] In some embodiments, the antibody or binding fragment thereof is selected from the group consisting of TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5, 23 B10.2B12, 24D12.2H9, F846C.1B2, F846C.1F5, F846C.1H12, F846C.1H5, F 846C.2H3, F846TC.14A2, F846TC.14E4, F846TC.16B5, F846TC.7F10, F847C .10B9, F847C.11B1, F847C.12F12, F847C.26F5, F847C.4B10, F849C.8D10, F849C.8H3, 846.2B11, 846.4D5, 846T.1H2, 847.14H4, 846.2D4, 846.2F11, 846T.10B1, 846T.2E3, 846T.4C9, 846T.4E11, 846T.4F5, 846T.8D1, 847.1 0C9, 847.11D6, 847.15D12, 847.15F9, 847.15H11, 847.20H7, 847.21B11, 8 47.27B9, 847.28D1, 847.2B8, 847.3B3, 849.1D2, 849.2D7, 849.2F12, 849. 4B2, 849.4F12, 849.4F2, 849.5C2, 849.8D12, F847C.21H6, 849.5H1, 847.2 3F11, 847.16D10, 847.13E2-mH0mL1, 847.13E2-mH0mL2, 847.12C4, 847.4 D3, 2D10-VH0-VL0, 2D10-hVH4-HVL1, 2D10-hVH4-HVL2, 2D10-hVH4-HVL3, 2 D10-hVH4-HVL4, 2D10-hVH3-HVL1, 2D10-hVH3-HVL2, 2D10-hVH3-HVL3, 2D1 0-hVH3-HVL4, 20H5.A3-VH3VL1, 20H5.A3-VH3VL3, 20H5.A3-VH4VL1, 20H5.and / or 20H5.A3-VH5VL1, 20H5.A3-VH5VL3, 20H5.A3-VH6VL1, 20H5.A3-VH6VL3, or a binding fragment thereof, having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity or similarity to the sequence of 20H5.A3-VH5VL1, 20H5.A3-VH5VL3, 20H5.A3-VH6VL1, 20H5.A3-VH6VL3, or a binding fragment thereof (e.g., CDRs, VL, VH, LC, HC).

[0227] In some embodiments, the anti-Gal3 antibody or binding fragment thereof excludes a subset of the listed anti-Gal3 antibodies or binding fragments thereof depicted in any one of Figures 19A-D. In some embodiments, CDRs (including heavy and light chain CDRs), heavy chain variable regions, light chain variable regions, heavy chains, and / or light chains are excluded from the sequences associated with the subset of listed anti-Gal3 antibodies or binding fragments thereof depicted in any one of Figures 19A-D. In some embodiments, combinations of CDRs (including heavy and light chain CDRs), heavy chain variable regions, light chain variable regions, heavy chains, and / or light chains are excluded from the sequences associated with the subset of listed anti-Gal3 antibodies or binding fragments thereof depicted in any one of Figures 19A-D. In some embodiments, the anti-Gal3 antibody or binding fragment thereof excludes one selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 19A, or excludes any one or more of their CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof excludes one selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 19B, or excludes any one or more of their CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof excludes one selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 19C, or excludes any one or more of their CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof excludes one selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 19D, or excludes any one or more of their CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof excludes one selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 19A, or excludes any one or more of their CDRs, VH, VL, HC, and / or LC.In some embodiments, the anti-Gal3 antibody or binding fragment thereof excludes one selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 19B, or excludes any one or more of their CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof excludes one selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 19C, or excludes any one or more of their CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof excludes one selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 19D, or excludes any one or more of their CDRs, VH, VL, HC, and / or LC. In other embodiments, any of these constructs are used for any of the methods provided herein.

[0228] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is selected from the subset of listed anti-Gal3 antibodies or binding fragments thereof depicted in any one of Figures 20A-D. In some embodiments, the CDRs (including heavy and light chain CDRs), heavy chain variable region, light chain variable region, heavy chain, and / or light chain are selected from sequences associated with the subset of listed anti-Gal3 antibodies or binding fragments thereof depicted in any one of Figures 20A-D. In some embodiments, a combination of CDRs (including heavy and light chain CDRs), heavy chain variable region, light chain variable region, heavy chain, and / or light chain is selected from sequences associated with the subset of listed anti-Gal3 antibodies or binding fragments thereof depicted in any one of Figures 20A-D. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 20A, or comprises any one or more of their CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 20B, or comprises any one or more of their CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 20C, or comprises any one or more of their CDRs, VH, VL, HC, and / or LC. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is selected from the group of listed anti-Gal3 antibodies or binding fragments thereof depicted in Figure 20D, or comprises any one or more of their CDRs, VH, VL, HC, and / or LC.

[0229] In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to the Gal3 protein. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to a specific epitope within a Gal3 protein having an amino acid sequence according to SEQ ID NOs: 1-2, as provided in FIG.

[0230] In some embodiments, the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within the peptide shown in Figure 2 (SEQ ID NOs: 3-26).

[0231] In some embodiments, the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within amino acid residues 1-20 of SEQ ID NOs: 1-2. In some embodiments, the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within amino acid residues 31-50 of SEQ ID NOs: 1-2. In some embodiments, the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within amino acid residues 51 to 70 of SEQ ID NOs: 1 to 2. In some embodiments, the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within amino acid residues 61 to 80 of SEQ ID NOs: 1 to 2.

[0232] In some embodiments, the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within peptide 1 (SEQ ID NO: 3), peptide 4 (SEQ ID NO: 6), peptide 6 (SEQ ID NO: 8), or peptide 7 (SEQ ID NO: 9). In some embodiments, the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within peptide 1 (SEQ ID NO: 3). In some embodiments, the anti-Gal3 antibody or binding fragment thereof may bind to at least 11, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within peptide 4 (SEQ ID NO: 6). In some embodiments, the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within peptide 6 (SEQ ID NO: 8). In some embodiments, the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within peptide 7 (SEQ ID NO: 9). In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to an epitope present within the region of Gal3 defined by peptide 1 (SEQ ID NO: 3). In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to an epitope present within the region of Gal3 defined by peptide 4 (SEQ ID NO: 6). In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to an epitope present within the region of Gal3 defined by peptide 6 (SEQ ID NO: 8). In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to an epitope present within the region of Gal3 defined by peptide 7 (SEQ ID NO: 9).In some embodiments, the antibody is an antibody that binds to one, two, or all three of peptides 1, 6, and / or 7.

[0233] In some embodiments, the anti-Gal3 antibodies or binding fragments thereof described herein may bind to the N-terminal domain of Gal3 or a portion thereof. In some embodiments, the anti-Gal3 antibodies or binding fragments thereof described herein may bind to an epitope of Gal3 containing a GxYPG motif (where x is the amino acid alanine (A), glycine (G), or valine (V)). In some embodiments, the anti-Gal3 antibodies or binding fragments thereof described herein may bind to an epitope of Gal3 containing two GxYPG motifs (where x is A, G, or V) separated by three amino acids.

[0234] In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to the N-terminus of Gal3, the N-terminal domain of Gal3, or the TRD of Gal3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof does not bind to the N-terminus of Gal3, the N-terminal domain of Gal3, or the TRD of Gal3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to the C-terminus of Gal3, the C-terminal domain of Gal3, or the CRD of Gal3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof does not bind to the C-terminus of Gal3, the C-terminal domain of Gal3, or the CRD of Gal3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 isoform 1. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to the N-terminus of Gal3 isoform 1, the N-terminal domain of Gal3 isoform 1, amino acids 1-111 of Gal3 isoform 1, the TRD of Gal3 isoform 1, or amino acids 36-109 of Gal3 isoform 1. In some embodiments, the anti-Gal3 antibody or binding fragment thereof does not bind to the N-terminus of Gal3 isoform 1, the N-terminal domain of Gal3 isoform 1, amino acids 1-111 of Gal3, the TRD of Gal3 isoform 1, or amino acids 36-109 of Gal3 isoform 1. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to the C-terminus of Gal3 isoform 1, the C-terminal domain of Gal3 isoform 1, amino acids 112-250 of Gal3, or the CRD of Gal3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof does not bind to the C-terminus of Gal3 isoform 1, the C-terminal domain of Gal3 isoform 1, amino acids 112-250 of Gal3 isoform 1, or the CRD of Gal3.In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to the N-terminus of Gal3 isoform 3, the N-terminal domain of Gal3 isoform 3, amino acids 1-125 of Gal3, the TRD of Gal3 isoform 3, or amino acids 50-123 of Gal3 isoform 3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof does not bind to any of the N-terminus of Gal3 isoform 3, the N-terminal domain of Gal3 isoform 3, amino acids 1-125 of Gal3 isoform 3, the TRD of Gal3, or amino acids 50-123 of Gal3 isoform 3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to the C-terminus of Gal3 isoform 3, the C-terminal domain of Gal3 isoform 3, amino acids 126-264 of Gal3 isoform 3, or the CRD of Gal3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof does not bind to the C-terminus of Gal3 isoform 3, the C-terminal domain of Gal3 isoform 3, amino acids 126-264 of Gal3 isoform 3, or the CRD of Gal3 isoform 3.

[0235] In some embodiments, the anti-Gal3 antibody or binding fragment thereof reduces the interaction between Gal3 and the target protein by less than 80%, less than 75%, less than 70%, less than 60%, less than 59%, less than 50%, less than 40%, less than 34%, less than 30%, less than 20%, less than 14%, less than 10%, less than 7%, less than 5%, less than 4%, or less than 1%.

[0236] In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a dissociation constant (KD) of less than 1 nM, less than 1.2 nM, less than 2 nM, less than 5 nM, less than 10 nM, less than 13.5 nM, less than 15 nM, less than 20 nM, less than 25 nM, or less than 30 nM. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 1 nM. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 1.2 nM. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 2 nM. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 5 nM. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 10 nM. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 13.5 nM. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 15 nM. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 20 nM. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 25 nM. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 30 nM.

[0237] In some embodiments, an anti-Gal3 antibody or binding fragment thereof comprises any one of the variable heavy chain complementarity determining region 1 (VH-CDR1) sequences shown in Figure 3A (SEQ ID NOS: 27-70). In some embodiments, the anti-Gal3 antibody comprises a VH-CDR1 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity or similarity to any one of SEQ ID NOS: 27-70.

[0238] In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises any one of the variable heavy chain complementarity determining region 2 (VH-CDR2) sequences shown in Figure 3B (SEQ ID NOS: 71-111, 801). In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a VH-CDR2 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity or similarity to any one of SEQ ID NOS: 71-111, 801.

[0239] In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises any one of the variable heavy chain complementarity-determining region 3 (VH-CDR3) sequences shown in Figure 3C (SEQ ID NOS: 112-169, 802). In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a VH-CDR3 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity or similarity to any one of SEQ ID NOS: 112-169, 802.

[0240] In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises any one of the variable light chain complementarity determining region 1 (VL-CDR1) sequences shown in Figure 4A (SEQ ID NOs: 170-220). In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises any one of the variable light chain complementarity determining region 1 (VL-CDR1) sequences shown in Figure 4A (SEQ ID NOs: 170-220). and VL-CDR1 sequences having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity or similarity to any one of numbers 170 to 220.

[0241] In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises any one of the variable light chain complementarity determining region 2 (VL-CDR2) sequences shown in Figure 4B (SEQ ID NOS:221-247). In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a VL-CDR2 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity or similarity to any one of SEQ ID NOS:221-247.

[0242] In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises any one of the variable light chain complementarity-determining region 3 (VL-CDR3) sequences shown in Figure 4C (SEQ ID NOS:248-296). In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a VL-CDR3 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity or similarity to any one of SEQ ID NOS:248-296.

[0243] In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL). In some embodiments, the VH may comprise a VH-CDR1, a VH-CDR2, and / or a VH-CDR3 selected from any of Figures 3A-C. In some embodiments, the VL may comprise a VL-CDR1, a VL-CDR2, and / or a VL-CDR3 selected from any of Figures 4A-C. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises the CDRs within the VH and VL sequences shown in Figures 5 and 6.

[0244] In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain variable region (VH) sequence selected from Figure 5 (SEQ ID NOS: 297-373, 803, 806-820, 926). In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a VH sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity or similarity to any one of SEQ ID NOS: 297-373, 803, 806-820, 926.

[0245] In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a light chain variable region (VL) sequence selected from Figure 6 (SEQ ID NOs: 374-447, 821-835, 927-929). In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a VL sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity or similarity to any one of SEQ ID NOs: 374-447, 821-835, and 927-929.

[0246] In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a combination of heavy and light chain variable regions shown in FIG.

[0247] In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises the heavy and light chain sequences shown in Figure 9 (SEQ ID NOS: 448-538, 804-805, 836-865).

[0248] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is selected from the group consisting of TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E 5, 23B10.2B12, 24D12.2H9, F846C.1B2, F846C.1F5, F846C.1H12, F846C.1H 5, F846C.2H3, F846TC.14A2, F846TC.14E4, F846TC.16B5, F846TC.7F10, F8 47C.10B9, F847C.11B1, F847C.12F12, F847C.26F5, F847C.4B10, F849C.8D 10, F849C.8H3, 846.2B11, 846.4D5, 846T.1H2, 847.14H4, 846.2D4, 846.2F 11, 846T.10B1, 846T.2E3, 846T.4C9, 846T.4E11, 846T.4F5, 846T.8D1, 847 .10C9, 847.11D6, 847.15D12, 847.15F9, 847.15H11, 847.20H7, 847.21B11 , 847.27B9, 847.28D1, 847.2B8, 847.3B3, 849.1D2, 849.2D7, 849.2F12, 84 9.4B2, 849.4F12, 849.4F2, 849.5C2, 849.8D12, F847C.21H6, 849.5H1, 847 .23F11, 847.16D10, 847.13E2-mH0mL1, 847.13E2-mH0mL2, 847.12C4, 847. 4D3, 2D10-VH0-VL0, 2D10-hVH4-HVL1, 2D10-hVH4-HVL2, 2D10-hVH4-HVL3, 2D10-hVH4-HVL4, 2D10-hVH3-HVL1, 2D10-hVH3-HVL2, 2D10-hVH3-HVL3, 2D 10-hVH3-HVL4, 20H5.A3-VH3VL1, 20H5.A3-VH3VL3, 20H5.A3-VH4VL1, 20H5.and 20H5.A3-VH5VL1, 20H5.A3-VH5VL3, 20H5.A3-VH6VL1, 20H5.A3-VH6VL3, or a binding fragment thereof.

[0249] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is selected from the group consisting of TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E 5, 23B10.2B12, 24D12.2H9, F846C.1B2, F846C.1F5, F846C.1H12, F846C.1H 5, F846C.2H3, F846TC.14A2, F846TC.14E4, F846TC.16B5, F846TC.7F10, F8 47C.10B9, F847C.11B1, F847C.12F12, F847C.26F5, F847C.4B10, F849C.8D 10, F849C.8H3, 846.2B11, 846.4D5, 846T.1H2, 847.14H4, 846.2D4, 846.2F 11, 846T.10B1, 846T.2E3, 846T.4C9, 846T.4E11, 846T.4F5, 846T.8D1, 847 .10C9, 847.11D6, 847.15D12, 847.15F9, 847.15H11, 847.20H7, 847.21B11 , 847.27B9, 847.28D1, 847.2B8, 847.3B3, 849.1D2, 849.2D7, 849.2F12, 84 9.4B2, 849.4F12, 849.4F2, 849.5C2, 849.8D12, F847C.21H6, 849.5H1, 847 .23F11, 847.16D10, 847.13E2-mH0mL1, 847.13E2-mH0mL2, 847.12C4, 847. 4D3, 2D10-VH0-VL0, 2D10-hVH4-HVL1, 2D10-hVH4-HVL2, 2D10-hVH4-HVL3, 2D10-hVH4-HVL4, 2D10-hVH3-HVL1, 2D10-hVH3-HVL2, 2D10-hVH3-HVL3, 2D 10-hVH3-HVL4, 20H5.A3-VH3VL1, 20H5.A3-VH3VL3, 20H5.A3-VH4VL1, 20H5.Comprising, consisting essentially of, or consisting of 20H5.A3-VH5VL1, 20H5.A3-VH5VL3, 20H5.A3-VH6VL1, 20H5.A3-VH6VL3, or a binding fragment thereof.

[0250] In some embodiments, an anti-Gal3 antibody or binding fragment thereof comprises one or more heavy chain variable region CDRs depicted in Figures 3A-C. In some embodiments, an anti-Gal3 antibody or binding fragment thereof comprises one or more light chain variable region CDRs depicted in Figures 4A-C. In some embodiments, an anti-Gal3 antibody or binding fragment thereof comprises a heavy chain variable region depicted in Figure 5. In some embodiments, an anti-Gal3 antibody or binding fragment thereof comprises a light chain variable region depicted in Figure 6. In some embodiments, an anti-Gal3 antibody or binding fragment thereof comprises a combination of heavy and light chain variable regions depicted in Figure 8. In some embodiments, an anti-Gal3 antibody or binding fragment thereof comprises a heavy chain and / or light chain depicted in Figure 9. In some embodiments, the anti-Gal3 antibody or binding fragment thereof can comprise or include any one or more of the sequences provided in any one or more of Figures 3A-C, 4A-C, 5, 6, 7, 8, 9, or any one or more sequences at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more identical thereto. In some embodiments, the anti-Gal3 antibody or binding fragment thereof can comprise or include any one or more of the sequences provided in any one or more of Figures 3A-C, 4A-C, 5, 6, 7, 8, 9, or any one or more sequences at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more similar thereto.

[0251] In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a humanized antibody or binding fragment thereof. In other cases, the anti-Gal3 antibody or binding fragment thereof comprises a chimeric antibody or binding fragment thereof. In some embodiments, the anti-Gal3 antibody comprises a full-length antibody or binding fragment thereof. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a bispecific antibody or binding fragment thereof. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is a monovalent Fab', a bivalent Fab2, a single-chain variable fragment (scFv), a diabody, a minibody, a nanobody, a single-domain antibody (sdAb), or or camelid antibodies, or binding fragments thereof.

[0252] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is a bispecific antibody or binding fragment thereof. Exemplary bispecific antibody formats include, but are not limited to, Knobs-into-Holes (KiH), Asymmetric Re-engineering Technology-immunoglobulin (ART-Ig), Triomab quadroma, bispecific monoclonal antibody (BiMAb, BsmAb, BsAb, bsMab, BS-Mab, or Bi-MAb), Azymetric, Biclonics, Fab-scFv-Fc, Two-in-one / Dual Action Fab (DAF), FinomAb, scFv-Fc-(Fab) fusion, Dock-aNd-Lock (DNL), Tandem diAbody (TandAb), Dual-affinity-ReTargeting (DART), nanobody, triple body, tandem scFv (taFv), triple head, tandem dAb / VHH, triple dAb / VHH, or tetravalent dAb / VHH. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is a bispecific antibody or binding fragment thereof, including the bispecific antibody format set forth in Brinkmann and Kontermann, "The making of bispecific antibodies," MABS 9(2): 182-212 (2017).

[0253] In some embodiments, the anti-Gal3 antibody or binding fragment thereof can comprise an IgM, IgG (e.g., IgG1, IgG2, IgG3, or IgG4), IgA, or IgE framework. The IgG framework can be IgG1, IgG2, IgG3, or IgG4. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises an IgG1 framework. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises an IgG2 framework. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises an IgG4 framework. The anti-Gal3 antibody or binding fragment thereof can further comprise an Fc mutation.

[0254] In some embodiments, the Fc region comprises one or more mutations that modulate Fc receptor interaction, e.g., to enhance effector function, e.g., ADCC and / or CDC. In such cases, exemplary residues that modulate effector function when mutated include S239, K326, A330, I332, or E333, where the residue positions correspond to IgG1 and the residue numbering is according to Kabat numbering (EU index of Kabat et al. 1991 Sequences of Proteins of Immunological Interest). In some embodiments, the one or more mutations comprise S239D, K326W, A330L, I332E, E333A, E333S, or a combination thereof. In some embodiments, the one or more mutations comprise S239D, I332E, or a combination thereof. In some embodiments, the one or more mutations comprise S239D, A330L, I332E, or a combination thereof. In some embodiments, the one or more mutations comprise K326W, E333S, or a combination thereof. In some embodiments, the mutation comprises E333A.

[0255] In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a humanization score greater than 70, greater than 80, greater than 81, greater than 82, greater than 83, greater than 84, greater than 85, greater than 86, greater than 87, greater than 88, greater than 89, greater than 90, or greater than 95. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a humanization score greater than 80. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a humanization score greater than 83. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a humanization score greater than 85. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a humanization score greater than 87. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a humanization score greater than 90. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain humanization score of greater than 70, greater than 80, greater than 81, greater than 82, greater than 83, greater than 84, greater than 85, greater than 86, greater than 87, greater than 88, greater than 89, greater than 90, or greater than 95, optionally greater than 80, greater than 85, or greater than 87. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a light chain humanization score of greater than 70, greater than 80, greater than 81, greater than 82, greater than 83, greater than 84, greater than 85, greater than 86, greater than 87, greater than 88, greater than 89, greater than 90, or greater than 95, optionally greater than 80, greater than 83, or greater than 85.

[0256] Pharmaceutical preparations The pharmaceutical preparations for treating diseases provided herein can include the anti-Gal3 antibody or binding fragment thereof described herein.The anti-Gal3 antibody or binding fragment thereof can be formulated for systemic administration.Alternatively, the anti-Gal3 antibody or binding fragment thereof can be formulated for parenteral administration.

[0257] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is formulated as a pharmaceutical composition for administration to a subject by, but not limited to, parenteral (e.g., intravenous, subcutaneous, intramuscular, intraarterial, intradermal, intraperitoneal, intravitreal, intracerebral, or intracerebroventricular), oral, intranasal, buccal, rectal, or transdermal routes of administration. In some cases, the pharmaceutical compositions described herein are formulated for parenteral (e.g., intravenous, subcutaneous, intramuscular, intraarterial, intradermal, intraperitoneal, intravitreal, intracerebral, or intracerebroventricular) administration. In other cases, the pharmaceutical compositions described herein are formulated for systemic administration. In other cases, the pharmaceutical compositions described herein are formulated for oral administration. In still other cases, the pharmaceutical compositions described herein are formulated for intranasal administration. In some embodiments, the antibodies or binding fragments thereof disclosed herein are provided in subcutaneous or intravenous formulations. In some embodiments, the antibodies or binding fragments thereof disclosed herein are provided in intravenous formulations.

[0258] In some cases, the pharmaceutical composition further comprises a pH adjusting or buffering agent, including acids such as acetic acid, boric acid, citric acid, lactic acid, phosphoric acid, and hydrochloric acid; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate, and tris-hydroxymethylaminomethane; and buffers such as citric acid (salt) / dextrose, sodium bicarbonate, and ammonium chloride. Such acids, bases, and buffers are included in the amounts required to maintain the pH of the composition within an acceptable range.

[0259] In some cases, the pharmaceutical composition contains one or more salts in an amount required to bring the osmolality of the composition into an acceptable range. Such salts include salts having sodium, potassium, or ammonium cations and chloride, citrate, ascorbic acid, borate, phosphate, bicarbonate, sulfate, thiosulfate, or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite, and ammonium sulfate.

[0260] In some cases, the pharmaceutical composition further comprises a diluent, which is used to stabilize the compound because it can provide a more stable environment. Salts dissolved in buffered solutions (which can also provide pH control or maintenance) are utilized as diluents in the art. Diluents include, but are not limited to, phosphate buffered saline solutions. In certain cases, diluents increase the bulk of the composition to facilitate compression or create sufficient bulk for a homogeneous blend for capsule filling. Such compounds can include, for example, lactose, starch, mannitol, sorbitol, dextrose, microcrystalline cellulose, such as Avicel®; dibasic calcium phosphate, dicalcium phosphate dihydrate; tricalcium phosphate, calcium phosphate; anhydrous lactose, spray-dried lactose; pregelatinized starch, compressible sugar, such as Di-Pac® (Amstar); mannitol, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate stearate, sucrose-based diluents, sugar; monobasic calcium sulfate monohydrate, calcium sulfate dihydrate; calcium lactate trihydrate, dextrates; hydrolyzed cereal solids, amylose; powdered cellulose, calcium carbonate; glycine, kaolin; mannitol, sodium chloride; inositol, and bentonite.

[0261] In some embodiments, pharmaceutical formulations include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, sustained release formulations, pulsatile release formulations, multiparticulate formulations (e.g., nanoparticle formulations), and mixed immediate and controlled release formulations.

[0262] In some embodiments, the present disclosure provides pharmaceutical preparations of any one or more of the anti-Gal3 antibodies or binding fragments disclosed herein. These pharmaceutical preparations may be in the form of a prepared solution suitable for administration, for example, contained in a sterile IV infusion bag or other container. In some embodiments, the pharmaceutical preparations are prepared as unit doses. In some embodiments, the pharmaceutical formulation is a unit dose formulated as 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500, or 5000 mg of anti-Gal3 antibody or binding fragment thereof per unit dose, or any amount per unit dose within a range defined by any two of the above amounts per unit dose. In some embodiments, the pharmaceutical formulation is a unit dose formulated as 1000 mg or about 1000 mg of anti-Gal3 antibody or binding fragment thereof. In some embodiments, the pharmaceutical formulation is a unit dose (e.g., in the amounts provided herein) prepared in 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, or 300 mL of sterile saline or other compatible excipient, carrier, or diluent known in the art. In some embodiments, the pharmaceutical formulation is a unit dose (e.g., in the amounts provided herein) prepared in 250 mL or about 250 mL of sterile saline or other compatible excipient, carrier, or diluent known in the art.

[0263] Also provided herein is a pharmaceutical formulation comprising 1000 mg or about 1000 mg of an anti-Gal3 antibody or binding fragment thereof dissolved in 250 mL or about 250 mL of saline. In some embodiments, the pharmaceutical formulation is prepared in an IV infusion bag.

[0264] Also provided herein is a pharmaceutical formulation comprising 1000 mg or about 1000 mg of an anti-Gal3 antibody diluted in a volume of 250 mL of 0.9% Sodium Chloride Injection, USP (usually sterile saline). In some embodiments, the anti-Gal3 antibody is TB006.

[0265] Also provided herein are single-use, sealed glass injection vials containing any one or more pharmaceutical formulations of anti-Gal3 antibodies or binding fragments thereof disclosed herein. In some embodiments, the vials contain 4, 5, 6, 7, 8, 9, 10, 11, or 12 mL of a concentrated solution of anti-Gal3 antibodies or binding fragments thereof. In some embodiments, the vials contain 8 mL of a concentrated solution of anti-Gal3 antibodies or binding fragments thereof. In some ...

Claims

1. A method for inhibiting, reducing, preventing, and / or treating stroke in a subject in need thereof, comprising administering to the subject an anti-Gal3 antibody or a binding fragment thereof, thereby inhibiting, reducing, preventing, and / or treating the stroke.

2. 10. The method of claim 1, further comprising selecting the subject as having or at risk of having the stroke prior to the administering step.

3. 3. The method of claim 2, wherein selecting said subject as having or at risk of having said stroke comprises assessing said subject by NIHSS, modified Rankin Scale (mRS), Hugel-Meyer Assessment (FMA), Montreal Cognitive Assessment (MoCA), neuroimaging, optionally CT or MRI, and / or detecting stroke biomarkers, optionally S100 calcium binding protein B (S100B), glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), and / or matrix metalloproteinase-9 (MMP9).

4. 4. The method of any one of claims 1 to 3, further comprising detecting amelioration of symptoms associated with the stroke after the administering step.

5. 5. The method of claim 4, wherein detecting amelioration of symptoms associated with the stroke after the administering step comprises detecting improvement in the subject by the NIHSS, mRS, FMA, or MoCA.

6. When assessed after said administering step, optionally 7, 35, and / or 75 days after said administering step: a) said improvement in said subject by said NIHSS comprises at least a 4 point reduction in said NIHSS; b) the improvement in the subject according to the mRS comprises at least a 1 point reduction in the mRS; c) said improvement of said subject according to said FMA comprises an increase of at least 1 point on said FMA; and / or d) said improvement of said subject with said MoCA comprises an increase of at least one point on said MoCA; The method according to claim 5.

7. The method of any one of claims 1 to 6, wherein the stroke is an ischemic stroke, a thrombotic stroke, an embolic stroke, a transient ischemic attack, a hemorrhagic stroke, an intracerebral hemorrhage, or a subarachnoid hemorrhage.

8. 8. The method of any one of claims 1 to 7, wherein the stroke is intracerebral hemorrhage (ICH), optionally wherein the ICH is associated with amyloid aggregate deposition and / or cerebral amyloid angiopathy (CAA).

9. The method of any one of claims 1 to 8, wherein administering to the subject the anti-Gal3 antibody or binding fragment thereof prevents the stroke.

10. Administration of the anti-Gal3 antibody or binding fragment thereof prevents motor dysfunction, prevents the occurrence of microhemorrhages, or reduces the level of activated microglia in the subject.

10. The method of any one of claims 1 to 9, wherein the method prevents an increase in levels of activated astrocytes, prevents an increase in circulating pro-inflammatory immune cells, prevents an increase in circulating pro-inflammatory cytokines, or any combination thereof.

11. The method of any one of claims 1 to 10, wherein administering to the subject the anti-Gal3 antibody or binding fragment thereof treats the stroke.

12. The method of any one of claims 1 to 11, wherein administration of the anti-Gal3 antibody or binding fragment thereof reduces motor dysfunction, reduces microhemorrhages, reduces levels of activated microglia, reduces levels of activated astrocytes, reduces levels of circulating pro-inflammatory immune cells, reduces levels of circulating pro-inflammatory cytokines, or any combination thereof in the subject.

13. 13. The method of claim 12, wherein the reduction in motor dysfunction, the reduction in microhemorrhages, the reduction in levels of activated microglia, the reduction in levels of activated astrocytes, the reduction in levels of circulating pro-inflammatory cytokines, or any combination thereof, in the subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the aforesaid reductions.

14. 14. The method of claim 12 or 13, wherein the reduction in motor dysfunction in the subject is at least 50%.

15. The method of any one of claims 12 to 14, wherein the reduction in motor impairment is assessed by the Hugelmeyer Assessment (FMA), the Motor Assessment Scale (MAS), and / or the Chedock-McMaster Stroke Assessment (CMSA).

16. The method of any one of claims 12 to 15, wherein the reduction in microhemorrhages in the subject is at least 50%.

17. The method of any one of claims 12 to 16, wherein said reduction in microhemorrhages is assessed by neuroimaging, MRI, and / or Prussian blue staining.

18. The method of any one of claims 12 to 17, wherein the reduction in the level of activated microglia in the subject is at least 20%.

19. 19. The method of any one of claims 12 to 18, wherein said reduction in levels of activated microglia is assessed by detection of microglial activation markers, optionally ionized calcium-binding adaptor molecule 1 (Iba1), monocyte chemoattractant protein-1 (MCP-1), chitinase-3-like protein 1 (YKL-40), and / or soluble CD14 (sCD14), optionally from cerebrospinal fluid of said subject.

20. The method of any one of claims 12 to 19, wherein the reduction in the level of activated astrocytes in the subject is at least 30%.

21. 21. The method of any one of claims 12 to 20, wherein said reduction in the level of activated astrocytes is assessed by detection of astrocyte activation markers, optionally GFAP and / or S100B, optionally from cerebrospinal fluid of said subject.

22. The method of any one of claims 12 to 21, wherein the pro-inflammatory immune cells comprise NK cells, monocytes, and / or lymphocytes.

23. The method of any one of claims 12 to 22, wherein the pro-inflammatory cytokines comprise IL-6, TNF-α, and / or IL-1β.

24. The method of any one of claims 1 to 23, wherein administering an anti-Gal3 antibody or binding fragment thereof to the subject comprises administration of one or more unit doses, optionally 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 unit doses, of the anti-Gal3 antibody or binding fragment thereof.

25. 25. The method of claim 24, wherein the one or more unit doses comprise 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500 or 5000 mg of the anti-Gal3 antibody or binding fragment thereof per unit dose, or any amount per unit dose within a range defined by any two of the above amounts per unit dose.

26. 26. The method of claim 24 or 25, wherein the one or more unit doses comprise 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 mg per kg of the subject's body weight, or any amount per unit dose within a range defined by any two of the aforementioned amounts per unit dose.

27. 27. The method of any one of claims 24-26, wherein the one or more unit doses are administered every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, or 4 weeks, or any interval within a range defined by any two of the aforementioned intervals.

28. The method of any one of claims 1 to 27, wherein the anti-Gal3 antibody or binding fragment thereof is administered enterally, orally, intranasally, parenterally, intracranially, subcutaneously, intramuscularly, intradermally, or intravenously, or any combination thereof, optionally intravenously.

29. The anti-Gal3 antibody or binding fragment thereof is selected from the group consisting of TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11. H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5, 23B10.2B12, 24D12.2H9, F846C. 1B2, F846C. 1F5, F846C. 1H12, F846C. 1H5, F846C. 2H3, F846TC. 14A2, F846TC. 14E4, F846TC. 16B5, F846TC. 7F10, F847C. 10B9, F847C. 11B1, F847C. 12F12, F847C. 26F5, F847C. 4B10, F849C. 8D10, F849C. 8H3, 846.2B11, 846.4D5, 846T. 1H2, 847.14H4, 846.2D4, 846.2F11, 846T. 10B1, 846T. 2E3, 846T. 4C9, 846T. 4E11, 846T. 4F5, 846T. 8D1, 847.10C9, 847.11D6, 847.15D12, 847.15F9, 847.15H11, 847.20H 7, 847.21B11, 847.27B9, 847.28D1, 847.2B8, 847.3B3, 849.1D2, 849.2 D7, 849.2F12, 849.4B2, 849.4F12, 849.4F2, 849.5C2, 849.8D12, F847C. 21H6, 849.5H1, 847.23F11, 847.16D10, 847.13E2-mH0mL1, 847.13E2-mH0mL2, 847.12C4, 847.4D3, 2D10-VH0-VL0, 2D10-hVH4-HVL1, 2D10-hVH4-HVL2, 2D10-hVH4-HVL3, 2D10-hVH4-HVL4, 2D10-hVH3-HVL1, 2D10-hVH3-HVL2, 2D10-hVH3-HVL3, 2D10-hVH3-HVL4, 20H5. A3-VH3VL1, 20H5.

29. The method of any one of claims 1 to 28, comprising one or more of: 20H5.A3-VH3VL3, 20H5.A3-VH4VL1, 20H5.A3-VH5VL1, 20H5.A3-VH5VL3, 20H5.A3-VH6VL1, 20H5.A3-VH6VL3, or a binding fragment thereof.

30. 30. The method of any one of claims 1-29, wherein the anti-Gal3 antibody or binding fragment thereof comprises one or more of TB001, TB006, F846C.1F5, F846TC.16B5, 14H10.2C9, 15G7.2A7, 20H5.A3, 19D9.2E5, 19B5.2E6, or F847C.21H6.

31. The method of any one of claims 1 to 30, wherein the anti-Gal3 antibody or binding fragment thereof comprises TB006.

32. The method of any one of claims 1 to 31, wherein the anti-Gal3 antibody or binding fragment thereof is administered in combination with one or more additional therapeutic compositions.

33. 33. The method of claim 32, wherein the stroke is an ischemic stroke, a thrombotic stroke, an embolic stroke, or a transient ischemic attack, and the one or more additional therapeutic compositions comprise a thrombolytic agent, tissue plasminogen activator (tPA), alteplase, reteplase, tenecteplase, desmoteplase, an anticoagulant, an ACE inhibitor, an antihypertensive agent, nicardipine, or any combination thereof.

34. 33. The method of claim 32, wherein the stroke is a hemorrhagic stroke, an intracerebral hemorrhage, or a subarachnoid hemorrhage, and the one or more additional therapeutic compositions comprise an antihypertensive agent, or nicardipine, or any combination thereof.

35. A method for inhibiting, reducing, preventing, and / or treating traumatic brain injury (TBI) in a subject in need thereof, comprising administering to the subject an anti-Gal3 antibody or a binding fragment thereof, thereby inhibiting, reducing, preventing, and / or treating the TBI.

36. 36. The method of claim 35, further comprising selecting the subject as having or at risk for having the TBI prior to the administering step.

37. 37. The method of claim 36, wherein selecting the subject as having TBI comprises evaluating the subject for level of consciousness, memory loss, and / or Glasgow Coma Scale, neuroimaging, optionally CT or MRI, and / or detection of TBI biomarkers, optionally GFAP and / or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1).

38. and detecting amelioration of symptoms associated with the TBI after the administering step. The method according to any one of claims 35 to 37, comprising:

39. 39. The method of any one of claims 35-38, wherein the TBI is associated with concussion, edema, diffuse axonal injury, spinal cord injury, coma, neuroinflammation, microhemorrhages, astrocytosis, activated microglia, and / or hematoma.

40. The method of any one of claims 35 to 39, wherein administration of the anti-Gal3 antibody or binding fragment thereof to the subject prevents the TBI, concussion, edema, diffuse axonal injury, spinal cord injury, coma, neuroinflammation, microhemorrhage, astrocytosis, activated microglia, and / or hematoma.

41. The method of any one of claims 35 to 40, wherein administration of the anti-Gal3 antibody or binding fragment thereof prevents increased levels of activated microglia, prevents increased levels of activated astrocytes, prevents increased levels of macrophages, prevents increased levels of hyperphosphorylated tau, prevents the occurrence of microhemorrhages, prevents neuroinflammation, prevents increased levels of circulating pro-inflammatory cytokines, or any combination thereof in the subject.

42. The method of any one of claims 35 to 41, wherein administration of the anti-Gal3 antibody or binding fragment thereof to the subject treats the TBI, concussion, edema, diffuse axonal injury, spinal cord injury, coma, neuroinflammation, microhemorrhage, astrocytosis, activated microglia, and / or hematoma.

43. The method of any one of claims 35-42, wherein administration of the anti-Gal3 antibody or binding fragment thereof improves the patient's level of consciousness, memory loss, and / or Glasgow Coma Scale; and / or reduces the level of activated microglia, reduces the level of activated astrocytes, reduces the level of macrophages, reduces the level of hyperphosphorylated tau, reduces microhemorrhages, reduces neuroinflammation, reduces the level of circulating pro-inflammatory cytokines, or any combination thereof, in the subject.

44. 44. The method of claim 43, wherein the reduction in levels of activated microglia, the reduction in levels of activated astrocytes, the reduction in levels of macrophages, the reduction in levels of hyperphosphorylated tau, the reduction in microhemorrhages, the reduction in neuroinflammation, the reduction in levels of circulating pro-inflammatory cytokines, or any combination thereof, in the subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the aforesaid reductions.

45. 45. The method of claim 43 or 44, wherein the reduction in the level of activated microglia in the subject is at least 70%.

46. 46. ​​The method of any one of claims 43 to 45, wherein said reduction in levels of activated microglia is assessed by detection of microglial activation markers, optionally ionized calcium-binding adaptor molecule 1 (Iba1), monocyte chemoattractant protein-1 (MCP-1), chitinase-3-like protein 1 (YKL-40), and / or soluble CD14 (sCD14), optionally from cerebrospinal fluid of said subject.

47. The method of any one of claims 43 to 46, wherein the reduction in the level of activated astrocytes in the subject is at least 90%.

48. 48. The method of any one of claims 43 to 47, wherein said reduction in levels of activated astrocytes is assessed by detection of an astrocyte activation marker, optionally GFAP, optionally from cerebrospinal fluid of said subject.

49. The method of any one of claims 43 to 48, wherein the reduction in levels of macrophages in the subject is at least 70%.

50. 50. The method of any one of claims 43 to 49, wherein said reduction in levels of macrophages is assessed by detection of a macrophage activation marker, optionally CD68, optionally from cerebrospinal fluid of said subject.

51. The method of any one of claims 43 to 50, wherein the reduction in the level of hyperphosphorylated tau in the subject is at least 80%.

52. 52. The method of any one of claims 43-51, wherein the reduction in the level of microhemorrhage in the subject is at least 80%.

53. 53. The method of any one of claims 43 to 52, wherein said reduction in levels of microhemorrhage is assessed by neuroimaging, MRI, and / or Prussian blue staining.

54. 54. The method of any one of claims 43 to 53, wherein the reduction in neuroinflammation in the subject is at least 70%.

55. 55. The method of any one of claims 43 to 54, wherein the pro-inflammatory cytokines comprise IL-6, IL-10, and / or TNF-α.

56. The method of any one of claims 35 to 55, wherein the anti-Gal3 antibody or binding fragment thereof is administered enterally, orally, intranasally, parenterally, intracranially, subcutaneously, intramuscularly, intradermally, or intravenously, or any combination thereof, optionally intravenously.

57. The method of any one of claims 35 to 56, wherein administering an anti-Gal3 antibody or binding fragment thereof to the subject comprises administration of one or more unit doses, optionally 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 unit doses, of the anti-Gal3 antibody or binding fragment thereof.

58. 58. The method of claim 57, wherein the one or more unit doses comprise 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500 or 5000 mg of the anti-Gal3 antibody or binding fragment thereof per unit dose, or any amount per unit dose within a range defined by any two of the above amounts per unit dose.

59. The one or more unit doses may be 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 1 60. The method of claim 57 or 58, comprising 30, 135, 140, 145, or 150 mg per unit dose, or any amount per unit dose within a range defined by any two of the aforementioned amounts per unit dose.

60. 60. The method of any one of claims 57-59, wherein the one or more unit doses are administered every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, or 4 weeks, or any interval within a range defined by any two of the aforementioned intervals.

61. The anti-Gal3 antibody or its binding fragment is TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5, 23B10.2B12, 24D12.2H9, F846C.1B2, F846C.1F5, F846C.1H12, F846C.1H5, F846C.2H3, F846TC.14A2, F846TC.14E4, F846TC.16B5, F846TC.7F10, F847C.10B9, F847C.11B1, F847C.12F12, F847C.26F5, F847C.4B10, F849C.8D10, F849C.8H3, 846.2B11, 846.4D5, 846T.1H2, 847.14H4, 846.2D4, 846.2F11, 846T.10B1, 846T.2E3, 846T.4C9, 846T.4E11, 846T.4F5, 846T.8D1, 847.10C9, 847.11D6, 847.15D12, 847.15F9, 847.15H11, 847.20H7, 847.21B11, 847.27B9, 847.28D1, 847.2B8, 847.3B3, 849.1D2, 849.2D7, 849.2F12, 849.4B2, 849.4F12, 849.4F2, 849.5C2, 849.8D12, F847C.21H6, 849.5H1, 847.23F11, 847.16D10, 847.13E2-mH0mL1, 847.13E2-mH0mL2, 847.12C4, 847.4D3, 2D10-VH0-VL0, 2D10-hVH4-HVL1, 2D10-hVH4-HVL2, 2D10-hVH4-HVL3, 2D10-hVH4-HVL4, 2D10-hVH3-HVL1, 2D10-hVH3-HVL2, 2D10-hVH3-HVL3, 2D10-hVH3-HVL4, 20H5.A3-VH3VL1, 20H5.A3-VH3VL3, 20H5.A3-VH4VL1, 20H5.A3-VH5VL1,61. The method of any one of claims 35 to 60, comprising one or more of 20H5.A3-VH5VL3, 20H5.A3-VH6VL1, 20H5.A3-VH6VL3, or a binding fragment thereof.

62. 62. The method of any one of claims 35-61, wherein the anti-Gal3 antibody or binding fragment thereof comprises one or more of TB001, TB006, F846C.1F5, F846TC.16B5, 14H10.2C9, 15G7.2A7, 20H5.A3, 19D9.2E5, 19B5.2E6, or F847C.21H6.

63. The method of any one of claims 35 to 62, wherein the anti-Gal3 antibody or binding fragment thereof comprises TB006.

64. The method of any one of claims 35 to 63, wherein the anti-Gal3 antibody or binding fragment thereof is administered with one or more additional therapeutic compositions.

65. The one or more additional therapeutic compositions may be selected from the group consisting of levodopa, bromocriptine, NMDA receptor antagonists, amantadine, memantine, cholinesterase inhibitors, tacrine, and rifabutin.

65. The method of claim 64 comprising bastigmine, galantamine, donepezil, or any combination thereof.

66. A method for inhibiting, reducing, preventing, and / or treating a disorder associated with fibrin activity or dysfunction in a subject in need thereof, comprising administering an anti-Gal3 antibody or a binding fragment thereof to the subject, thereby inhibiting, reducing, preventing, and / or treating the disorder associated with fibrin activity or dysfunction.

67. 67. The method of claim 66, wherein the disorder associated with fibrin activity or dysfunction comprises atherosclerosis, thrombosis, thromboembolism, carotid artery disease, coronary artery disease, peripheral artery disease, myocardial infarction, heart failure, heart attack, hypertension, chronic kidney disease, coagulation disorders, or thrombocytopathy.

68. 68. The method of claim 67, further comprising selecting the subject as having or at risk of developing the disorder associated with fibrin activity or dysfunction prior to the administering step.

69. 69. The method of claim 68, wherein selecting said subject as having said disorder associated with fibrin activity or dysfunction comprises detecting a thrombus biomarker, optionally fibrinogen, C-reactive protein (CRP), and / or plasminogen activator inhibitor-1 (PAI-1).

70. 70. The method of any one of claims 66 to 69, further comprising detecting amelioration of symptoms associated with said disorder associated with fibrin activity or dysfunction after said administering step.

71. The method of any one of claims 66 to 70, wherein administration of the anti-Gal3 antibody or binding fragment thereof to the subject prevents neuroinflammation and / or fibrin oligomerization in the subject.

72. The method of any one of claims 66 to 71, wherein administration of the anti-Gal3 antibody or binding fragment thereof to the subject reduces neuroinflammation and / or fibrin oligomerization in the subject.

73. 73. The method of claim 72, wherein the reduction in neuroinflammation and / or the reduction in fibrin oligomerization in the subject is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or any percentage within a range defined by any two of the above reductions.

74. The method of any one of claims 66 to 73, wherein the anti-Gal3 antibody or binding fragment thereof is administered enterally, orally, intranasally, parenterally, intracranially, subcutaneously, intramuscularly, intradermally, or intravenously, or any combination thereof, optionally intravenously.

75. The method of any one of claims 66 to 74, wherein administering an anti-Gal3 antibody or binding fragment thereof to the subject comprises administration of one or more unit doses, optionally 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 unit doses, of the anti-Gal3 antibody or binding fragment thereof.

76. The one or more unit doses may be 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 110, 76. The method of claim 75, comprising 0, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500 or 5000 mg of the anti-Gal3 antibody or binding fragment thereof, or any amount per unit dose within a range defined by any two of the above amounts per unit dose.

77. 77. The method of claim 75 or 76, wherein the one or more unit doses comprise 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 mg per kg of the subject's body weight, or any amount per unit dose within a range defined by any two of the aforementioned amounts per unit dose.

78. 78. The method of any one of claims 75-77, wherein the one or more unit doses are administered every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, or 4 weeks, or any interval within a range defined by any two of the aforementioned intervals.

79. The anti-Gal3 antibody or its binding fragment is TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5, 23B10.2B12, 24D12.2H9, F846C.1B2, F846C.1F5, F846C.1H12, F846C.1H5, F846C.2H3, F846TC.14A2, F846TC.14E4, F846TC.16B5, F846TC.7F10, F847C.10B9, F847C.11B1, F847C.12F12, F847C.26F5, F847C.4B10, F849C.8D10, F849C.8H3, 846.2B11, 846.4D5, 846T.1H2, 847.14H4, 846.2D4, 846.2F11, 846T.10B1, 846T.2E3, 846T.4C9, 846T.4E11, 846T.4F5, 846T.8D1, 847.10C9, 847.11D6, 847.15D12, 847.15F9, 847.15H11, 847.20H7, 847.21B11, 847.27B9, 847.28D1, 847.2B8, 847.3B3, 849.1D2, 849.2D7, 849.2F12, 849.4B2, 849.4F12, 849.4F2, 849.5C2, 849.8D12, F847C.21H6, 849.5H1, 847.23F11, 847.16D10, 847.13E2-mH0mL1, 847.13E2-mH0mL2, 847.12C4, 847.4D3, 2D10-VH0-VL0, 2D10-hVH4-HVL1, 2D10-hVH4-HVL2, 2D10-hVH4-HVL3, 2D10-hVH4-HVL4, 2D10-hVH3-HVL1, 2D10-hVH3-HVL2, 2D10-hVH3-HVL3, 2D10-hVH3-HVL4, 20H5.A3-VH3VL1, 20H5.A3-VH3VL3, 20H5.A3-VH4VL1, 20H5.A3-VH5VL1,79. The method of any one of claims 66 to 78, comprising one or more of 20H5.A3-VH5VL3, 20H5.A3-VH6VL1, 20H5.A3-VH6VL3, or a binding fragment thereof.

80. The anti-Gal3 antibody or binding fragment thereof is one of TB001, TB006, F846C.1F5, F846TC.16B5, 14H10.2C9, 15G7.2A7, 20H5.A3, 19D9.2E5, 19B5.2E6, or F847C.21H6. The method according to any one of claims 66 to 79, comprising the above.

81. The method of any one of claims 66 to 80, wherein the anti-Gal3 antibody or binding fragment thereof comprises TB006.

82. The method of any one of claims 66 to 81, wherein the anti-Gal3 antibody or binding fragment thereof is administered with one or more additional therapeutic compositions.

83. 83. The method of claim 82, wherein the one or more additional therapeutic compositions comprise an anticoagulant, an aspirin, a statin, an antihypertensive, a diuretic, a calcium channel blocker, an ACE inhibitor, an angiotensin II receptor antagonist, an adrenergic receptor antagonist, a vasodilator, a renin inhibitor, an aldosterone receptor antagonist, an endothelial receptor blocker, or any combination thereof.

84. The method of any one of claims 1 to 83, wherein administering an anti-Gal3 antibody or binding fragment thereof to the subject comprises administration of 5 unit doses of the anti-Gal3 antibody or binding fragment thereof, each unit dose comprising 1000 mg or about 1000 mg of the anti-Gal3 antibody or binding fragment thereof, the unit doses being administered every 7 days or about 7 days, and each unit dose being administered over 1 hour or about 1 hour.

85. A method comprising administering 5 unit doses of an anti-Gal3 antibody or binding fragment thereof, each unit dose containing 1000 mg or about 1000 mg of the anti-Gal3 antibody or binding fragment thereof, the unit dose being administered every 7 days or about 7 days, and each unit dose being administered over 1 hour or about 1 hour.

86. The method of claim 84 or 85, wherein the anti-Gal3 antibody or binding fragment thereof is TB006 or a binding fragment thereof.

87. 87. The method of any one of claims 84-86, wherein each unit dose is formulated at or about 1000 mg of the anti-Gal3 antibody or binding fragment thereof in 250 mL of sterile saline.

88. The method of any one of claims 84 to 87, wherein each unit dose is prepared from a single-use sealed glass injection vial containing 8 mL of 20 mg / mL of said anti-Gal3 antibody or binding fragment thereof.

89. The method of any one of claims 84 to 88, wherein the anti-Gal3 antibody or binding fragment thereof is administered intravenously.

90. A sealed glass injection vial for single use containing 8 mL of 20 mg / mL anti-Gal antibody or binding fragment thereof, optionally wherein the anti-Gal3 antibody or binding fragment thereof is TB006 or a binding fragment thereof.

91. An IV infusion bag comprising 1000 mg or about 1000 mg of an anti-Gal3 antibody or binding fragment thereof dissolved in 250 mL or about 250 mL of saline, optionally wherein the anti-Gal3 antibody or binding fragment thereof is TB006 or a binding fragment thereof.